Title of Invention

"N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS"

Abstract Disclosed are compounds of the formula I. and pharmaceutically acceptable salts and prodrugs thereof, wherein W. R1 . R2. R7. R8. R9 and R10 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferaiive diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferaiive diseases in mammals, and pharmaceutical compositions containing such compounds.
Full Text N3 Alkylated Benzimidazole Derivatives as MEK Inhibitors BACKGROUND OF THE INVENTION
Field of the Invention
This invention relates to a series of alkylated (lH-Benzoimidazol-5-yl)-(4-substituted-phenyl)-amine derivatives that are useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. This invention also relates to a method of using such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and to pharmaceutical compositions containing such compounds. Summary of the Related Art
Cell signaling through growth factor receptors and protein kinases is an important
regulator of cell growth, proliferation and differentiation. In normal cell growth, growth
factors, through receptor activation (i.e. PDGF or EGF and others), activate MAP kinase
pathways. One of the most important and most well understood MAP kinase pathways
involved in normal and uncontrolled cell growth is the Ras/ Raf kinase pathway. Active
GTP-bound Ras results in the activation and indirect phosphorylation of Raf kinase. Raf
then phosphorylates MEK1 and 2 on two serine residues (S218 and S222 for MEK1 and
S222and S226 for MEK2) (Ann et al, Methods in Efizymology 2001, 332, 417-431).
Activated MEK then phosphorylates its only known substrates, the MAP kinases, ERK1
and 2. ERK phosphorylation by MEK occurs on Y204 and T202 for ERK1 and Yl 85 and
T183 for ERK2 (Abu et al., Methods in Enzymology 2001, 332,417-431). Phosphorylated
ERK dimerizes and then translocates to the nucleus where it accumulates (Khokhlatchev
et al, Cell 1998, 93, 605-615). In the nucleus, ERK is involved in several important
cellular functions, including but not limited to nuclear transport, signal transduction,
DNA repair, nucleosome assembly and translocation, and mRNA processing and
translation (Ahn et al, Molecular Cell 2000, 6, 1343-1354). Overall, treatment of cells with growth factors leads to the activation of ERKl and 2 which results in proliferation and, in some cases, differentiation (Lewis et al, Adv. Cancer Res. 1998, 74,49-139).
In proliferative diseases, genetic mutations and/or overexpression of the growth factor receptors, downstream signaling proteins, or protein kinases involved in the ERK kinase pathway lead to uncontrolled cell proliferation and, eventually, tumor formation. For example, some cancers contain mutations which result in the continuous activation of this pathway due to continuous production of growth factors. Other mutations can lead to defects in the deactivation of the activated GTP-bound Ras complex, again resulting in activation of the MAP kinase pathway. Mutated, oncogenic forms of Ras are found in 50% of colon and >90% pancreatic cancers as well as many others types of cancers (Kohl et al, Science 1993, 260, 1834-1837). Recently, bRaf mutations have been identified in more than 60% of malignant melanoma (Davies, H. et al, Nature 2002, 417, 949-954). These mutations in bRaf result in a constitutively active MAP kinase cascade. Studies of primary tumor samples and cell lines have also shown constitutive or overactivation of the MAP kinase pathway in cancers of pancreas, colon, lung, ovary and kidney (Hoshino, R. et al, Oncogene 1999, 18, 813-822). Hence, there is a strong correlation between cancers and an overactive MAP kinase pathway resulting from genetic mutations.
As constitutive or overactivation of MAP kinase cascade plays a pivotal role in
cell proliferation and differentiation, inhibition of this pathway is believed to be
beneficial in hyperproliferative diseases. MEK is a key player in this pathway as it is
downstream of Ras and Raf. Additionally, it is an attractive therapeutic target because
the only known substrates for MEK phosphorylation are the MAP kinases, ERKl and 2.
Inhibition of MEK has been shown to have potential therapeutic benefit in several studies.
For example, small molecule MEK inhibitors have been shown to inhibit human tumor
growth in nude mouse xenografts, (Sebolt-Leopold et al., Nature-Medicine 1999, δ (7), 810-816; Trachet et al., AACR April 6-10, 2002, Poster #5426; Tecle, H. IBC 2nd International Conference of Protein Kinases, September 9-10, 2002), block static allodynia in animals (WO 01/05390 published January 25, 2001) and inhibit growth of acute myeloid leukemia cells (Milella et al, J Clin Invest 2001,108 (6), 851-859).
Small molecule inhibitors of MEK have been disclosed. At least thirteen patent applications have appeared in the last several years: US δ,525,625 filed January 24,1995; WO 98/43960 published October 8, 1998; WO 99/01421 published January 14, 1999; WO 99/01426 pubUshed January 14, 1999; WO 00/41505 published July 20, 2000; WO 00/42002 published July 20, 2000; WO 00/42003 published July 20, 2000; WO 00/41994 published July 20, 2000; WO 00/42022 published July 20, 2000; WO 00/42029 pubUshed July 20, 2000; WO 00/68201 published November 16, 2000; WO 01/68619 published September 20, 2001; and WO 02/06213 pubUshed January 24,2002.
SUMMARY OF THE INVENTION
This invention provides for alkylated (lH-benzoimidazol-5-yl)-(4-substituted phenyl)-amine compounds of formula I, and pharmaceutically acceptable salts and prodrugs thereof that are useful in the treatment of hyperproliferative diseases. Specifically, the present invention relates to compounds of formula I that act as MEK inhibitors. Also provided is a method for treatment of cancer. Also provided are formulations containing compounds of formula I and methods of using the compounds to treat a patient in need thereof. In addition, there are described processes for preparing the inhibitory compounds of formula I.
Accordingly, the present invention provides compounds of the formula I:
(Formula removed)

and pharmaceutically accepted salts, prodrugs and solvates thereof, wherein:
is an optional bond, provided that one and only one nitrogen of the ring is double-bonded;
Rl, R2, R9 and R10 are independently selected from hydrogen, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -OR3, -C(O)R3, -C(O)OR3, NR4C(O)OR6, -OC(O)R3, -NR4SO2R6, -SO2NR3R4, -NR4C(O)R3, -C(O)NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -NR3R4, and
C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, -S(O)j(C1-C6 alkyl), -S(O)j(CR4R5)m-aryl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, -O(CR4R5)m-aryl, -NR4(CR4R5)m-aryl, -O(CR4R5)m-heteroaryl, -NR4(CR4R5)m-heteroaryl, -O(CR4R5)m-heterocyclyl and -HR4(CR4R5)m-heterocyclyl, where each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl portion is optionally substituted with one to five groups independently selected from oxo, halogen, cyano, nitro, trifhioromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR4SO2R6, -SO2NR3R4, -C(O)R3, -C(O)OR3, -OC(O)R3, -NR4C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -OR3, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R3 is selected from hydrogen, trifluoromethyl, and
C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, where each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl portion is optionally substituted with one to five groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NRSO2R"", -SO2NRR", -C(O)R, -C(O)OR, -OC(O)R, -NRC(O)OR"", -NRC(O)R", -C(O)NRR", -SR', -S(O)R"", -SO2R"", -NR'R", -NR'C(O)NR"R'", -NR'C(NCN)NR"R'", -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R', R" aad R'" independently are selected from hydrogen, lower alkyl, lower alkenyl,
aryl and arylalkyl;
R"" is selected from lower alkyl, lower alkenyl, aryl and arylalkyl; or
Any two of R', R", R'" or R"" can be taken together with the atom to which they are attached to form a 4 to 10 membered carbocyclic, heteroaryl or heterocyclic ring, each of which is optionally substituted with one to three groups independently selected from halogen, cyano, nitro, trifluoromethyl, difiuoromethoxy, trifmoromethoxy, azido, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; or
R3 and R4 can be taken together with the atom to which they are attached to form a 4 to 10 membered carbocyclic, heteroaryl or heterocyclic ring, each of which is optionally substituted with one to three groups independently selected from halogen, cyano, nitro, trifluoromethyl, difiuoromethoxy, trifmoromethoxy, azido, -NRSO2R"", -SO2NR'R", -C(O)R, -C(O)OR, -OC(O)R', -NRC(O)OR"", -NR'C(O)R", -C(O)NR'R",, -SO2R"", -NR'R", -NR'C(O)NR"R"', -NR'C(NCN)NR"R"', -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; or
R4 and R5 independently represent hydrogen or C1-C6 alkyl; or
R4 and R5 together with the atom to which they are attached form a 4 to 10 membered carbocyclic, heteroaryl or heterocyclic ring, each of which is optionally substituted with one to three groups independently selected from halogen, cyano, nitro, trifluoromethyl, difiuoromethoxy, trifluoromethoxy, azido, -NRSO2R"", -SO2NRR", -C(O)R""', -C(O)OR, -OC(O)R, -NR'C(O)OR"", -NR'C(O)R", -C(O)NRR", -SO2R"", -NR'R", -NR"C(O)NR"R"', -NR'C(NCN)NR"R"', -OR, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R6 is selected from trifluoromethyl, and
C1-C10 alkyl, C3-C10 cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, where each alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl portion is optionally substituted with one to five groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NRSO2R"", -SO2NRR", -C(O)R", -C(O)OR, -OC(O)R, -NR'C(O)0R"", -NR'C(O)R", -C(O)NRR", -SO2R"", -NR'R, -NR'C(O)NR"R"', -NR'C(NCN)NR"R"', -OR, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; R7 is selected from hydrogen, and
C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, where each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl portion is optionally substituted with one to five groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR4SO2R6, -SO2NR3R4, -C(O)R3, -C(O)OR3, -OC(O)R3, -NR4C(O)0R6, -NR4C(O)R3, -C(O)NR3R4, -SO2R6, -NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -OR3, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; W is selected from heteroaryl, heterocyclyl, -C(O)OR3, -C(O)NR3R4, -C(O)NR4OR3, -
C(O)R4OR3, -C(O)(C3-C10 cycloalkyl), -C(O)(C1-C10 alkyl), -C(O)(aryl), -
C(O)(heteroaryl) and -C(O)(heterocyclyl), each of which is optionally substituted
with 1-δ groups independently selected from
-NR3R4, -OR3, -R2, and
C1-C10 alkyl, C2-C10 alkenyl, and C2-C10 alkynyl, each of which is
optionally substituted with 1 or 2 groups independently selected
from - NR3R4 and-OR3;
R8 is selected from hydrogen, -SCF3, -C1, -Br, -F, cyano, nitro, trifluorometliyl,
difluoromethoxy, trifluoromethoxy, azido, -OR3, -C(O)R3, -C(O)OR3,
-NR4C(O)OR6, -OC(O)R3, -NR4SO2R6, -SO2NR3R4, -NR4C(O)R3, -C(O)NR3R4,
-NR5C(O)NR3R4, -NR3R4, and
C1-Cio alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyi, C3-C10 cycloalkylalkyl, -S(O)j(C1-C6 alkyl), -S(O)j(CR4R5)m-aryl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, -O(CR4R5)m-aryl, -NR4(CR4R5)m-aryl, -OCCRVWheteroaryl, -NR4(CR4R5)m-heteroaryl, -O(CR4R5)m-heterocyclyl and -NR4(CR4R5)m-heterocyclyl, where each alkyl, alkenyl, alkynyl, cycloalkyi, aryl, heteroaryl and heterocyclyl portion is optionally substituted with one to five groups independently selected from oxo, halogen, cyano, nitro, trifluorometliyl, difluoromethoxy, trifluoromethoxy, azido, -NR4SO2R6, -SO2NE3R4, -C(O)R3, -C(O)OR3, -OC(O)R3, -NR4C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -OR3, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; m is 0, 1, 2, 3, 4 or δ; and j is 1 or 2.
DETAILED DESCRIPTION OF THE INVENTION
The novel compounds encompassed by the instant invention are those described by the general formula I set forth above, and the pharmaceutically acceptable salts and prodrugs thereof.
The present invention also provides compounds of formula I in which R is C1-C10 alkyl, C3-C7 cycloalkyl, C3-C7 cycloalkylalkyl, C3-C7 heterocycloalkyl or C3-C7 heterocycloalkylalkyl each of which can be optionally substituted with 1-3 groups independently selected from oxo, halogen, cyano, nitro, trifiuoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR4SO2R6, -SO2NR3R4, -C(O)R3, -C(O)OR3, -0C(O)R3, -SO2R3, -NR4C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -OR3, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl.
The present invention also provides compounds of formula I wherein R8 is -OCF3, -Br or -CI, R2 is hydrogen, and R1 is lower alkyl or halogen.
The present invention also provides compounds of formula I wherein R9 is hydrogen or halogen, and R10 is hydrogen.
The present invention also provides compounds of formula I wherein W is -C(O)OR3 or -C(O)NR4OR3.
The present invention also provides compounds of formula II:
(Formula removed)
wherein W, R1, R7, R8, R9 and R10 are as defined above for formula I.
The present invention also provides compounds of formula II in which R7 is C1-C10 alkyl, C3-C7 cycloalkyl or C3-C7 cycloalkylalkyl, each of which can be optionally substituted with 1-3 groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR4SO2R6, -SO2NR3R4, -C(O)R3, -C(O)OR3, -OC(O)R3, -SO2R3, -NR4C(O)0R6, -NR4C(O)R3, -C(O)NR3R4, -NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -OR3, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl.
The present invention also provides compounds of formula II wherein R8 is -OCF3, -Br or -C1, and R1 is lower alkyl or halogen.
The present invention also provides compounds of formula II wherein R9 is hydrogen or halogen, and R10 is hydrogen.
The present invention also provides compounds of formula II wherein W is -C(O)OR3 or -C(O)NR4OR3.
The present invention also provides compounds of formula IE:
(Formula removed)
wherein R1, R2, R7, R8 and R9 are as defined above for formula I, and A is -OR3 or -NR4OR3, wherein R3 and R4 are as defined above for formula I.
The present invention also provides compounds of formula III in which R7 is C1-C10 alkyl, C3-C7 cycloalkyl or C3-C7 cycloalkylalkyl, each of which can be optionally substituted with 1-3 groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR4SO2R6, -SO2NR3R4, -C(O)R3, -C(O)OR3, -OC(O)R3, -SO2R3, -NR4C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -OR3, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl.
The present invention also provides compounds of formula III wherein R8 is -OCF3, -Br or -C1, R2 is hydrogen, and R1 is lower alkyl or halogen.
The present invention also provides compounds of formula III wherein R9 is hydrogen or halogen.
The present invention also provides compounds of formula III wherein R3 is hydrogen or lower alkyl when A is -OR3; and R4 is hydrogen when A is -NR4OR3.
The present invention also provides compounds of formula IIIa:
(Formula removed)

wherein R1, R2, R7, R8 and R9 are as defined above for formula I, and A is -OR3 or
-NR4OR3, wherein R3 and R4 are as defined above for formula I.
The present invention also provides compounds of formula IIIa in which R7 is C1-
C10 alkyl, C3-C7 cycloalkyl or C3-C7 cycloalkylalkyl, each of which can be optionally
substituted with 1-3 groups independently selected from oxo, halogen, cyano, nitro,
trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR4SO2R6, -SO2NR3R4, -C(O)R3, -C(O)OR3, -OC(O)R3, -SO2R3, -NR4C(O)0R6, -NR4C(O)R3, -C(O)NR3R4, -NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -OR3, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl.
The present invention also provides compounds of formula IIIa wherein R8 is -OCF3, -Br or -CI, R2 is hydrogen, and R1 is lower alkyl or halogen.
The present invention also provides compounds of formula IIIa wherein R is hydrogen or halogen.
The present invention also provides compounds of formula IIIa wherein R3 is hydrogen or lower alkyl when A is -OR3; and R4 is hydrogen when A is -NR4OR3.
The present invention also provides compounds of formula IIIb:

n(Formula removed)
wherein R1, R7, R8 and R9 are as defined above for formula I, and A is -OR3 or -NR4OR3, wherein R3 and R4 are as defined above for formula I.
The present invention also provides compounds of formula IIIb in which R7 is C1-C10 alkyl, C3-C7 cycloalkyl or C3-C7 cycloalkylalkyl, each of which can be optionally substituted with 1-3 groups independently selected from oxo, halogen, cyano, nitro, tiifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR4SO2R6, -SO2NR3R4, -C(O)R3, -C(O)OR3, -OC(O)R3, -SO2R3, -NR4C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -
NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -OR3, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl.
The present invention also provides compounds of formula IIIb wherein R is -OCF3, -Br or -CI, and R1 is lower alkyl or halogen.
The present invention also provides compounds of formula IIIb wherein R is fluoro or chloro.
The present invention also provides compounds of formula nib wherein R3 is hydrogen or lower alkyl when A is -OR3; and R4 is hydrogen when A is -NR4OR3.
Except as expressly defined otherwise, the following definition of terms is employed throughout this specification.
By "C1-C10 alkyl", "alkyl" and "lower alkyl" in the present invention is meant straight or branched chain alkyl groups having 1-10 carbon atoms, such as, methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, 3-methylpentyl, heptyl, octyl, and the like. Preferred alkyl radicals are C1-6 alkyl. More preferred alkyl radicals are C1-3 alkyl.
By "C2-C10 alkenyl", "lower alkenyl" and "alkenyl" means straight and branched hydrocarbon radicals having from 2 to 10 carbon atoms and at least one double bond and includes ethenyl, propenyl, l-but-3-enyl, l-pent-3-enyl, l-hex-5-enyl and the like. More preferred are lower alkenyl having 3-δ carbon atoms.
By "C2-C10 alkynyl", "lower alkynyl" and "alkynyl" means straight and branched hydrocarbon radicals having from 2 to 10 carbon atoms and at least one triple bond and includes ethynyl, propynyl, butynyl, pentyn-2-yl and the like. More preferred are alkynyl having 3-δ carbon atoms.
By the term "halogen" in the present invention is meant fluorine, bromine,
chlorine, and iodine.
By "aryl" is meant an aromatic carbocyclic group having a single ring (e.g., phenyl), multiple rings (e.g., biphenyl), or multiple condensed rings in which at least one is aromatic, (e.g., 1,2,3,4-tetrahydronaphthyl, naphthyl), which is optionally mono-, di-, or trisubstituted with, e.g., halogen, lower alkyl, lower alkoxy, trifluoromethyl, aryl, heteroaryl, and hydroxy.
By "heteroaryl" is meant one or more aromatic ring systems of δ-, 6-, or 7-membered rings which includes fused ring systems (at least one of which is aromatic) of δ-10 atoms containing at least one and up to four heteroatoms selected from nitrogen, oxygen, or sulfur. Examples of heteroaryl groups are pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, triazolyl, thiadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, and furopyridinyl. Spiro moieties are also included within the scope of this definition. Heteroaryl groups are optionally mono-, di-, or trisubstituted with, e.g., halogen, lower alkyl, lower alkoxy, haloalkyl, aryl, heteroaryl, and hydroxy.
As used herein, the term "carbocycle", "carbocyclyl", "cycloalkyl" or "C3-C10
cycloalkyl" refers to saturated carbocyclic radicals having three to ten carbon atoms. The
cycloalkyl can be monocyclic, or a polycyclic fused system, and can be fused to an
aromatic ring. Examples of such radicals include cyc10propyl, cyclobutyl, cyc10pentyl
and cyclohexyl. The cycloalkyl groups herein are unsubstituted or, as specified,
substituted in one or more substitutable positions with various groups. For example, such
cycloalkyl groups may be optionally substituted with, for example, C1-C6 alkyl, C1-C6
alkoxy, halogen, hydroxy, cyano, nitro, amino, mono(C1-C6)alkylamino, di(C1-
C6)alkylamino, C2-C6alkenyl, C2-C6alkynyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, amino(C1-C6)alkyl, mono(C1-C6)alkylamino(C1-C6)alkyl or di(C1-C6)alkylamino(C1-
C6)alkyl.
By "heterocycle" or "heterocyclyl" is meant one or more carbocyclic ring systems
of δ-, 6-, or 7-membered rings which includes fused ring systems of 4-10 atoms
containing at least one and up to four heteroatoms selected from nitrogen, oxygen, or
sulfur, and with the proviso that the ring of the group does not contain two adjacent O or
S atoms. A fused system can be a heterocycle fused to an aromatic group. Preferred
heterocycles include, but are not limited to, pyrrolidinyl, tetrahydrofuranyl,
dihydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, dihydropyranyl,
tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino, thioxanyl, piperazinyl,
homopiperazdnyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl,
oxazepinyl, diazepinyl, thiazepinyl, 1,2,3,6-tetrahydropyridinyl, 2-pyrrolinyl, 3-
pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl,
dithianyl, dithiolanyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl,
pyrazolidinylimidazolinyl, imidazolidinyl, 3-azabicyco[3.1.0]hexanyl, 3-
azabicyclo[4.1.0]heptanyl, azabicyclo[2.2.2]hexanyl, 3H-indolyl and quinolizinyl. Spiro
moieties are also included within the scope of this definition. The foregoing groups, as
derived from the groups listed above, may be C-attached or N-attached where such is
possible. For instance, a group derived from pyrrole may be pyrrol-1-yl (N-attached) or
pyrrol-3-yl (C-attached). Further, a group derived from imidazole may be imidazol-1-yl
(N-attached) or imidazol-3-yl (C-attached). An example of a heterocyclic group wherein
2 ring carbon atoms are substituted with oxo (=O) moieties is 1,1-dioxo-thiomorpholinyl.
The heterocycle groups herein are unsubstituted or, as specified, substituted in one or
more substitutable positions with various groups. For example, such heterocycle groups
may be optionally substituted with, for example, C1-C6 alkyl, C1-C6 alkoxy, halogen, hydroxy, cyano, nitro, amino, mono(C1-C6)alkylamuio, di(C1-C6)alkylamino, C2-C6alkenyl, C2-C6alkynyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, ammo(C1-C6)alkyl, mono(C1-C6)alkylamino(C1-C6)alkyl or m(C1-C6)alkylarnino(C1-C6)alkyl.
The term "arylalkyl" means an alkyl moiety (as defined above) substituted with one or more aryl moiety (also as defined above). More preferred arylalkyl radicals are aryl-C1-3-alkyls. Examples include benzyl, phenylethyl, and the like.
The term "heteroarylalkyl" means an alkyl moiety (as defined above) substituted with a heteroaryl moiety (also as defined above). More preferred heteroarylalkyl radicals are δ- or 6-membered heteroaryl-C1-3-alkyls. Examples include, oxazolylmethyl, pyridylethyl and the like.
The term "heterocyclylalkyl" means an alkyl moiety (as defined above) substituted with a heterocyclyl moiety (also defined above). More preferred heterocyclylalkyl radicals are δ- or 6-membered heterocyclyl-C1-3-alkyls. Examples include tetrahydropyranylmethyl.
The term "cycloalkylalkyl" means an alkyl moiety (as defined above) substituted with a cycloalkyl moiety (also defined above). More preferred heterocyclyl radicals are δ- or 6-membered cycloalkyl-C1-3-alkyls. Examples include cyc10propylmethyl.
The term "Me" means methyl, "Et" means ethyl, "Bu" means butyl and "Ac" means acetyl.
The phrase "pharmaceutically acceptable salt(s)", as used herein, unless otherwise
indicated, includes salts of acidic and basic groups which may be present in the
compounds of the present invention. The compounds of the present invention that are
basic in nature are capable of forming a wide variety of salts with various inorganic and
organic acids. The acids that may be used to prepare pharmaceutically acceptable acid
addition salts of such basic compounds of the present invention are those that form nontoxic acid addition salts, i.e., salts containing pharmaceutically acceptable anions, such as the acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edislyate, estolate, esylate, ethylsuccinate, fumarate, gluceptate, gluconate, giutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylsulfate, mucate, napsylate, nitrate, oleate, oxalate, pamoate (embonate), palimitate, pantothenate, phosphate/diphosphate, polygalacturonate, saUcylate, stearate, subacetate, succinate, tannate, tartrate, teoclate, tosylate, trietniodode, and valerate salts. Since a single compound of the present invention may include more than one acidic or basic moieties, the compounds of the present invention may include mono, di or tri-salts in a single compound.
In the case of an acidic moiety in a compound of the present invention, a salt may
be formed by treatment of a compound of the present invention with a basic compound,
particularly an inorganic base. Preferred inorganic salts are those formed with alkali and
alkaline earth metals such as lithium, sodium, potassium, barium and calcium. Preferred
organic base salts include, for example, ammonium, dibenzylammonium,
benzylammonium, 2-hydroxyethylammonium, bis(2-hydroxyethyl)ammonium,
phenylethylbenzylamine, dibenzyl-emylenediamine, and the like salts. Other salts of acidic moieties may include, for example, those salts formed with procaine, quinine and N-metnylglusoamine, plus salts formed with basic amino acids such as glycine, ornithine, histidine, phenylglycine, lysine and arginine. An especially preferred salt is a sodium or potassium salt of a compound of the present invention.
With respect to basic moieties, a salt is formed by the treatment of a compound of the present invention with an acidic compound, particularly an inorganic acid. Preferred inorganic salts of this type may include, for example, the hydrochloric, hydrobromic, hydroiodic, sulfuric, phosphoric or the like salts. Preferred organic salts of this type, may include, for example, salts formed with formic, acetic, succinic, citric, lactic, maleic, fumaric, palmitic, cholic, pamoic, mucic, D-glutamic, D-camphoric, glutaric, glycolic, phthalic, tartaric, lauric, stearic, salicyclic, methanesulfonic, benzenesulfonic, paratoluenesulfonic, sorbic, puric, benzoic, cinnamic and the like organic acids. An especially preferred salt of this type is a hydrochloride or sulfate salt of a compound of the present invention.
In the compounds of the present invention, where terms such as (CR4R5)m or (CR4R5), are used, R4 and R5 may vary with each iteration of m or t above 1. For instance, where m or t is 2, the terms (CR4R5)m or (CR4R5)t may equal -CH2CH2- or -CH(CH3)C(CH2CH3)(CH2CH2CH3)- or any number of similar moieties falling within the scope of the definitions of R4 and R5.
Certain compounds of the present invention may have asymmetric centers and therefore exist in different enantiomeric forms. All optical isomers and stereoisomers of the compounds of the present invention, and mixtures thereof, are considered to be within the scope of the invention. With respect to the compounds of the present invention, the invention includes the use of a racemate, one or more enantiomeric forms, one or more diastereomeric forms, or mixtures thereof. The compounds of the present invention may also exist as tautomers. This invention relates to the use of all such tautomers and mixtures thereof.
The subject invention also includes isotopically-labeled compounds, which are
identical to those recited in the present invention, but for the fact that one or more atoms
are replaced by an atom having an atomic mass or mass number different from the atomic
mass or mass number usually found in nature. Examples of isotopes that can be
incorporated into compounds of the invention include isotopes of hydrogen, carbon,
nitrogen, oxygen, phosphorous, sulfur, fluorine and chloride, such as H, 3H, I3C, ' C,
l5N, 18O, 17O, 31P, 32P, 35S, l8F, and 36C1, respectively. Compounds of the present
invention, prodrugs thereof, and pharmaceutically acceptable salts of said compounds or
of said prodrugs which contain the aforementioned isotopes and/or other isotopes of other
atoms are within the scope of this invention. Certain isotopically-labeled compounds of
the present invention, for example those into which radioactive isotopes such as 3H and
14C are incorporated, are useful in drug and/or substrate tissue distribution assays.
Tritiated, i.e., 3H and carbon-14, i.e., 14C, isotopes are particularly preferred for their ease
of preparation and detectability. Futher, substitution with heavier isotopes such as
deuterium, i.e., 2H, can afford certain therapeutic advantages resulting from greater
metabolic stability, for example increased in vivo half-life or reduced dosage
requirements and, hence, may be preferred in some circumstances. Isotopically labeled
compound of the present invention and prodrugs thereof can generally be prepared by
carrying out procedures disclosed in the Schemes and/or in the Examples and
Preparations below, by substituting a readily available isotopically labeled reagent for a
non-isotopically labeled reagent.
This invention also encompasses pharmaceutical compositions containing a
compound of formulas I-IIIb and methods of treating proliferative disorders, or abnormal
cell growth, by administering prodrugs of compounds of the the present invention.
Compounds of the present invention having free amino, amido, hydroxy or carboxylic
groups can be converted into prodrugs. Prodrugs include compounds wherein an amino
acid residue, or a polypeptide chain of two or more (e.g., two, three or four) amino acid
residues is covalently joined through an amide or ester bond to a free amino, hydroxy or carboxylic acid group of compounds of the present invention. The amino acid residues include but are not limited to the 20 naturally occurring amino acids commonly designated by three letter symbols and also includes 4-hydroxyprolrne, hydroxylysine, demosine, isodemosine, 3-methylhistidine, norvaline, beta-alanine, garrmia-aminobutyric acid, cirtulline, homocysteine, homoserine, ornithine and methionine sulfone. Additional types of prodrugs are also encompassed. For instance, free cafboxyl groups can be derivatized as amides or alkyl esters. Free hydroxy groups may be derivatized using groups including but not limited to hemisuccinates, phosphate esters, dimethylaminoacetates, and phosphoryloxymethyloxycarbonyls, as outlined in Advanced Drug Delivery Reviews 1996,19, 115. Carbamate prodrugs of hydroxy and amino groups are also included, as are carbonate prodrugs, sulfonate esters and sulfate esters of hydroxy groups. Derivatization of hydroxy groups as (acyloxy)methyl and (acyloxy)ethyl ethers wherein the acyl group may be an alkyl ester, optionally substituted with groups including but not limited to ether, amine and carboxylic acid functionalities, or where the acyl group is an amino acid ester as described above, are also encompassed. Prodrugs of this type are described in /. Med. Chem. 1996, 39, 10. Free amines can also be derivatized as amides, sulfonamides or phosphonamides. All of these prodrug moieties may incorporate groups including but not limited to ether, amine and carboxylic acid functionalities.
It is to be understood that in instances where two or more radicals are used in succession to define a substituent attached to a structure, the first named radical is considered to be terminal and the last named radical is considered to be attached to the structure in question. Thus, for example, the radical arylalkyl is attached to the structure in question by the alkyl group.
The invention also relates to a pharmaceutical composition for the treatment of a hyperproliferative disorder in a mammal which comprises a therapeutically effective amount of a compound of the present invention, or a phannaceutically acceptable salt, prodrug or hydrate thereof, and a pharmaceutically acceptable carrier. In one embodiment, said pharmaceutical composition is for the treatment of cancer such as brain, lung, squamous cell, bladder, gastic, pancreatic, breast, head, neck, renal, kidney, ovarian, prostate, colorectal, esophageal, testicular, gynecological or thyroid cancer. In another embodiment, said pharmaceutical composition is for the treatment of a noncancerous hyperproliferative disorder such as benign hyperplasia of the skin (e.g., psoriasis), restenosis, or prostate (e.g.,benign prostatic hypertrophy (BPH)).
The invention also relates to a pharmaceutical composition for the treatment of pancreatitis or kidney disease (including proliferative glomerulonephritis and diabetes-induced renal disease) or the treatment of pain in a mammal which comprises a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, prodrug or hydrate thereof, and a pharmaceutically acceptable carrier.
The invention also relates to a pharmaceutical composition for the prevention of blastocyte implantation in a mammal which comprises a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, prodrug or hydrate thereof, and a pharmaceutically acceptable carrier.
The invention also relates to a pharmaceutical composition for treating a disease
related to vasculogenesis or angiogenesis in a mammal which comprises a therapeutically
effective amount of a compound of the present invention, or a phannaceutically
acceptable salt, prodrug or hydrate thereof, and a pharmaceutically acceptable carrier. In
one embodiment, said pharmaceutical composition is for treating a disease selected from
the group consisting of tumor angiogenesis, chronic uiflarnmatory disease such as rheumatoid arthritis, atherosclerosis, inflammatory bowel disease, skin diseases such as psoriasis, excema, and scleroderma, diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma, glioma, melanoma, Kaposi's sarcoma and ovarian, breast, lung, pancreatic, prostate, colon and epidermoid cancer.
The invention also relates to a method of treating a hyperproliferative disorder in a mammal that comprises administering to said mammal a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, prodrug or hydrate thereof. In one embodiment, said method relates to the treatment of cancer such as brain, lung, squamous cell, bladder, gastic, pancreatic, breast, head, neck, renal, kidney, ovarian, prostate, colorectal, esophageal, testicular, gynecological or thyroid cancer. In another embodiment, said method relates to the treatment of a non-cancerous hyperproliferative disorder such as benign hyperplasia of the skin (e.g., psoriasis), restenosis, or prostate (e.g.,benign prostatic hypertrophy (BPH)).
The invention also relates to a method for the treatment of a hyperproliferative disorder in a mammal that comprises administering to said mammal a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, prodrug or hydrate thereof, in combination with an anti-tumor agent selected from the group consisting of mitotic inhibitors, alkylating agents, antimetabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzyme inhibitors, topoisomerase inhibitors, biological response modifiers, anti-hormones, angiogenesis inhibitors, and anti-androgens.
The invention also relates to a method of treating pancreatitis or kidney disease in
a mammal that comprises administering to said mammal a therapeutically effective
amount of a compound of the present invention, or a pharmaceutically acceptable salt, prodrug or hydrate thereof.
The invention also relates to a method of preventing blastocyte implantation in a mammal that comprises administering to said mammal a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, prodrug or hydrate thereof.
The invention also relates to a method of treating diseases related to vasculogenesis or angiogenesis in a mammal that comprises adrninistering to said mammal a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, prodrug or hydrate thereof. In one embodiment, said method is for treating a disease selected from the group consisting of tumor angiogenesis, chronic inflammatory disease such as rheumatoid arthritis, atherosclerosis, inflammatory bowel disease, skin diseases such as psoriasis, excema, and scleroderma, diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma, glioma, melanoma, Kaposi's sarcoma and ovarian, breast, lung, pancreatic, prostate, colon and epidermoid cancer.
Patients that can be treated with compounds of the present invention, or
pharmaceutically acceptable salts, prodrugs and hydrates of said compounds, according to
the methods of this invention include, for example, patients that have been diagnosed as
having psoriasis, restenosis, atherosclerosis, BPH, lung cancer, bone cancer, CMML,
pancreatic cancer, skin cancer, cancer of the head and neck, cutaneous or intraocular
melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region,
stomach cancer, colon cancer, breast cancer, testicular, gynecologic tumors (e.g., uterine
sarcomas, carcinoma of the fal10pian tubes, carcinoma of the endometrium, carcinoma of
the cervix, carcinoma of the vagina or carcinoma of the vulva), Hodgkin's disease, cancer
of the esophagus, cancer of the small intestine, cancer of the endocrine system (e.g., cancer of the thyroid, parathyroid or adrenal glands), sarcomas of soft tissues, cancer of the urethra, cancer of the penis, prostate cancer, chronic or acute leukemia, solid tumors of childhood, lymphocytic lymphomas, cancer of the bladder, cancer of the kidney or ureter (e.g., renal cell carcinoma, carcinoma of the renal pelvis), or neoplasms of the central nervous system (e.g., primary CNS lymphona, spinal axis tumors, brain stem gliomas or pituitary adenomas).
This invention also relates to a pharmaceutical composition for inhibiting abnormal cell growth in a mammal which comprises an amount of a compound of the present invention, or a pharmaceutically acceptable salt or solvate or prodrug thereof, in combination with an amount of a chemotherapeutic, wherein the amounts of the compound, salt, solvate, or prodrug, and of the chemotherapeutic are together effective in inhibiting abnormal cell growth. Many chemotherapeutics are presently known in the art. In one embodiment, the chemotherapeutic is selected from the group consisting of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, anti-hormones, angjogenesis inhibitors, and anti-androgens.
This invention further relates to a method for inhibiting abnormal cell growth in a mammal or treating a hyperproliferative disorder which method comprises administering to the mammal an amount of a compound of the present invention, or a pharmaceutically acceptable salt or solvate or prodrug thereof, in combination with radiation therapy, wherein the amounts of the compound, salt, solvate, or prodrug, is in combination with the radiation therapy effective in inhibiting abnormal cell growth or treating the hyperproliferative disorder in the mammal. Techniques for administering radiation
therapy are known in the art, and these techniques can be used in the combination therapy
described herein. The administration of the compound of the invention in this combination therapy can be determined, as described herein.
It is believed that the compounds of the present invention can render abnormal cells more sensitive to treatment with radiation for purposes of killing and/or inhibiting the growth of such cells. Accordingly, this invention further relates to a method for sensitizing abnormal cells in a mammal to treatment with radiation which comprises administering to the mammal an amount of a compound of the present invention or phamiaceutically acceptable salt or solvate or prodrug thereof, which amount is effective is sensitizing abnormal cells to treatment with radiation. The amount of the compound, salt, or solvate in this method can be determined according to the means for ascertaining effective amounts of such compounds described herein.
The invention also relates to a method of and to a pharmaceutical composition of inhibiting abnormal cell growth in a mammal which comprises an amount of a compound of the present invention, or a pharmaceutically acceptable salt or solvate thereof, a prodrug thereof, or an isotopically-labeled derivative thereof, and an amount of one or more substances selected from anti-angiogenesis agents, signal transduction inhibitors, and antiproliferative agents.
Anti-angiogenesis agents, such as MMP-2 (matrix-metal10protienase 2) inhibitors, MMP-9 (matrix-metal10protienase 9) inhibitors, and COX-II (cyclooxygenase H) inhibitors, can be used in conjunction with a compound of the present invention and pharmaceutical compositions described herein. Examples of useful COX-II inhibitors include CELEBREX™ (alecoxib), valdecoxib, and rofecoxib. Examples of useful matrix metal10protienase inhibitors are described in WO 96/33172 (published October 24, 1996), WO 96/27583 (published March 7, 1996), European Patent Application No. 97304971.1
(filed July 8, 1997), European Patent Application No. 99308617.2 (filed October 29,
1999), WO 98/07697 (published February 26, 1998), WO 98/03516 (published January 29, 1998), WO 98/34918 (published August 13, 1998), WO 98/34915 (published August 13, 1998), WO 98/33768 (published August 6, 1998), WO 98/30566 (published July 16, 1998), European Patent Publication 606,046 (published July 13, 1994), European Patent Publication 931,788 (published July 28, 1999), WO 90/05719 (published May 31, 1990), WO 99/52910 (published October 21, 1999), WO 99/52889 (published October 21, 1999), WO 99/29667 (published June 17, 1999), PCT International Application No. PCT/B98/01113 (filed July 21, 1998), European Patent Application No. 99302232.1 (filed March 25, 1999), Great Britain Patent Application No. 9912961.1 (filed June 3, 1999), United States Provisional Application No. 60/148,464 (filed August 12, 1999), United States Patent δ,863,949 (issued January 26, 1999), United States Patent δ,861,510 (issued January 19, 1999), and European Patent Publication 780,386 (published June 25, 1997), all of which are incorporated herein in their entireties by reference. Preferred MMP-2 and MMP-9 inhibitors are those that have little or no activity inhibiting MMP-1. More preferred, are those that selectively inhibit MMP-2 and/or MMP-9 relative to the other matrix-metal10proteinases (i.e., MMP-1, MMP-3, MMP-4, MMP-δ, MMP-6, MMP-7, MMP-8, MMP-10, MMP-11, MMP-12, and MMP-13).
Some specific examples of MMP inhibitors useful in the present invention are AG-3340, RO 32-3555, and RS 13-0830.
The terms "abnormal cell growth" and "hyperproliferative disorder" are used interchangeably in this application.
"Abnormal cell growth", as used herein, unless otherwise indicated, refers to cell growth that is independent of normal regulatory mechanisms (e.g., loss of contact inhibition). This includes, for example, the abnormal growth of: (1) tumor cells (tumors)
that proliferate by expressing a mutated tyrosine kinase or overexpression of a receptor
tyrosine kinase; (2) benign and malignant cells of other proliferative diseases in which aberrant tyrosine kinase activation occurs; (3) any tumors that proliferate by receptor tyrosine kinases; (4) any tumors that proliferate by aberrant serine/threonine kinase activation; and (δ) benign and malignant cells of other proliferative diseases in which aberrant serine/theroine kinase activation occurs.
The term "treating", as used herein, unless otherwise indicated, means reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition. The term "treatment", as used herein, unless otherwise indicated, refers to the act of treating as "treating" is defined immediately above.
Representative compounds of the present invention, which are encompassed by the present invention include, but are not limited to the compounds of the examples and their pharmaceutically acceptable acid or base addition salts or prodrugs thereof.
The examples presented below are intended to illustrate particular embodiments of the invention, and are not intended to limit the scope of the specification or the claims in any way.
An illustration of the preparation of compounds of the present invention is shown in Schemes 1-4.
(Formula removed)
General synthetic methods which may be referred to for preparing some of the compounds of the present invention are provided in PCT published apphcation number WO 00/42022 (published July 20, 2000). The foregoing patent apphcation is incorporated herein by reference in its entirety.
The examples presented below are intended to illustrate particular embodiments of the invention, and are not intended to limit the scope of the specification or the claims in any way.
An illustration of the preparation of compounds of the present invention is shown in Schemes 1-4.
Scheme 1 illustrates the synthesis of compounds of the present invention. In step 1, the acid is nitrated using standard conditions preferable fuming nitric acid in H2SO4. In step 2, the aniline is prepared by fluoride displacement with NH4OH at room
temperature in water followed by careful acidification with concentrated mineral acid to pH near 0. In step 3, the ester is prepared by standard methods including by not limited to Fisher Esterification (MeOH, H2SO4), and reaction with TMSCHN2 in suitable organic solvents like PhMe/MeOH or THF/MeOH. In step 4, the dianilino derivative is prepared by heating (60 to 200 °C) the ester with an excess of the appropriate aniline neat or in an organic solvent like xylenes. For example, when Rl = Me and R2 = H the preferred method is stirring the ester with 10 equivalents aniline in xylenes at reflux until complete reaction. In step δ, the nitro arene is reduced to produce the diamine by standard reduction conditions, including by not limited to H2, and Pd/C or Pd(OH)2/C or Raney Nickel in organic solvent like EtOH or THF, Fe in AcOH, Zn in AcOH or Zn, NH4CI (aq) in MeOH. In step 6, the diamine is cyclization by heating with formic acid neat or formamidine acetate in an appropriate solvent like EtOH. Alternatively, when R1 or R2 does not equal halo the nitro arene can be converted directly to the benzimidazole in step 7 by heating in formic acid with Pd(OH)2/C or other palladium source like Pd/C. In step 8, a halide can be incorporated by standard methods, including but not limited to NBS or NCS and pTsOH in organic cosolvents like THF and MeOH. In step 9, the benzimidazole is alkylated to give a near equal mixture of Nl and N3 products which are separable by standard techniques, including, for example, chromatography and trituration. The alkylation is accomplished by use of an alkylating agent like an alkyl halide and base like NaH, or K2CO3 in suitable organic solvent like DMF or THF at temperatures ranging from 0 to 80 °C. R7 can be further modified by various synthetic methods known in the art, as exemplified below. In step 10, the ester is hydrolysized by standard saponification methods. The acid is then converted to the desired hydroxamate in step 11 by standard coupling procedures including but not limited to EDCI, HOBt or PyBOP and the
appropriate hydroxylamine in suitable organic solvents like DMF, THF or methylene chloride.
Scheme 2 illustrates an example in which the R8 substituent is on the aniline prior to the coupling procedure with the nitro ester. The reaction description is exactly like that for Scheme 1 except that there is no need to incorporated R8 as it is present in the aniline from the beginning.
In Scheme 3, the preparation of N3 alkyl amino benzimidazole derivatives is illustrated. In step 1, the terminal alkene of the N3 alkylated benzimidazole hydroxamate is dihydroxylated using a suitable oxidant like OsO4 in suitable solvent or KMnO4 or I2, AgOAc, AcOH, water. The diol is then further oxidized in step 2 by NalO4 or Pb(OAc)4 in suitable biphasic mixture to give the aldehyde. Alternatively (step 3), the alkene can be directly converted to the aldehyde by standard methods including but not limited to ozone/Me2S, NaI(VOSO4 or KMNO4. In step 4, the amine is prepared by reductive amination using standard methods such as Na(CN)BH3, Na(OAc)3BH, NMe4BH(OAc)3 with or without AcOH in a suitable solvent such as methylene chloride, acetonitrile or THF. The preferable reduction amination is to treat the aldehyde with amine, Me4NBH(OAc)3 and acetic acid in MeCN at room temperature.
Scheme 4 illustrates the preparation of compounds of the present invention where
W is heterocyclic. In step 1, the methyl ester is converted to the hydrazide by stirring
with hydrazine in a suitable solvent like EtOH at temperatures from 50 to 100 °C. The
desired heterocyclic derivative is then prepared by cyclization with the appropriate
reagent. For oxadiazole 21 the hydrazide is treated with an orthoformate like triethyl
orthoformate, and an acid catalyst like pTsOH in a suitable organic solvent like EtOH at
elevated temperatures (50 - 100 °C). For hydroxy oxadiazole 22 the hydrazide can be
cyclized with phosgene or a phosgene equivalent like triphosgene or carbonyl diimidazole
in a suitable organic solvent like toluene at temperatures ranging from 50 to 120 °C. The mercapto oxadizaole 23 can be prepared by reaction with carbon disulfide, and base like KOH in suitable organic solvent like EtOH at elevated temperatures (50 - 100 °C). The amino oxadiazole 24 can be made by reaction with BrCN and base like NaHCO3, in a suitable biphasic solvent system like dioxane and water at room temperature. Finally, the substituted amino oxadiazole 25 can be prepared by first reacting the hydrazide with an appropriate isothiocyanate in a suitable organic solvent like DMF or THF at temperatures ranging from 25 to 100 °C. The intermediate can be isolated or can be cyclized directly with the treatment of EDCI or other carbodiimide in suitable organic solvent like THF or DMF at temperatures ranging from room temperature to 80 °C.
In Scheme δ, the preparation of keto benzimidazole derivatives are illustrated. In step 1, the methyl ester is converted to the benzyl alcohol by standard reductive methods, preferably LAH in THF at 0 °C or NaBH4 in EtOH:THF at room temperature. Oxidation to the aldehyde can be accomplished in step 2 using MNO2 in acetone:THF at 50 °C. In step 3, organometallic reageants, such as organolithium reagents and Grignard reagents, can be added to the aldehyde in THF at low temperature (e.g., -78 °C) to give the substituted benzyl alcohol. The keto derivatives can be prepared in step 4 by oxidation of the benyzl alcohol under standard conditions such as Swern or Dess-Martin oxidation.
The compounds of the present invention may have asymmetric carbon atoms.
Diastereomeric mixtures can be separated into their individual diastereomers on the basis
of their physical chemical differences by methods known to those skilled in the art, for
example, by chromatography or fractional crystallization. Enantiomers can be separated
by converting the enantiomer mixture into a diastereomeric mixture by reaction with an
appropriate optically active compound (e.g., alcohol), separating the diastereomers and
converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure
enantiomers. All such isomers, including diastereomeric mixtures and pure enantiomers are considered as part of the invention.
The activity of the compounds of the present invention may be determined by the following procedure. l N-terminal 6 His-tagged, constitutively active MEK1 (2-393) is expressed in E. coli and protein is purified by conventional methods (Ahn et ah, Science 1994, 265, 966-970). The activity of MEK1 is assessed by measuring the incorporation of y-33P-phosphate from y-33P-ATP onto N-terminal His tagged ERK2, which is expressed in E. coli and is purified by conventional methods, in the presence of MEK1. The assay is carried out in 96-well polypropylene plate. The incubation mixture (100 \xL) comprises of 25 mM Hepes, pH 7.4, 10 mM MgCl2, δ mM p-glycerolphosphate, 100 uM Na-orthovanadate, δ mM DTT, δ nM MEK1, and 1 uM ERK2. Inhibitors are suspended in DMSO, and all reactions, including controls are performed at a final concentration of 1% DMSO. Reactions are initiated by the addition of 10 uM ATP (with 0.δ uCi y-33P-ATP/well) and incubated at ambient temperature for 45 minutes. Equal volume of 25% TCA is added to stop the reaction and precipitate the proteins. Precipitated proteins are trapped onto glass fiber B filterplates, and excess labeled ATP washed off using a Tomtec MACH III harvestor. Plates are allowed to air-dry prior to adding 30 ul/well of Packard Microscint 20, and plates are counted using a Packard TopCount. In this assay, compounds of the invention exhibited an IC50 of less than 50 micromolar.
The following compounds exemplify compounds of such activity.
(Table removed)

Administration of the compounds of the present invention (hereinafter the "active compound(s)") can be effected by any method that enables delivery of the compounds to the site of action. These methods include oral routes, intraduodenal routes, parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion), topical, and rectal administration.
The amount of the active compound administered will be dependent on the subject being treated, the severity of the disorder or condition, the rate of administration, the disposition of the compound and the discretion of the prescribing physician. However, an effective dosage is in the range of about 0.001 to about 100 mg per kg body weight per day, preferably about 1 to about 35 mg/kg/day, in single or divided doses. For a 70 kg human, this would amount to about 0.05 to 7 g/day, preferably about 0.05 to about 2.δ g/day. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, provided that such larger doses are first divided into several small doses for administration throughout the day.
The active compound may be applied as a sole therapy or may involve one or more other anti-tumor substances, for example those selected from, for example, mitotic inhibitors, for example vinblastine; alkylating agents, for example cis-platin, carboplatin and cyc10phosphamide; anti-metabolites, for example δ-fluorouracil, cytosine arabinside and hydroxyurea, or, for example, one of the preferred anti-metabolites disclosed in European Patent Application No. 239362 such as N-(δ-[N-(3,4-dihydro-2-methyl-4-
oxoqumazolm-6-ylmethyl)-N-methylarmno]-2-thenoyl)-L-glutamic acid; growth factor
inhibitors; cell cycle inhibitors; intercalating antibiotics, for example adriamycin and
bleomycin; enzymes, for example, interferon; and anti-hormones, for example anti-
estrogens such as NolvadexTM (tamoxifen) or, for example anti-androgens such as
CasodexTM (4'-cyano-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methyl-3'-
(trifluoromethyl)propionanilide). Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate dosing of the individual components of treatment.
The pharmaceutical composition may, for example, be in a form suitable for oral administration as a tablet, capsule, pill, powder, sustained release formulations, solution, suspension, for parenteral injection as a sterile solution, suspension or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository. The pharmaceutical composition may be in unit dosage forms suitable for single administration of precise dosages. The pharmaceutical composition will include a conventional pharmaceutical carrier or excipient and a compound according to the invention as an active ingredient. In addition, it may include other medicinal or pharmaceutical agents, carriers, adjuvants, etc.
Exemplary parenteral administration forms include solutions or suspensions of active compounds in sterile aqueous solutions, for example, aqueous propylene glycol or dextrose solutions. Such dosage forms can be suitably buffered, if desired.
Suitable pharmaceutical carriers include inert diluents or fillers, water and various
organic solvents. The pharmaceutical compositions may, if desired, contain additional
ingredients such as flavorings, binders, excipients and the like. Thus for oral
administration, tablets containing various excipients, such as citric acid may be employed
together with various disintegrants such as starch, alginic acid and certain complex
silicates and with binding agents such as sucrose, gelatin and acacia. Additionally,
lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often useful for tableting purposes. Solid compositions of a similar type may also be employed in soft and hard filled gelatin capsules. Preferred materials, therefore, include lactose or milk sugar and high molecular weight polyethylene glycols. When aqueous suspensions or elixirs are desired for oral administration the active compound therein may be combined with various sweetening or flavoring agents, coloring matters or dyes and, if desired, emulsifying agents or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerin, or combinations thereof.
Methods of preparing various pharmaceutical compositions with a specific amount of active compound are known, or will be apparent, to those skilled in this art. For examples, see Remington's Pharmaceutical Sciences. Mack Publishing Company, Ester, Pa., 15th Edition (1975).
The examples and preparations provided below further illustrate and exemplify the compounds of the present invention and methods of preparing such compounds. It is to be understood that the scope of the present invention is not limited in any way by the scope of the following examples and preparations. In the following examples molecules with a single chiral center, unless otherwise noted, exist as a racemic mixture. Those molecules with two or more chiral centers, unless otherwise noted, exist as a racemic mixture of diastereomers. Single enantiomers/diastereomers may be obtained by methods known to those skilled in the art.
The disclosures in this application of all articles and references, including patents, are incorporated herein by reference.
The invention is illustrated further by the following examples which are not to be
construed as limiting the invention in scope or spirit to the specific procedures described
in them.
The starting materials and various intermediates may be obtained from commercial sources, prepared from commercially available organic compounds, or prepared using well known synthetic methods.
Representative examples of methods for preparing intermediates of the invention are set forth below.
Examples Example 1
(Formula removed)

7-Fluoro-6-(4-bromo-2-methyl-phenylamino)-3H-benzpiniidazole-5-carboxylicacid
cyc10propylmethoxy-amide (11a)
Step A: 2,3,4-Trifluoro-5-nitro-benzoic acid 2
A 3 liter three neck round bottom flask is charged with 125 ml H2SO4. Fuming nitric acid is added (8.4 ml, 199 mmol) and the mixture gently stirred. 2,3,4-Trifluorobenzoic acid 1 (25 g, 142 mmol) is added in δ g portions over 90 minutes. The dark brownish yellow solution is stirred for 60 min at which time the reaction is complete. The reaction mixture is poured into 1 liter of an icerwater mixture and extracted with diethyl ether (3 x 600 ml). The combined organic extracts are dried (MgSO4) and concentrated under reduced pressure to give a yellow solid. The solid is suspended in hexanes and stirred for 30 min after which time it is filtered to give 29 g (92%) of clean desired product as an off-yellow solid: MS APCI (-) m/z 220 (M-l) detected.
Step B: 4-Amino-2,3-difluoro-5-nitro-benzoic acid 3
Ammonium hydroxide solution (~30% in water) (35 ml, 271 mmol) is added to a solution of 2,3,4-trifluoro-5-nitro-benzoic acid 2 (15 g, 67.8 mmol) in 30 ml water at 0 °C with stirring. Upon completion of ammonium hydroxide addition the reaction mixture is
warmed to room temperature with stirring. After 2.δ h, the reaction mixture is cooled to 0 °C and concentrated HC1 is carefully added until pH of reaction mixture is near 0. The reaction mixture is diluted with water (30 ml) and extracted with diethyl ether (3 x 50 ml). The combined organic extracts are dried (MgSO4) and concentrated under reduced pressure to give 14 g (95%) of pure desired product: MS APCI (-) m/z 211 (M-l) detected.
Step C: 4-Amino-2,3-difluoro-5-nitro-benzoic acid methyl ester 4
A 2 M solution of TMS diazomethane in hexanes (6.88 ml, 13.75 mmol) is added to a suspension of 4-amino-2,3-difluoro-5-nitro-benzoic acid 3 (2.00 g, 9.17 mmol) in 25 ml of 4:1 THF:MeOH at 0 °C under nitrogen atmosphere. Upon completion of addition, reaction mixture is warmed to room temperature. After 0.δ h, excess TMS diazomethane is destroyed by the careful addition of acetic acid. The reaction is then concentrated under reduced pressure and dried in vacuo to give 1.95 g (92%) of pure desired product: MS APCI (-) m/z 231 (M-l) detected.
Step D: 4-Amino-3-fluoro-5-nitro-2-o-tolylamino-benzoic acid methyl ester 5a
4-Amino-2,3-difluoro-5-nitro-benzoic acid methyl ester 4 (12.0 g, 51.7 mmol) is suspended in xylenes (60 ml) and ortho-toluidine is added (55.2 ml, 517 mmol). The reaction mixture is heated to reflux with stirring under a nitrogen atmosphere. After 36 h, the reaction mixture is cooled to room temperature, diluted with diethyl ether and washed with 10% aqueous HC1 solution. The aqueous washings are extracted with diethyl ether. The combined organic extracts are concentrated under reduced pressure. The residue is dissolved in methylene chloride and filtered through silica gel in a fritted funnel, rinsing
with methylene chloride. Three fractions are recovered. The first (2 Uter) is nearly clean by HPLC. The second (1 liter) and third (1 liter) fractions are only partially pure. The first fraction is concentrated under reduced pressure and triturated with diethyl ether to give 11.2 g (68%) of clean desired product as a bright yellow solid: MS APCI (-) m/z 318 (M-l) detected.
Step E: 7-Fluoro-6-o-tolylamino-lH-benzoimidazole-5-carboxylic acid methyl ester 7a
4-Arnmo-3-fluoro-5-nifro-2-o-tolylamino-benzoic acid methyl ester 5a (1.57 g, 4.92 mmol), formic acid (25 ml, 26.δ mmol) and 20% Pd(OH)2/C (1.57 g, 2.95 mmol) in 25 ml EtOH are heating with stirring to 95 °C. After 16 h, the reaction mixture is cooled to room temperature and 0.δ g 20% Pd(OH)2/C and 10 ml formic acid added. The reaction mixture is heated to 95 °C with stirring. After 16 h, the reaction mixture is cooled to room temperature and filtered through Celite rinsing with EtOH. The filtrate is concentrated under reduced pressure until the desired product precipitates. The desired product is collected by filtration. The filtrate is concentrated again until more desired product precipitates. The product is collected by filtration. Repeated EtOH concentration, product filtration several times. Recovered 1.09 g (74%) pure desired product: MS APCI (+) m/z 300 (M+l) detected; MS APCI (-) m/z 298 (M-l) detected.
Step F: 7-Fluoro-6-(4-brorno-2-methyl-phenylamino)-lH-benzoimidazole-5-carboxylic acid methyl ester 8a
7-Fluoro-6-o-tolylammo-lif-benzoimidazole-5-carboxylic acid methyl ester 7a (2.00 g, 6.68 mmol) is suspended in 1:1 THF:MeOH mixture (60 ml) and cooled to -78 °C under a nitrogen atmosphere. A solution of NBS (1.20 g, 6.75 mmol) in 1:1
THF/MeOH (δ ml) is added followed by a MeOH (δ ml) solution of TsOHH2O (1.9 g, 10.0 mmol). After 30 minutes, the reaction mixture is warmed to 0 °C and then after 1 h warmed to rt. After 16 h, more NBS (0.12 g, 0.67 mmol) is added and the reaction mixture is allowed to stir for 3 h. The reaction mixture is quenched by the addition of 10% Na2S2O4 solution. After 30 min, the reaction mixture is diluted with water and ethyl acetate and the layers separated. The aqueous layer is extracted with ethyl acetate. The combined organic extracts are dried (Na2SO4) and concentrated under reduced pressure. The recovered solid is triturated with methylene chloride to give 2.00 g (79%) pure desired product: MS APCI (+) m/z 380, 378 (M+l Br partem) detected.
Step G: 7-Fluoro-6-(4-bromo-2-methyl-phenylamitio)-lH-benzoimidazole-5-carboxylic acid 10a
7-Fluoro-6-(4-bromo-2-memyl-phenylammo)-lF-benzoimidazole-5-carboxylic acid methyl ester 8a (63 mg, 0.167 mmol) is suspended in MeOH (1.δ ml) and 20% NaOH (400 µ1) is added. After 16 h, the reaction mixture is cooled to 0 °C and 1 N HC1 solution is added dropwise until pH is 2 to 3. The reaction mixture is diluted with ethyl acetate and water and the layers separated. The organic layer is washed with brine, dried (Na2SO4) and concentrated under reduced pressure to give 58 mg (95%) of desired product: MS APCI (+) m/z 366, 364 (M+l Br pattern) detected; MS APCI (-) m/z 364, 362 (M-l Br pattern) detected.
Step H: 7-Fhioro-6-(4-bromo-2-methyl-phenylamino)-lH-benzoimidazole-5-carboxylic acid cyc10propylmethoxy-amide 11a 7-Fluoro-6-(4-bromo-2-memyl-phenylammo)-lH-benzoimidazole-5-carboxylic acid 10a
(48 mg, 0.132 mmol) is dissolved in 1:1 THF: methylene chloride (1 ml) and Hunig's base (0.23 µ1, 1.32 mmol) is added followed by PyBOP (82 mg, 0.158 mmol). After a few minutes, cyc10propyl methyl hydroxylamine hydrochloride (20 mg, 0.158 mmol) (WO 0042022) is added. After the reaction is complete, the mixture is partitioned between methylene chloride and saturated NaHCO3 solution. The layers are separated and the organic layer is washed with saturated NaHCO3 and brine. The organic layer is dried (Na2SO4) and concentrated under reduced pressure. After purification by FCC (elute with 20:1 methlene chloride:MeOH), 25 mg (45%) of pure desired product is isolated: MS ESI (+) m/z 435, 433.(M+l Br pattern) detected; MS ESI (-) m/z 433, 431 (M-l Br pattern) detected; lE NMR (400MHz, CDC13) δ 8.15 (s, 1H), 8.02 (s, 1H), 7.28 (s, 1H), 7.43 (d, 1H), 7.07 (dd, 1H), 6.36 (m, 1H), 3.70 (d, 2H), 2.38 (s, 3H), 0.86 (m, 1H), 0.41 (m, 2H), 0.13 (m, 2H); 19F NMR (376MHz, CDC13) -134.05 (s).
Example 2
(Formula removed)

7-Fluoro-6-phenylamino-3H-benzoimidazole-5-carboxylic acid methyl ester (27a) Step A: 4-Amino-3-fluoro-5-nitro-2-phenylamino-benzoic acid methyl ester 26a
4-Amino-2,3-difluoro-5-nitro-benzoic acid methyl ester 4 (23.48 g, 101.1 mmol), the product of Example 1, Step C, is suspended in xylenes (125 mL) and aniline (92 mL, 1011 mmol) is added. The reaction mixture is stirred at 125 °C for 16 hours under N2. The reaction mixture is cooled to room temperature and solids precipitate out of solution. The solids are collected by filtration and are washed with xylenes and then diethyl ether.
Recovered 22.22 g (72.78 mmol) of yellow solid which is pure desired product The filtrate is concentrated under reduced pressure, redissolved in methylene chloride and flushed through a plug of silica gel eluting with methylene chloride. The desired fractions are concentrated under reduced pressure to give a brown solid which is triturated with diethyl ether to give δ.47 g (17.91 mmol) of yellow solid which is pure desired product. Combined product yield is 27.69 g (90%). MS APCI (-) m/z 304 (M-l) detected.
Step B: 7-Fluoro-6-phenylamino~3H-benzoimidazole-5-carboxylic acid methyl ester 27a
4-Amino-3-fluoro-5-nitro-2-phenylamino-benzoic acid methyl ester 26a (16.70 g, 54.71 mmol), formic acid (250 mL, 6.63 mol) and 20% Pd(OH)2/C (9.00 g, 16.91 mmol) in ethanol (250 mL) are stirred at 40 °C for two hours under N2 and then at 95 °C for 16 hours. The reaction mixture is cooled to room temperature and filtered through Celite rinsing with ethyl acetate. The filtrate is concentrated under reduced pressure to give a yellow solid. The solid is triturated with diethyl ether to give 13.47 g (86%) of the desired product as a tan solid. MS APCI (+) m/z 286 (M+l) detected; MS APCI (-) m/z 284 (M-l) detected.
6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3H-benzoimidazole-5-carboxylicacid
methyl ester (8b)
Al
Example 3
(Formula removed)
Step A: 6-(4-Bromo-phenylamino)- 7-fluoro-3H-benzoimidazole-5-carboxyIic acid methyl
ester 28a
7-Fluoro-6-phenylamino-3H-beraoirnidazole-5-carboxylic acid methyl ester 27a (4.99 g, 17.51 mmol) is dissolved in N,N-dimethylformarnide (275 mL). N-bromosuccinimide (3.15 g, 17.70 mmol) is added as a solid and the reaction mixture is stirred at room temperature under N2. After 30 min, the reaction mixture is quenched by the addition of aqueous saturated sodium bisulfite solution. The reaction mixture is then poured into a separatory funnel, diluted with water and ethyl acetate and the layers separated. The aqueous layer is extracted with ethyl acetate. The combined organic extracts are washed three times with water, once with brine and men are dried (Na2SO4) and concentrated under reduced pressure to yield 6.38 g (100%) of the pure desired product as a tan solid. MS ESI (+) m/z 364,366 (M+ Br pattern) detected.
Step B: 6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3H-benzoimidazole-5-carboxylic acid methyl ester 8b
6-(4-Bromo-phenylammo)-7-fluoro-3H-benzoimidazole-5-carboxylic acid methyl ester 28a (6.38 g, 17.51 mmol) is dissolved in N,N-dimethylformamide (275 mL). N-chlorosuccinimide (2.36 g, 17.70 mmol) is added as a solid and the reaction mixture is stirred at room temperature under N2 until the reaction is complete (δ-6 days). The reaction mixture is quenched by the addition of aqueous saturated sodium bisulfite solution to give a suspension. The resulting solids are collected by filtration, washed with water and diethyl ether and dried under reduced pressure to yield 6.07 g (87%) of the pure desired product as a beige solid. MS ESI (+) m/z 398,400 (M+ Br pattern) detected.
Example 4
(Formula removed)

6-(2,4-Dichloro-phenylamino)-7-fluoro-3H-benzoimidazole-5-carboxylic acid
methyl ester (8c)
7-Fluoro-6-phenylamino-3H-benzoimidazole-5-carboxylic acid methyl ester 27a (1.00 g, 3.51 mmol) is suspended in 1:1 tetrahydromran/methanol (20 mL) and cooled to -78 °C under N2. TsOHH2O (3.00 g, 10.50 mmol) is added followed by N-chlorosuccinimide (0.95 g, 7.08 mmol). After 10 minutes, the reaction mixture is warmed to 0 °C to give a solution and then 30 min later warmed to room temperature. After stirring for 16 hours, the reaction is complete. The reaction mixture is quenched by the addition of aqueous saturated sodium bisulfite solution and diluted with ethyl acetate and water and the layers separated. The aqueous layer is extracted with ethyl acetate. The combined organic extracts are washed with brine, dried (Na2SO4) and concentrated under reduced pressure. The resulting solid residue is triturated with methylene chloride to yield a white solid which is collected by filtration to yield 1.05 g (85%) of the pure desired product. MS ESI (+) m/z 355, 357 (M+ CI pattern) detected.
6-(4-Bromo-2-fluoro-phenylamino)-7-fluoro-3H-benzoimidazole-5-carboxylicacid
(Formula removed)

methyl ester (8d)
Step A: 4-Amino-3-fluoro-2-(2-fluoro-phenylamino)-5-nitro-benzoic acid methyl ester 5b
4-Amino-2,3-difluoro-5-nitro-benzoic acid methyl ester 4 (1.50 g, 6.46 mmol) is suspended in xylenes (7.δ mL) and 2-fluoro-phenylamine (6.24 mL, 64.6 mmol) is added. The reaction mixture is stirred at 140 °C under N2. After stirring for 6 days, the reaction is complete. The reaction mixture is cooled to room temperature and diluted with methylene chloride and filtered through a silica gel plug eluting with methylene chloride (1L) to give an orange filtrate. The filtrate is concentrated to dryness and then triturated with diethyl ether to yield a bright yellow solid. The trituration is repeated. The yellow solid is collected to yield 1.08 g (52%) of the pure desired product. MS APCl (-) m/z 322 (M-l) detected.
Step B: 6-(4-Bromo-2-fluoro-phenylamino)- 7-fluoro-3H-benzoimidazole-5-carboxylic acid methyl ester 8d
4-Amino-3-fluoro-2-(2-fluoro-phenylamino)-5-nitro-benzoic acid methyl ester 5b is converted by the reduction/cyclization and bromination procedures already described to yield the desired product. MS ESI (+) m/z 382, 384 (M+, Br pattern) detected.
Example 6
(Formula removed)
6-(4-Chloro'2-methyl-phenylamino)-7-fluoro-3H-benzoimidazole-5-carboxylicacid
methyl ester (He)
7-Fluoro-6-o-tolylammo-3H-benzoimidazole-5-carboxylic acid methyl ester 7a is
converted by the procedure already described for bromination, except N-chloiosuccinimide is used instead of N-bromosuccinirnide, to yield the desired product. MS ESI (+) m/z 334, 336 (M+, CI pattern) detected.
(Formula removed)

7-Fluoro-6-(2-methyl-4-trifluoromethoxy-phenylamino)-3H-benzoimidazole-5-carboxylic acid methyl ester (8J)
Step A. 4-Ainino-3-fluoro-2-(2-methyl-4-trifluoromethoxy-phenylamino)-5-nitro-benzoic acid methyl ester 12a
4-Amino-2,3-difluoro-5-nitro-benzoic acid methyl ester 4 (0.50 g, 2.15 mmol) is
suspended in xylenes (3 mL) and 2-methyl-4-trifluoromethoxy-phenylamine (1.00 g, δ.23
mmol) is added. The reaction mixture is stirred at 140 °C under N2. After stirring for 7
days, the reaction is a mixture of starting material and product. The reaction mixture is
cooled to room temperature. The reaction mixture is poured into a separatory funnel and
diethyl ether and 10% aqueous HC1 are added and the layers separated. The aqueous
phase is extracted with three portions of diethyl ether. The combined diethyl ether layers
are dried (MgSO4) and concentrated under reduced pressure. The residue is redissolved
in methylene chloride and flushed through a plug of silica gel eluting with methylene
chloride. The filtrate is concentrated under reduced pressure to give a bright yellow solid.
The solid is washed with diethyl ether and the filtrate is concentrated under reduced
pressure and the residue is further purified by FCC (eluting with 100% methylene
chloride) to yield 0.39 g (45%) of the desired pure product as a yellow solid. MS APCI (-
)m/z 402 (M-l) detected.
Step B. 7-Fluoro-6-(2-methyl-4-trifluoromethoxy-phenylamino)-3H-
benzoimidazole-5-carboxylic acid methyl ester 8f
4-Ainino-3-fluoro-2-(2-methy-4-trifluoromethoxy-phenylammo)-5-nitro-benzoic acid methyl ester 12a is converted by the reduction/cyclization procedure already described to yield the desired product. MS APCI (+) m/z 384 (M+1) detected; MS APCI (-) m/z 382 (M-l) detected.
Example 8 Preparation of Hydroxylamines
Hydroxylamines useful for synthesizing compounds of the present invention may be prepared as follows
(i) 0-(2-Methoxy-ethyl)-hydroxylamine
Step A: 2-(2-Methoxy-ethoxy)-isoindole-l,3-dione
DEAD (10 mL, 63 mmol) is added to a mixture of 2-methoxyethanol (δ.0 mL, 63 mmol), PPh3 (17 g, 63 mmol), and N-hydroxyphthalimide (10 g, 62 mmol) in THF (170 mL). The resulting orange solution is stirred 16 h at room temperature. The reaction mixture is concentrated in vacuo, and the solids are filtered washing with CHCI3. The filtrate is concentrated again, and the solids are filtered washing with CHCI3. This process is repeated until no precipitate forms. The final yellowish solids are recrystallized from EtOH to give the desired product (7.7 g, 55 %). Step B: 0-(2-Methoxy-eihyl)-hydroxylamine
To a solution of 2-(2-methoxy-ethoxy)-isoindole-l,3-dione (7.7 g, 35 mmol) in CH2C12 (30 mL) at room temperature is added methylhydrazine (2.0 mL, 36 mmol). The
resulting solution is stirred for 16 h at room temperature. The white solids are filtered off. The solvent is carefully distilled off under reduced pressure, then the concentrate is distilled under vacuum (20 torr, 57-58 °C) to afford the desired product (2.2 g, 68%).
(if) The following hydroxylamines are prepared as described above using the appropriate alcohols. The isoindole-l,3-dione intermediates are purified by flash chromatography.
(Formula removed)
2-Isobutoxy-ethyl)-hydroxylamine is used directly without purification.
(Formula removed)
O-(2-Pyrrolidin-l-yl-ethyl)-hydroxylarnine is used directly without purification.
(Formula removed)
-(2-Piperidin-l-yl-emyl)-hydroxylamine is purified by Kugelrohr distillation (chamber temperature 140 °C, 1 torr).
(Formula removed)
O-(2-Memylsulfanyl-emyl)-hydroxylamine is purified by vacuum distillation (76-78 °C, 20 torr).
(Formula removed)
O-(2-Phenylsulfanyl-emyl)-hydroxylamine is used directly without purification.
(Formula removed)
O-(3-Memylsulfanyl-propyl)-hydroxylamine is used directly without purification.
(iii) The following hydroxylamines are prepared from the appropriate isoindole-1,3-dione by oxidation using oxone {Tetrahedron Lett. 1981, 22, 1287), and then
deprotection as described above.
(Formula removed)
O-(2-Methanesulfonyl-ethyl)-hydroxylamine is used directly without punticauon.
(Formula removed)
O-(2-Benzenesulfonyl-ethyl)-hydroxylamine is purified by flash chromatography (1% MeOH in CH2C12).
(Formula removed)
O-(3-Memanesulfonyl-propyl)-hydroxylaniine is used directly witliout purification.
(Formula removed)
-(3-Phenylsulfanvi-propyl)-hydroxylamine is prepared from PhSCH2CH2CH2Br and N-hydroxyphthalimide by the patent procedure WO 0018790 and then is deprotected by the procedure described above and used directly without purification.
(Formula removed)
O-(3-BenzenesuIfonyl-propyl)-hydroxylamine is prepared from the above isoindole-l,3-dione through its oxidation with oxone followed by deprotection as described above and is purified by flash chromatography (100% CH2C12 to 2% MeOH in CH2C12).
(v) 0-(2-Morpholin-4-yl-ethyl)-hydroxylamine dihydrochloride
Step A: 0-(2-Bromo-ethyl)-hydroxylamine hydrobromide
2-(2-Bromo-ethoxy)-isoindole-l,3-dione is prepared from 1,2-dibromoethane and
N-hydroxyphthalimide as described in WO 0018790, and is then subjected to the
procedure in J. Org. Chem. 1963,28,1604 to yield the desired product.
Step B: (2-Bromo-ethoxy)-carbamic acid tert-butyl ester
To a solution of 0-(2-bromo-ethyl)-hydroxylamine hydrobromide (100 mg, 0.45
mmol) and di-t-butyl dicarbonate (110 mg, 0.49 mmol) in CH2C12 (1 mL) at room
temperature is added Et3N (0.08 mL, 0.56 mmol). The resulting suspension is stirred for
16 h room temperature. The reaction mixture is diluted with EtOAc, washed with 1 N aq
HCl and brine, dried over MgSO4, filtered, concentrated, and purified by flash
chromatography (100% CH2C12) to give the desired product (81 mg, 75%).
Step C: (2-Morpholin-4-yl-ethoxy)-carbamic acid tert-butyl ester
To a solution of (2-bromo-ethoxy)-carbamic acid tert-butyl ester (252 mg, 1.05 mmol) in DMF (2 mL) at room temperature is added morpholine (0.14 mL, 1.6 mmol). The reaction mixture is stirred for 7h at 50 °C. The reaction mixture is diluted with EtOAc, and washed with water. The organic layer is dried over MgSCU, filtered, concentrated, and purified by flash chromatography (2% MeOH in CH2C12) to give the desired product (118 mg, 46%): MS APCI (+) m/z 247 detected. Step D: 0-(2-Morpholin-4-yl-ethyl)-hydroxylamine dihydrochloride
To a solution of (2-morpholin-4-yl-ethoxy)-carbamic acid tert-butyl ester (118 mg, 0.48 mmol) in MeOH (1 mL) is added 4 M dioxane solution of HCl (2.4 mL, 9.60 mmol) at room temperature. The resulting solution is stirred for 16 h at room temperature. After addition of additional HCl (2.4 mL) followed by stirring for 4 h, the reaction mixture is concentrated in vacuo to give yellow solids (82 mg, 78%).
(vi) The isoindole-l,3-dione intermediates of the following hydroxylamines are prepared from the appropriate alkyl halide and N-hydroxyphthalimide by the procedure described within J. Heterocyclic Chern. 2000, 37, 827-830. The isoindole-l,3-diones are deprotected by the procedure described above: O-but-3-enyl-hydroxylamine; O-
(tetrahydro-furan-2-ylmethyl) and O-(3-benzyloxy-propyl)-hydroxylamine.
(vii) The following hydroxylamines are prepared as described in WO 0206213: 0-(2-vinyloxy-etliyl)-hydroxylamine; 2-aminooxy-2-methyl-propan- l-ol; 1 -aminooxy-2-methyl-propan-2-ol; 3-aminooxy-propan-l-ol; and (2-aminooxy-ethyl)-methyl-carbamic acid tert-butyl ester.
(Formula removed)

6-(4-Bromo-2-chloro-phenylamiiio)-7-fluoro-3H-benzoitnidazole-5-carboxylicacid
cyc10propylmethoxy-amide (lib) Step A: 4-Amino-2-(2-chloro-phenylamino)-3-fluoro-5-nitro-benzoic acid methyl ester 5b
4-Amino-2,3-difluoro-5-nitro-benzoic acid methyl ester 4 (2.00 g, 8.62 mmol) is
suspended in xylenes (15 ml) and 2-chloro aniline (9.06 ml, 86.15 mmol) is added. The
reaction mixture is heated to 140 °C under a nitrogen atmosphere. After 6 days, the
reaction mixture is cooled to room temperature, and diluted with ethyl acetate. The
reaction mixture is washed with water, 10% HC1 solution and brine. The organic layer is
dried (MgSO-O and concentrated under reduced pressure. The crude product is triturated
with diethyl ether, twice, to give 0.35 g (12%) pure desired product as a brownish solid.
Step B: 4,δ-Diamino-2-(2-chloro-phenylamino)-3-flnoro-benzoic acid methyl ester 6a
4-Animo-2-(2-chloro-phenylaniino)-3-fluoro-5-riitro-benzoic acid methyl ester 5b
(0.30 g, 0.88 mmol) is suspended in AcOH (δ ml) and zinc dust (0.29 g, 4.42 mmol) is added. After 15 minutes, the reaction is complete. The reaction mixture is diluted with ethyl acetate and filtered through Celite. The filtrate is washed with water, saturated NaHCO3, 10% K2CO3 and brine. The organic layer is dried (MgSO4) and concentrated under reduced pressure to give 0.13 g (48%) pure desired product as an whitish brown foam.
Step C: 6-(2-Chloro~phenylamino)-7-fluoro-3H-benzoimidazole-5-carboxylic acid methyl ester 7b
4,δ-Diamino-2-(2-chloro-phenylamino)-3-fluoro-benzoic acid methyl ester 6a (0.125 g, 0.404 mmol) is suspended in EtOH (2 ml) and formamidine acetate (63 mg, 0.605 mmol) is added. The reaction mixture is heated to reflux. After 16 hours, the reaction mixture is cooled to rt and diluted with ethyl acetate. The organic layer is washed with water, saturated NaHCO3,10% K2CO3 and brine. The organic layer is dried (MgSO4 and concentrated under reduced pressure to give 0.109 g (85%) pure desired product.
Step D: 6-(4-Bromo-2-chloro-phenylamino)- 7-fluoro-3H-benzoimidazole-5-carboxylic acid methyl ester 8b
6-(2-Chloro-phenylamino)-7-fluoro-3H-benzoimidazole-5-carboxylic acid methyl ester 7b (55 mg, 0.172 mmol) is dissolved in 1:1 THF:MeOH (2 ml) and cooled to -78 °C under an atmosphere of nitrogen. TsOH1H2O (49 mg, 0.258 mmol) is added followed by NBS (31 mg, 0.174 mmol). After 10 minutes, the reaction mixture is warmed to 0 °C and then 2 hours later warmed to rt. After 16 hours, the reaction mixture is quenched by the
addition of 10% Na2S2O3 and diluted with ethyl acetate and water. The layers are separated and the aqueous layer is extracted with ethyl acetate. The combined organic extracts are dried (MgSO4) and concentrated under reduced pressure. The crude product is triturated with methylene chloride to give 58 mg (85%) of pure desired product as a tan solid.
Step E: 6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3H-benzoimidazole-5-carboxylic acid 10b
6-(4-Bromo-2-chloro-phenylammo)-7-fluoro-3H-benzoirnidazole-5-carboxylic acid methyl ester 8b (58 mg, 0.146 mmol) is suspended in EtOH (2 ml) and 1 ml 2 N NaOH is added. After 16 hours, the reaction mixture is diluted with ethyl acetate, water, and 10% HC1 solution. The layers are separated and the organic layer is washed with brine. The organic layer is dried (MgSO4) and concentrated under reduced pressure. Trituration with MeOH gives 22 mg (39%) pure desired product.
Step F: 6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3H-benzoimidazole-5-carboxylic acid cyc10propylmethoxy-amide (lib)
6-(4-Bromo-2-Chloro-phenylanimo)-7-fluoro-3H-benzoimidazole-5-carboxylic acid 10b (22 mg, 0.057 mmol) is dissolved in DMF (1 ml) and HOBt (9 mg, 0.062 mmol) followed by triethyl amine (18 yl, 0.132 mmol) is added. Cyc10propyl methyl hydroxylamine hydrochloride (8 mg, 0.062 mmol) is added followed by EDCI (14 mg, 0.074 mmol). After 16 hours, the reaction mixture is diluted with ethyl acetate and water and the layers separated. The organic layer is washed with saturated NH4CI, brine, saturated NaHCO3, water and brine. The organic layer is dried (MgSO4) and
concentrated under reduced pressure to give 23 mg (89%) pure desired product. MS APCI (+) m/z 455, 453 (M+ Br pattern) detected; MS APCI (-) m/z 453, 451 (M- Br pattern) detected; 1H NMR (400MHz, DMSO-d6) δ 11.69 (broad s, 1H), 8.43 (s, 1H), 7.62 (d, 1H), 7.28 (dd, 1H), 6.42 (m, 1H), 3.63 (d, 2H), 1.03 (m, 1H), 0.48 (m, 2H), 0.19 (m, 2H); 19F NMR (376MHz, DMSO-d6) -132.95 (s).
The following compounds are prepared by methods similar to those described in Example 1 and in this Example 9 by using the appropriate carboxylic acid and the appropriate hydroxylamine:
(Formula removed)

6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzPimidazole-5-carboxylic
acid (2-hydroxy-ethoxy)-amide (29c)
Step A. 6-(4-Bromo-2-chloro-phenylamino)- 7-fliioro-3-meihyl-3H-benzoimidazole-5-carboxylic acid methyl ester 9a and 6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-l-methyl-lH-benzoimidazole-5-carboxylic acid methyl ester
A solution of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3H-benzoimidazole-5-
carboxylic acid methyl ester 8b (150 mg, 0.38 mmol), iodomethane (28 uL, 0.45 mmol)
and potassium carbonate (78 mg, 0.56 mmol) in dimethylformamide (1.δ mL) is stirred at
75 °C for one hour. The reaction mixture is diluted with ethyl acetate, washed with
saturated aqueous potassium carbonate (2x), brine, and dried (Na2SO4). Flash column
chromatography (20:1 methylene chloride/ethyl acetate) provides 56 mg (36%) of the
more mobile 6-(4-bromo-2-chloro-phenylammo)-7-fluoro-3-memyl-3H-benzoimidazole-
δ-carboxylic acid methyl ester 9a as a white solid. 19F NMR (376 MHz, CD3OD) -133.δ
(s). MS APCI (+) m/z 412, 414 (M+, Br pattern) detected. Also isolated is 54 mg (35%)
of 6-(4-bromo-2-crdoro-phenylammo)-7-fluoro-1 -methyl-1 H-benzoimidazole-δ -
carboxylic acid methyl ester as a white solid. 19F NMR (376 MHz, CD3OD) -139.9 (s).
MS APCI (+) m/z 412,414 (M+, Br pattern) detected.
Step B. 6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid 10c
6-(4-Bromo-2-chloro-phenylarnmo)-7-fluoro-3-memyl-3H-berizoimidazole-5-carboxylic acid methyl ester 9a (56 mg, 0.14 mmol) is dissolved into 2:1 THF/water (3 mL ) and NaOH (0.55 mL, 1.0 M aqueous solution, 0.55 mmol) is added. After stirring for two hours the reaction is reduced to one quarter initial volume via rotary evaporation and the remainder diluted to 50 mL with water. The aqueous solution is acidified to pH 2
by the addition of 1.0 M aqueous HCl and extracted with 1:1 tetrahydrofuran/ethyl acetate (3x), dried (Na2SO4) and concentrated under reduced pressure to provide 43 mg (79%) pure carboxyUc acid as an off white solid. MS ESI (+) m/z 397, 398 (M+, Br pattern) detected.
Step C: 6-(4-Bromo-2-chloro-phenylamino)- 7-fluoro-3-methyl-3H-benzoimidazole-δ~ carboxyUc acid (2-vinyloxy-ethoxy)-amide 29a
6-(4-Bromo-2-chloro-phenylammo)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid 10c (2.00 g, δ.0 mmol), 0-(2-vinyloxy-ethyl)-hydroxylamine (0.776 g, 7.δ mmol), HOBt (0.88 g, 6.δ mmol), triethylamine (1.61 mL, 2.3 mmol) and EDCI (1.3 g, 6.δ mmol) are dissolved in dimethylformamide (52 mL) and stirred at room temperature for 48 hours. The reaction mixture is diluted with ethyl acetate, washed with water (3x), saturated potassium carbonate (2x), saturated ammonium chloride (2x), brine, dried (Na2SO4) and concentrated under reduced pressure to an off-white solid. Trituration of the solid with diethyl ether provides 2.18 g (90%) desired product as an off-white solid. MS ESI (+) m/z 483,485 (M+ Br pattern) detected.
Step D: 6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide 29c
Hydrochloric acid (14 mL, 1.0 M aqueous solution, 14 mmol) is added to a suspension of 6-(4-bromo-2-chloro-phenylammo)-7-fluoro-3-methyl-3H-benzoimidazole -5-carboxylic acid (2-vinyloxy-ethoxy)-amide 29a (2.18 g, 4.50 mmol) in ethanol (50 mL) and the reaction mixture allowed to stir for 24 hours. The reaction mixture is concentrated to dryness by rotary evaporation and the solids partitioned between 3:1 ethyl
acetate/tetrahydrofuran and saturated potassium carbonate. The aqueous phase is extracted with 3:1 ethyl acetate/tetrahydrorUran (3x), the combined organics dried (Na2SO4), and concentrated to provide 2.11 g (100%) 6-(4-bromo-2-chloro-phenylammo)-7-fluoro-3-memyl-3H-beru»imidazole-5-carboxylicacid(2-hydroxy-ethoxy)-amide as an off-white solid. MS ESI (+) m/z 457,459 (M+, Br pattern) detected. 1H NMR (400 MHz, MeOH-d4) δ 8.26 (s, 1H), 7.78 (s, 1H), 7.57 (d, 1H), 7.24 (dd, 1H), 6.40 (dd, 1H), 3.86 (s, 3H), 3.79 (m, 2H), 3.49 (m, 2H). 19F NMR (376 MHz, MeOH-d4) -133.68 (s).
Example 11
The following compounds are prepared by methods similar to those described in Example 10 by using methyl ester 8b and the appropriate alkylating agent (Step A) and the appropriate hydroxylamine (Step C):
(Formula removed)

Example 12
(Formula removed)

6-(4-Bromo-2~chloro-phenylamino)-7-fluoro-3-methyl-3H-benioimidazole-5-carboxylic acid (2,3-dihydroxy-propoxy)-amide (29hhh)
To a solution of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-
benzoimidazole-5-carboxylic acid allyloxy-amide 29tt (20 mg, 0.04 mmol) in 0.50 mL 4:1 tetrahydrofuran/water is added OSO4 (41 uL, 0.054 M solution in r-BuOH, 0.002 mmol) followed by NMO (7 mg, 0.06 mmol). The solution is stirred at room temperature for eight hours after which time HPLC analysis showed complete conversion to product. The solution is then stirred with saturated NaHSO3 and diluted with ethyl acetate. The organic phase is dried (Na2SO4). Purification by FCC (DCM -> 20:1 DCM/MeOH) provided 16 mg desired product as an off-white solid. MS ESI (+) m/z 487, 489 (M+, Br pattern) detected.
Example 13
(Formula removed)

6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (3,4-dihydroxy-butoxy)-amide (29iii)
6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazoIe-5-
carboxylic acid but-3-enyloxy-amide 29un is subjected to the dihydroxylation method described in Example 12. MS APCI (+) m/z 501,503 (M+ Br pattern) detected.
Example 14
(Formula removed)

6-(4-Bronio-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-methylamino-ethoxy)-amide TFA salt (29jjj)
Prepared from (2- {[6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzomndazole-5-carbonyl]-aminooxy}-ethyl)-methyl-carbamic acid tert-butyl ester 29ww by trifluoroacetic acid deprotection in methylene chloride. MS APCI (+) m/z 470, 472 (M+, Br pattern) detected; 1H NMR (400 MHz, CD3OD) 8 8.31 (s, 1H), 7.74 (s, 1H), 7.51 (d, 1H), 7.19 (dd, 1H), 6.39 (dd, 1H), 4.11 (m, 2H), 3.97 (s, 3H), 3.12 (m, 2H), 2.72 (s, 3H); 19F NMR (376 MHz, CD3OD) -77.41 (s, 3F), -134.79 (s, IF).
Example 15
The following compounds are prepared by methods similar to those described in
Example 10 by using methyl ester 8a and the appropriate alkylating agent (Step A) and the appropriate hydroxylamine (Step Q:
(Formula removed)

Example 16
The following compounds are prepared by methods similar to those described in
Example 10 by using methyl ester 8e and the appropriate alkylating agent (Step A) and the appropriate hydroxylamine (Step C):
(Formula removed)

Example 17
The following compounds are prepared by methods similar to those described in
Example 10 by using methyl ester 8c and the appropriate alkylating agent (Step A) and the appropriate hydroxylamine (Step C):

Example 18
The following compounds are prepared by methods similar to those described in
Example 10 by using methyl ester 8d and the appropriate alkylating agent (Step A) and the appropriate hydroxylamine (Step C):
(Formula removed)
6-(4-Bromo-2-methyl-phenylamino)-7-fluoro-3-[4-(4-methyl-piperazin-l-yl)-butyl]-3H-benzoimidazole-5-carboxylic acid cyc10propylmethoxy-amide (llo)
Step A: 6-(4-Bromo-2-methyl-phenylamino)-7-fluoro-3-pent-4-enyl-3H-bemoimidazole-δ-carboxylic acid methyl ester 9b
7-Fluoro-6-(4-bromo-2-memyl-phenylanmo)-lH-benzoimidazole-5-carboxylic acid methyl ester 8a (0.915 g, 2.419 mmol) is suspended in DMF (18 ml) under an atmosphere of nitrogen. Bromopentene (0.430 ml, 3.629 mmol) and K2CO3 (0.502 g,
3.629 mmol) are added and the reaction mixture was warmed to 80 °C. After 1 hour, the reaction mixture is cooled to room temperature and poured into 100 ml of 1:1 ethyl acetate:diethyl ether. The organic layer is washed with water and brine, dried (Na2SO4) and concentrated under reduced pressure. The N3 and Nl alkylated products are separated by flash column chromatography, eluted with 20:1 methylene chloride:ethyl acetate. Complete separation of the isomers is obtained by performing two chromatographic separations. The higher Rf product is the N3 product 9b, while the lower Rf product is the Nl product. The recovery of the N3 product 9b is 0.415 g (38%): LC/MS ESI (+) m/z 448, 446 (M+l Br pattern) detected. The recovery of the Nl product was 0.486 g (45%): LC/MS ESI (+) m/z 448, 446 (M+l Br pattern) detected.
Step B: 6-(4-Bromo-2-methyl-phenylamino)-7-fluoro-3-pent-4-enyl-3H-benzoimidazole-δ-carboxylic acid lOd
6-(4-Bromo-2-memyl-phenylamino)-7-fluoro-3-pent-4-enyl-3H-benzoimidazole-δ-carboxylic acid methyl ester 9b is dissolved in 1:1 THF:MeOH (10 ml) and 1 N NaOH solution (2.3 ml) is added. After 5h, the organic solvents are removed under reduced pressure and the residue diluted with water and 100 ml 1:1 THF:ethyl acetate. The layers are separated and the aqueous layer extracted with ethyl acetate. The combined organic extracts are dried (Na2SO4) and concentrated under reduced pressure to afford 0.39 g (100%) clean desired product as a light yellow solid.
Step C: 6-(4-Bromo-2-methyl-phenylamino)- 7-fluoro-3-pent-4-enyl-3H-benzoimidazole-δ-carboxylic acid cyc10propylmethoxy-amide I If
6-(4-Bromo-2-methyl-phenylamino)-7-fluoro-3-pent-4-enyl-3H-benzoimidazole-
δ-carboxylic acid lOd (0.390 g, 0.902 mmol) is dissolved in 1:1 THFmethylene chloride (6 ml) and Hunig's base (0.346 ml, 1.985 mmol) is added followed by PyBOP (0.563 g, 1.083 mmol). After 10 minutes, cyc10propyl methyl hydroxylamine hydrochloride (0.134 g, 1.083 mmol) is added. After 16 hours, the reaction mixture is diluted with ethyl acetate and washed with 0.1 N HC1, saturated NaHCO3, and brine. The organic layer is dried (Na2SO4) and concentrated under reduced pressure. The crude yellow residue is purified by FCC eluted with ethyl acetate to give 0.315 g (70%) pure desired product as a yellow solid: MS APCI (+) m/z 503, 501 (M+l Br pattern) detected.
Step D: 6-(4-Bromo-2-methyl-phenylamino)-3-(4,δ-dihydroxy-pentyl)-7-fluoro-3H-benzoimidazole-5-carboxylic acid cyc10propylmethoxy-amide 11m
6-(4-Bromo-2-memyl-phenylammo)-7-fluoro-3-pent-4-enyl-3i/-beri2»imidazole-δ-carboxylic acid cyc10propylmethoxy-amide llf (0.307 g, 0.612 mmol) is dissolved in 4:1 THF:water (8 ml) and 1.134 ml (0.061 mmol) of an 0.054 M OSO4 solution in t-BuOH iias added followed by NMO (0.093 g, 0.796 mmol). After 5h, the reaction mixture is quenched by the addition of 10% NaHS2O3 solution. After 10 min, the reaction mixture is filtered through Celite rinsing with ethyl acetate and methylene chloride. The filtrate is diluted with ethyl acetate and washed with 0.01 N HC1, and brine. The organic layer is dried (Na2SO4) and concentrated under reduced pressure. The crude product is purified by FCC eluted with 9:1 ethyl acetate:MeOH to give 0.244 g (74%) pure desired product.
Step E: 6-(4-Bromo-2-methyl-phenylamino)- 7-fluoro-3-(4-oxo-butyl)-3H
benzoimidazole-5-carboxylic acid cyc10propylmethoxy-amide lln
To a mixture of 6-(4-bromo-2-methyl-phenylamino)-3-(4,δ-diliydroxy-pentyl)-7-fluoro-3Hbenzoimidazole-5-carboxylic acid cyc10propylmethoxy-amide 11m (0.244 g, 0.456 mmol), THF (δ ml) and pH 7 phosphate buffer (3 ml) is added sodium periodate (0.195 g, 0.911 mmol). After 16 hours, the reaction mixture is diluted with ethyl acetate and washed with NaHCO3, and brine. The organic layer is dried (Na2SO4) and concentrated under reduced pressure to give an orange solid. Purification by FCC eluted with 4:1 methylene chlorideMeOH yields 0.189 g (82%) pure desired product as a yellow solid: MS APCI (+) m/z 505, 503 (M+1 Br pattern) detected; MS APCI (-) m/z 503, 501 (M-l Br pattern) detected.
Step F: 6-(4-Bromo-2-methyl-phenylamino)-7-fluoro-3-[4-(4-methyl-piperazin-l-yl)-butyl]-3H-benzoimidazole-5-carboxylic acid cyc10propylmethoxy-amide Ho 6-(4-Bromo-2-methyl-phenylamino)-7-fluoro-3-(4-oxo-butyl)-3i?benzoimidazole-5-carboxylic acid cyc10propylmethoxy-amide 11n (15 mg, 0.030 mmol) is dissolved in MeCN (500 µ1) and methylpiperazine (10 µl, 0.089 mmol) is added followed by AcOH (δ µl, 0.089 mmol). After δ min, tetramethylammonium triacetoxyborohydride (12 mg, 0.045 mmol) is added. After δ min, the reaction mixture is diluted with ethyl acetate and washed with NaHCOa and brine. The organic layer is dried (Na2SO4) and concentrated under reduced pressure to give 12 mg (69%) of pure desired product as a white solid. MS APCI (-) m/z 587, 585 (M-l Br pattern) detected; 1H NMR (400 MHz, CDC13) 8 7.99 (s, 1H), 7.98 (s, 1H), 7.30 (d, 1H), 7.08 (dd, 1H), 6.30 (d, 1H), 6.1 (broad singlet, 1H), 4.26 (t, 2H), 3.64 (d, 2H), 3.37 (s, 1H), 2.45 (broad, 8H), 2.41 (s, 3H), 2.38 (t, 2H), 2.28 (s, 3H), 1.95 (quin, 2H), 1.55 (quin, 2H), 0.98 (m, 1H), 0.50 (qt, 2H), 0.22 (qt, 2H).
Example 20
The following compounds are prepared by methods similar to those described in
Example 19 by using the appropriate alkenyl substituted benzimidazole and the appropriate amine in the reductive amination (step F):
(Formula removed)
6-(4-Bromo-2-meihyl-phmylamino)-3-[4-(l,l-dioxo-l6-thiomorpholin-4-yl)-butyl]-7-fluoro-3H-benzoimidazole-5-carboxylic acid cyc10propylmethoxy-amide (18cc) To a solution of 6-(4-bromo-2-methyl-phenylamino)-7-fluoro-3-(4-thioniorpholiii-
4-yl-butyl)-3H-benzoimidazole-5-carboxylic acid cyc10propylmethoxy-amide 181 (8 mg,
0.014 mmol) in 1:1:1 water/acetone/MeOH (1 mL) is added NMO (1.6 mg, 0.014 mmol)
and osmium tetroxide (250 µL, 0.054 M solution in t-BuOH, 0.014 mmol). After stirring
for 24 hours, the solution is diluted with saturated sodium thiosulfate, stirred for 10
minutes and diluted with ethyl acetate. The solution is washed with brine (2x), dried
(Na2SO4) and concentrated under reduced pressure to a grey solid. FCC (10:1
dichloromethane/methanol) provides 6 mg (71%) desired product as an off-white solid.
MS ESI (+) rn/z 622, 624 (M+, Br pattern) detected.
Example 22
(Formula removed)

6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-[4-(4-methyl-piperazin-l~yl)-butyl]-3H-
benzoimidazole-5-carboxylic acid cyc10propylmethoxy-amide (18dd)
A solution of 6-(4-bromo-2-chloro-phenylamino)-3-(4-chloro-butyl)-7-fluoro-3H-
benzoimidazole-5-carboxylic acid cyc10propylmethoxy-amide 18ee (10 mg, 0.018 mmol),
sodium iodide (14 mg, 0.092 mmol), and 1-methyl-piperazine (10 yiL, 0.092 mmol) are
stirred at 85 °C for three hours. The reaction mixture is diluted with ethyl acetate and
washed three times with water, washed twice with saturated aqueous potassium
carbonate, dried (Na2SO4) and concentrated under reduced pressure to a yellow oil. Flash
column chromatography (1:1 dichloromethane/methanol followed by methanol followed
by 20:1 methanol/triethylamine) yields clean product (8 mg, 72%) as an off-white foam.
MS ESI (+) m/z 607, 609 (M+, Br pattern) detected. 1H NMR (400 MHz, DMSO-d6)
δ 8.37 (s, 1H), 7.71 (s, 1H), 7.49 (d, 1H), 7.18 (dd, 1H), 6.40 (dd, 1H), 4.38 (t, 2H), 3.62
(d, 2H), 2.45 (broad, 8H), 2.41 (t, 2H), 2.28 (s, 3H), 1.96 (m, 2H), 1.54 (m, 2H), 1.07 (m,
1H), 0.50 (d, 2H), 0.22 (d, 2H).
Example 23
The following compounds are prepared by methods similar to those described in
Example 22, using an appropriate amine and primary alkyl chloride.
(Formula removed)

6-(4-Chloro-2-niethyl-phenylammo)-7-fluoro-3-oxazol-S-ylmethyl-3H-benzoimidazole-δ-carboxylic acid cyc10propylmethoxy-amide (18ggg)
6-(4-Chloro-2-methyl-phenylamino)-7-fluoro-3-(2-oxo-ethyl)-3H-
benzoimidazole-5-carboxylic acid cyc10propylmethoxy-amide (0.020 g, 0.046 mmol) is dissolved in methanol (2 mL). Potassium carbonate (0.013 g, 0.093 mmol) and 1-isocyanomethanesulfonyl-4-methyl-benzene (0.010 g, 0.051 mmol) are added. The reaction mixture is stirred at reflux for 16 hours under N2, then concentrated under reduced pressure. The residue is dissolved in ethyl acetate and poured into a separatory funnel and washed with water and brine. The combined aqueous layers are reextracted
with ethyl acetate (2x). The combined ethyl acetate layers are dried (Na2SO4,) and concentrated under reduced pressure. The resulting solid was purified by flash column chromatography (eluting with 15:1 methylene chloride:methanol) to yield 0.011 g (50%) of the desired product. MS APCI (+) m/z 470, 472 (M+, CI pattern) detected; 1H NMR (400 MHz, CDC13) δ 10.51 (br s, 1H), 8.07 (s, 1H), 8.02 (s, 1H), 7.89 (s, 1H), 7.23 (s, 1H), 7.15 (d, 1H), 6.92 (dd, 1H), 6.31 (d, 1H), 6.11 (br s, 1H), δ.45 (s, 2H), 3.62 (d, 2H), 2.40 (s, 3H), 0.87 (m, 1H), 0.49 (m, 2H), 0.20 (m, 2H). 19F NMR (376 MHz, CDC13) -134.54 (s).
Example 25
(Formula removed)
6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-(3-oxo-3-pyrrolidin-l-yl-propyl)-3H-benzoimidazole-5-carboxylic acid cyc10propylmethoxy-amide (18hhh)
Step A: 6-(4-Bromo-2-chloro-phenylamino)-3-(2-tert-butoxycarbonyl-ethyl)-7-fluoro-
3H-benzoimidazole-5-carboxylic acid methyl ester
6-(4-Bromo-2-chloro-phenylammo)-7-fluoro-3H-benzoimidazole-5-carboxylic acid methyl ester 8b (0.50 g, 1.25 mmol) is dissolved in DMF (8 ml) under N2 and K2CO3 (0.26 g, 1.88 mmol) is added followed by t-butyl acrylate (1.84 ml, 12.54 mmol). The reaction mixture is heated to 90 °C with stirring. After 4 h, the reaction mixture is cooled to it and diluted with ethyl acetate. The organic layer is washed with water (3x) and brine, dried (MgSO4) and concentrated under reduced pressure. Purification by flash column chromatography eluted with 19:1 methylene chloride:ethyl acetate gives 0.41 g
(62%) desired product.
Step B: 6-(4-Bromo-2-chloro-phenylamino)-3-(2-carboxy-ethyl)-7-fluoro-3H-
benzoimidazole-5-carboxylic acid methyl ester TFA salt
6-(4-Bromo-2-chloro-phenylamino)-3-(2-tert-butoxycarbonyl-ethyl)-7-fluoro-3H-benzoimidazole-5-carboxylic acid methyl ester (0.050 g, 0.095 mmol) is dissolved in methylene chloride (0.δ ml) and TFA (0.δ ml) is added. After 45 min, the reaction mixture is concentrated to dryness to give 0.49 g (88%)desired product: LC/MS ESI (+) m/z All, 470 (M+ Br pattern) detected; 1H NMR (400MHz, DMSO-de) £ 8.51 (s, 1H), 8.20 (s, 1H), 8.13 (s, 1H), 7.64 (d, 1H), 7.29 (dd, 1H), 6.45 (dd, 1H), 4.55 (t, 2H), 2.89 (t, 2H).
Step C: 6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-(3-oxo-3-pyrrolidin-l-yl-propyl)-3H-benzoimidazole-5-carboxylic acid methyl ester
To solution of 6-(4-bromo-2-chloro-phenylarnino)-3-(2-carboxy-ethyl)-7-fluoro-3H-benzoimidazole-5-carboxylic acid methyl ester (60 mg, 0.13 mmol) in DMF (1.8 mL) is added HOBt-H2O (24 mg, 0.16 mmol), Et3N (0.043 mL, 0.31 mmol), pyrrolidine (0.011 mL, 0.13 mmol), and EDCI (34 mg, 0.18 mmol) at rt. The resulting yellow solution is stirred 16 h at rt. The reaction mixture is diluted with EtOAc and water, washed with sat'd aq NH4CI, brine, sat'd aq NaHCO3, and brine. The organic layer is dried over MgSO4, filtered, and concentrated in vacuo to give a crude material which is purified by flash chromatography (3% MeOH in CH2C12) to afford 45 mg (67%) of the desired product: MS APCI (+) m/z 523, 525 (M+, Br pattern) detected.
Step D: 6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-(3-oxo-3-pyrrolidin-l-yl-propyl)-3H-benzoimidazole-5-carboxylic acid
To a solution of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-(3-oxo-3-pyrrodin-l-yl-propyl)-3H-benzoirnidazole-5-carboxylic acid methyl ester (41 mg, 0.079 mmol) in THF/H2O (1.δ mL/0.75 mL) is added 0.20 mL (0.20 mmol) of 1 N aq LiOH at rt. The resulting solution is stirred 16 h. The reaction mixture is acidified with 1 N aq HO (pH ~2 to 3) and diluted with EtOAc. The organic layer is dried over MgSO4, filtered, and concentrated in vacuo to give a crude product (42 mg) which is directly used without further purification.
Step E: 6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-(3-oxo-3-pyrrolidin-l-yl-propyl)-3H-benzoimidazole-5-carboxylic acid cyc10propylmethoxy-amide 18hhh
The title compound is prepared from 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-(3-oxo-3-pyrrolidin-l-yl-propyl)-3H--benzoimidazole-5-carboxylic acid and O-cyc10propylmethyl-hydroxylamine hydrochloride by the standard coupling procedure described in Step A: MS APCI (+) m/z 578, 580 (M+, Br pattern) detected; 1H NMR (400 MHz, DMSO-40 δ 11.66 (s, 1H), 8.42 (s, 1H), 8.01 (s, 1H), 7.76 (s, 1H), 7.62 (s, 1H), 7.28 (d, 1H), 6.39 (m, 1H), 4.52 (t, 2H), 3.66 (d, 2H), 3.33 (t, 2H), 3.28 (t, 2H), 2.89 (t, 2H), 1.83 (m, 2H), 1.76 (m, 2H), 1.06 (m, 1H), 0.49 (m, 2H), 0.22 (m, 2H); 19F NMR (376 MHz, DMSO-d6) -132.94 (s, IF).
Example 26
The following compounds are prepared by methods similar to those described in
Example 25 using methyl ester 8b and the appropriate amines:
(Formula removed)

6-(4-Bromo-2-chloro-phenylamino)-7-fliwro-3-(tetrahydro-pyran-2-ylmethyl)-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide (lip)
Step A: 6-(4-Bromo-2-chloro-phenylamino)- 7-fluoro-3-(tetrahydro-pyran-2-ylmethyl)-3H-benzoimidazole-5-carboxylic acid methyl ester llq
6-(4-Bromo-2-chloro-phenyIarm^o)-7-fluoro-3H-beaizoimidazole-5-carboxylic acid methyl ester 8b (0.25 g, 0.63 mmol) is dissolved in N,N-dimethylformamide (δ mL). 2-Bromomethyl-tetrahydro-pyran (0.34 g, 1.88 mmol) and potassium carbonate (0.26 g, 1.88 mmol) are added and the reaction mixture is stirred at 60 °C for 12 hours under N2. The reaction mixture is poured into a separatory runnel, diluted with ethyl acetate and
water and the layers separated. The ethyl acetate layer is washed with water and brine, dried (Na2SO4) and concentrated under reduced pressure. The resulting solid residue is triturated with diethyl ether to yield a pale yellow solid (N3 regioisomer by NMR) and a yellow filtrate (mixture of Nl and N3 regioisomers by NMR). The solids are collected and washed with diethyl ether to yield 0.12 g (37%) of the pure desired N3 regioisomeric product as a pale yellow solid. MS ESI (+) m/z 496, 498 (M+, Br pattern) detected.
Step B: 6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-(tetrahydro-pyran-2-ylmethyl)-3H-benzoimidazole-5-carboxylic acid llr
6-(4-Bromo-2-chIoro-phenylammo)-7-fluoro-3-(tetrahydro-pyran-2-ylmethyI)-3H-benzoimidazole-5-carboxylic acid methyl ester llq is suspended in 4:1 tetrahydrofuran/water (2.δ mL) and aqueous 1 M LiOH is added (2.δ mL). After stirring at room temperature for 16 hours, the reaction mixture is homogeneous and the reaction is complete. The reaction mixture is cooled to 0 °C, diluted with water and aqueous 2 M HC1 is added dropwise until the pH of the solution is 1-2, at which time it turns to a suspension. The reaction mixture is poured into a separatory funnel and diluted with ethyl acetate/tetrahydrofuran and water and the layers separated. The aqueous layer is extracted with ethyl acetate. The combined organic layers are washed with brine, dried (Na2SO4) and concentrated under reduced pressure to yield 0.11 g (100%) of the pure desired product as a white solid. MS ESI (+) m/z 482, 484 (M+, Br pattern) detected.
Step C: 6-(4-Bromo~2-chloro-phenylamino)-7-fluoro-3-(tetrahydro-pyran-2-ylmethyl)-3H-benzoimidazole-5-carboxylic acid (2-vinyloxy-ethoxy)-amide lis
6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-(tetrahydro-pyran-2-ylmethyl)-
3H-benzoimidazole-5-carboxylic acid llr (0.11 g, 0.23 mmol) is dissolved in N,N-dimethylformamide (2 mL). HOBT (0.037 g, 0.27 mmol) and triemylamine (0.094 mL, 0.68 mmol) are added. Then 0-(2-vmyloxy-ethyl-hydroxylamine (0.028 g, 0.27 mmol) and EDCI (0.056 g, 0.29 mmol) are added and the reaction mixture is stirred at room temperature under N2 until HPLC shows the reaction is complete (2-3 days). The reaction mixture is poured into a separatory funnel, diluted with ethyl acetate and water and the layers separated. The ethyl acetate layer is washed successively with aqueous saturated NH4CI (2x), brine (lx), aqueous saturated sodium bicarbonate (2x), water (lx), and brine (lx), dried (Na2SO4) and concentrated under reduced pressure. The resulting solid is purified by FCC (eluting with 15:1 methylene chloride:methanol) to yield 0.039 g (79%) of the pure desired product as an off-white solid. MS ESI (+) m/z 567, 569 (M+, Br pattern) detected.
Step D: 6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-(tetrahydro-pyran-2-ylmethyl)-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide lip
6-(4-Bromo-2-chloro-phenylanmio)-7-fluoro-3-(tetrahydro-pyran-2-ylmethyl)-3H-benzoimidazole-5-carboxylic acid (2-vinyloxy-ethoxy)-amide lis (0.039 g, 0.068 mmol) is dissolved in ethanol (2 mL) and aqueous 2 M HC1 (200uL) is added. The reaction mixture is stirred at room temperature for 30 minutes. The reaction mixture is diluted with water and then neutralized with aqueous 2 M NaOH (~200 uL) until pH 7 and concentrated under reduced pressure. The residue is partitioned between ethyl acetate and brine in a separatory funnel and the layers separated. The ethyl acetate layer is dried (Na2SO4) and concentrated under reduced pressure to yield 0.034 g (91%) of the
1
pure desired product as an off-white solid. MS ESI (+) m/z 541, 543 (M+, Br pattern)
detected; 1H NMR (400 MHz, CD3OD) 8 8.29 (s, 1H), 7.75 (s, 1H), 7.49 (d, 1H), 7.18 (dd, 1H), 6.40 (dd, 1H), 4.40 (dd, A of ABX pattern, 1H), 4.28 (dd, B of ABX partem, 1H), 3.92 (m, X of ABX pattern, 1H), 3.66 (t, 2H), 3.35 (m, 1H), 1.89 (m, 1H), 1.76 (m, 1H), 2.28 (s, 3H), 1.54 (m, 3H), 1.30 (m, 1H). 19F NMR (376 MHz, CD3OD) -134.87 (s).
Example 28
The following compounds are prepared by methods similar to that described in
Example 27 by using the appropriate methyl ester and alkylating agent (Step A) and the appropriate hydroxylarnine in (Step C).
(Formula removed)
6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-(2-methanesulfonyl-ethyl)-3H-benzoimidazole-5-carboxylic acid cyc10propylmethoxy-amide (llbb)
Step A: 6-(4-Bromo-2-chloro-phenylamino)~7-fluoro-3-(2-methanesulfonyl-ethyl)-3H-
benzoimidazole-5-carboxylic acid methyl ester lice
6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3H-benzoimidazole-5-carboxylic acid methyl ester 8b (1.55 g, 3.89 mmol) is dissolved in 15 ml DMF under N2. K2CO3 (0.70 g, δ.06 mmol) is added followed by methyl vinyl sulfone (0.41 ml, 4.67 mmol). After stirring 16 h at room temperature, the reaction mixture is diluted with ethyl acetate and water. The layers are separated and the organic layer is washed with water (3x) and brine. The combined aqueous washes are extracted with ethyl acetate. The combined organic extracts are dried (MgSO4) and concentrated under reduced. Purification by dissolving the residue in methylene chloride and precipitating with diethyl ether, repeated several times, gives 1.16 g (59%) pure desired product as a yellow solid: MS APCI (+) m/z 506, 504 (M+ Br pattern) and 400,398 (M - methyl ethyl sulfone Br pattern).
Step B: 6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-(2-methanesulfonyl-ethyl)-3H-benzoimidazole-5-carboxylic acid cyc10propylmethoxy-amide llbb
6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-(2-methanesulfonyl-ethyl)-3H-benzoimidazole-5-carboxylic acid methyl ester lice is subjected to methods previously described to give 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-(2-methanesulfonyl-
ethyl)-3H-benzoimidazole-5-carboxylic acid cyc10propylmethoxy-amide: MS APCI (+) m/z 561, 559 (M+ Br pattern) and MS APCI (-) mlz 559, 557 (M- Br pattern) detected; 1H NMR (400MHz, DMSO-de) 811.75 (s, 1H), 8.47 (s, 1H), 8.04 (s, 1H), 7.77 (s, 1H), 7.62 (d, 1H), 7.28 (dd, 1H), 6.40 (dd, 1H), 4.78 (t, 2H), 3.82 (t, 2H), 3.62 (d, 2H), 3.07 (s, 3H), 1.02 (m, 1H), 0.49 (m, 2H), 0.21 (m, 2H); 19F NMR (376MHz, DMSO-d6) -132.66 (s).
Example 30
The following compounds were prepared similarly using the appropriate methyl
ester and Michael acceptor and methods described previously.
(Formula removed)


[6-(5-Amino-[l,3,4]oxadiazol-2-yl)-4-fluoro-lH-benzoimidazol-5-yl]-(4-bromo-2-
methyl-phenyl)-amine (24a)
Step A: 6-(4-Bromo-2-methyl-phenylamino)-7-fluoro-3H-benzoimidazole-5-carboxylic
acid hydrazide 20a
6-(4-Bromo-2-memyl-phenylamino)-7-fluoro-3H-benzoimidazole-5-carboxylic acid methyl ester 8a (0.051 g, 0.135 mmol) is suspended in EtOH (δ ml) and hydrazine hydrate (0.118 g, 2.023 mmol) is added. The reaction mixture is heated at reflux for 16 hours. The reaction mixture is concentrated under reduced pressure and purified by FCC eluted with 97:3 ethyl acetate:MeOH to give 0.041 g (81%) of clean desired product: LC/MS ESI (+) m/z 378,380 (M+ Br pattern) detected.
Step B: [6-(δ-Amino-[l,3,4]oxadiazol-2-yl)-4-fluoro-lH-bejuoimidazol-5-yl]-(4-bromo-2-methyl-phenyl)-amine 24a
6-(4-Bromo-2-methyl-phenylarmno)-7-fluoro-3^benzoimidazole-5-carboxylic acid hydrazide 20a (0.041 g, 0.109 mmol) is suspended in 1,4-dioxane (1.δ ml) and 36 ul of a 3 M solution of cyanogen bromide in methylene chloride is added. NaHCCb (9 mg, 0.109 mmol) in water (1.δ ml) is then added. After 16 hours, the reaction mixture is diluted with water and brine and extracted with THF. The combined organic extracts are dried (Na2SO4) and concentrated under reduced pressure. Purification by FCC eluted with 98:2 ethyl acetate:MeOH gives 24 mg (55%) of pure desired product as a yellow solid: LC/MS ESI (+) ni/z 403, 405 (M+ Br pattern) detected; 1H-NMR (400 MHz, DMSO-d6) δ 12.97 (s, 1H), 8.42 (s, 1H), 7.94 (s, 1H), 7.74 (s, 1H), 7.36 (s, 2H), 7.33 (d, 1H), 7.15 (d, 1H), 6.40 (bs, 1H), 2.34 (s, 3H).
Example 32
(Formula removed)

[6-(δ-Amino-[l,3,4]oxadiazol-2-yl)-4-fluoro-lH-benzoimidazol-5-yl]-(4-chloro-2-
methyl-phenyl)-amine (24b)
[6-(δ-Amino-[l,3,4]oxadiazol-2-yl)-4-fluoro-lH-benzoimidazol-5-yl]-(4-chloro-
2-methyl-phenyl)-amine 24b is prepared as described in example 31 starting with 6-(4-chloro-2-metliyl-phenylanuino)-7-fluoro-3H-benzoirnidazole-5-carboxylic acid methyl ester 8e. LC/MS ESI (+) m/z 359, 361 (M+ C1 pattern) detected; 1H NMR (400MHz, DMSO-d6) 8 8.42 (s, 1H), 8.00 (bs, 1H), 7.78 (bs, 1H) 7.48 (s, 2H), 7.22 (s, 1H), 7.04 (d, 1H), 6.48 (bs, 1H), 2.37 (s, 3H).
Example 33
(Formula removed)

[6-(5-Amino-[l,3,4Joxadiazol-2-yl)-4-fluoro-lH-benzoimidaz/ol-5-yl]-(4-bromo-2-
chloro-phenyl)-amine (24c) [6-(δ-Arnmo-[l,3,4]oxadiazol-2-yl)-4-£luoro-lH-benzoimidazol-5-yl]-(4-bromo-
2-chloro-phenyl)-amine 24c is prepared as described in example 31 starting with 6-(4-
bromo-2-Chloro-phenylarnino)-7-fluoro-3H-benzoimidazole-5-carboxylic acid methyl
ester 8b. MS APCI (+) m/z 425, 423 (M+ Br pattern) and MS APCI {-)m/z 423, 421 (M-
Br pattern) detected.
Example 34
(Formula removed)

6-(4-Chloro-2-methyl-phenylamuw)-7-fluoro-3H-benzoimidazole-5-carboxylicacid
hydrazide (20b)
6-(4-chloro-2-methyl-phenylaino)-7-fluoro-3H-berizoirnidazole-5-carboxylic
acid hydrazide 20b is prepared as described in example 31, step A from 6-(4-chloro-2-methyl-phenylarnmo)-7-fluoro-3H-benzoimidazole-5-carboxylic acid methyl ester 8e. LC/MS ESI (+) m/z 334, 336 (M+ CI pattern) detected; 1H NMR (400MHz, DMSO-d6)
6 13.09 (bs, 1H), 9.98 (s, 1H), 8.40 (s, 1H), 8.17 (bs, 1H), 7.64 (bs, 1H), 7.20 (s, 1H), 7.03 (d, 1H), 6.41 (bs, 1H), 4.49 (s, 2H), 2.23 (s, 3H).
Example 35
(Formula removed)

δ-[6-(4-Chloro-2-methyl-phenylamino)-7-fluoro-3H-benz0imidazol-5-yl]-[l,3,4]oxadiazol-2-ol (22a)
6-(4-chloro-2-methyl-phenylamino)-7-fluoro-3H-benzoimidazole-5-carboxylic
acid hydrazide 20b (0.050 g, 0.150 mmol) is suspended in PhMe (2 ml) and a 20% phosgene solution in PhMe (0.24 ml, 0.45 mmol) is added. The reaction mixture is stirred at reflux under N2 for lh and then cooled to rt. The reaction mixture is quenched by the addition of a 1:1 mixture of THF and 10% HCI (20 ml). The layers are separated and the aqueous layer is extracted with THF (3x). The combined organic layer is washed with brine, dried (Na2SO4) and concentrated under reduced pressure to give 54 mg (99%) of desired product as a yellow solid: LC/MS ESI (+) m/z 360, 362 (M+ CI pattern) detected; 1H NMR (400MHz, DMSO-d6) 8 12.64 (s, 1H), 8.83 (s, 1H), 7.88 (s, 1H), 7.30 (s, 1H), 7.20 (d, 1H), 7.00 (dd, 1H), 6.38 (dd, 1H), 2.30 (s, 3H).
Example 36
(Formula removed)

(4-Chloro-2-methyl-phenyl)-(4-fluoro-6-[l,3,4]oxadiazol-2-yl-lH-benzoimidazol-5-yl)-
amine (21a)
6-(4-Chloro-2-memyl-phenyianimo)-7-fluoro-3H-benzoimidazole-5-carboxylic acid hydrazide 20b (0.048 g, 0.144 mmol) is suspended in 3 ml absolute EtQH and HC(OEt)3 (0.60 ml, 3.54 mmol) is added followed by catalytic pTsOHH2O. The reaction mixture is heated to reflux under N2. After 2h, the reaction mixture is cooled to room temperature and concentrated under reduced pressure. Purification by flash column chromatography (97:3 ethyl acetate:MeOH) gives 36 mg (73%) desired product as a light yellow solid. LC/MS ESI (+) m/z 344, 346 (M+ CI pattern) detected; 1H NMR (400MHz, DMSO-d6) 513.10 (bs, 1H), 9.39 (s, 1H), 8.49 (s, 1H), 8.10 (bs, 1H), 7.78 (bs, 1H), 7.20 (d, 1H), 7.00 (dd, 1H), 6.41 (bs, 1H), 2.18 (s, 3H).
Example 37
(Formula removed)

δ-[6-(4-Chloro-2-methyl-phenylamino)-7-fluoro-3H-benzoimidazol-5-yl]-[l,3,4]oxadiazole-2-thiol (23a)
6-(4-Chloro-2-memyl-phenylarmno)-7-fluoro-3H-benzoimidazole-5H-carboxylic acid hydrazide 20b (0.050 g, 0.150 mmol) is suspended in 3 ml absolute EtOH and cooled to 0 °C under N2. CS2 is added (26 mg, 0.346 mmol) followed by powdered KOH (8 mg, 0.150 mmol). After stirring at 0 °C for 30 min, the reaction mixture is heated to reflux. After 3.δ h, the reaction mixture is quenched by the addition of water, followed by the addition of ethyl acetate and IN HC1. The layers are separated and the aqueous layer is extracted with ethyl acetate. The combined organic extracts are dried (Na2SO4) and concentrated under reduced pressure to give the desired product as a yellow solid: LC/MS ESI (+) mfz 376, 378 (M+ CI pattern) detected; 1H NMR (400MHz, DMSO-d6) δ 8.51 (s, 1H), 7.92 (s, 1H), 7.19 (s, 1H), 7.12 (s, 1H), 6.98 (d, 1H), 6.29 (d, 1H), 2.28 (s, 3H).
Example 38
(Formula removed)

6-(4-Bromo-2-chloro'phenylamino)-7-fluoro-3H-benzoimidazole-5-carboxyUcacid
methylamide (lloo)
6-(4-Bromo-2-chloro-phenylanimo)-7-fluoro-3H-benzoimidazole-5-carboxylic
acid 10c (0.029 g, 0.076 mmol) is dissolved in N,N-dimethylformamide (l.lmL). HOBT (0.016 g, 0.10 mmol), triethylamine (0.028 mL, 0.20 mmol), methylamine (0.059 mL, 0.12 mmol, 2 M solution in tetrahydrofuran), and EDCI (0.019 g, 0.10 mmol) are added consecutively to the reaction mixture at room temperature. The solution is stirred at room temperature for 16 hours under N2. The reaction mixture is poured into a separatory funnel and diluted with ethyl acetate and water and the layers separated. The ethyl acetate layer is washed successively with aqueous saturated NH4CI (2x), brine (lx), aqueous
saturated sodium bicarbonate (2x), water (lx), and brine (lx), dried (MgSO4) and concentrated under reduced pressure. The resulting solid is purified by FCC (eluting with 19:1 methylene chloride:methanol) to yield 0.013 g (42%) of the pure desired product. MS APCI (+) m/z 397, 399 (M+, Br pattern) detected; lH NMR (400 MHz, DMSO-d6) 8 8.76 (broad s, 1H), 8.69 (m, 1H), 8.41 (s, 1H), 7.76 (s, 1H), 7.63 (d, 1H), 7.30 (dd, 1H), 6.50 (dd, 1H), 2.76 and 2.75 (s and s, 3H total, amide rotamers). 19F MMR (376 MHz, DMSO-d6)-132.69 (s).
Example 39
The following compounds are prepared using methods similar to that described
above in Example 38 by using the appropriate carboxylic acid and amine. In those cases that contain two amine functionalities, the appropriate mono Boc protected amine is used in the coupling reaction and the Boc group is later removed in a final step under standard TFA deprotection conditions.
(Formula removed)
[6-(4-Bromo-2-chloro~phenylamino)-7-fluoro-3H-benzoimidazol-5-yl]-methanol(10e)
6-(4-Bromo-2-chloro-phenylammo)-7-fluoro-3H-benzoimidazole-5-carboxylic
acid methyl ester 8b (1.06 g, 2.65 mmol) is suspended in tetrahydrofuran (25 mL) and cooled to -78 °C. Lithium aluminum hydride (8.03 mL, 8.03 mmol, IM solution in tetrahydrofuran) is added dropwise to the reaction mixture. After stirring for 10 minutes at -78 °C, the reaction mixture is warmed to 0 °C and becomes a homogeneous solution. The reaction mixture is stirred for δ minutes at 0 °C and then cooled again to -78 °C. The reaction mixture is quenched with MeOH, diluted with Rochelle's salt, warmed to room temperature and stirred for 1 hour. The reaction mixture is then poured into a separatory funnel, diluted with ethyl acetate, and the layers separated. The aqueous phase is extracted with ethyl acetate. The combined ethyl acetate layers are dried (Na2SO4) and concentrated under reduced pressure to yield 0.98 g (100%) of the pure desired product as a pale yellow solid. MS ESI (+) m/z 370, 372 (M+, Br pattern) detected.
Example 41
(Formula removed)

6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3H-benzoimidazole-S-carbaldehyde(10J)
[6-(4-Bromo-2-chloro-phenylainmo)-7-fluoro-3H-benzoimidazol-5-yl]-methanol
l0e (0.96 g, 2.58 mmol) is dissolved in tetrahydrofuran/acetone (1:1, 15 mL), and Mn O2 (2.24 g, 25.8 mmol) is added. The reaction mixture is stirred at 50 °C for 10 hours under N2. The reaction mixture is filtered through silica gel and eluted with methylene chloride/methanol (10:1, 1 L). The filtrate is concentrated under reduced pressure to a small volume and then filtered through an Acrodisc syringe filter to remove small amounts of MNO2 that passed through the silica gel. The filtrate is concentrated under reduced pressure and the residue is purified by flash column chromatography (eluting with 20:1 methylene chloride:methanol) to yield 0.81 g (85%) of the pure desired product as a bright yellow solid. MS ESI (+) m/z 368,370 (M+, Br pattern) detected.
(Formula removed)

l-[6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazol-5-yl]-2-
hydroxy-ethanone (lOg)
Step A: l-[6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazol-5-yl] -2-methoxymethoxy-ethanol lOi
To a solution of tributyl-methoxymethoxymethyl-stannane (864 mg, 2.37 mmol, prepared by the procedure reported in J. Org. Chem. 1988, 53,4131) in THF (8 mL) at -78 °C is added n-BuLi (0.94 mL, 2.35 mmol, 2.δ M solution in hexane). After stirring for 3 min, a solution of 6-(4-bromo-2-chloro-phenylamino)-7-fiuoro-3-methyl-3/f-benzoimidazole-5-carbaldehyde lOh (59 mg, 0.15 mmol) in THF (2 mL) is added at -78 °C. After stirring for 40 min at -78 °C, the reaction is quenched with saturated aqueous NEUCl at -78 °C, warmed to room temperature, and diluted with EtOAc. The organic layer is washed with brine, dried over MgSCU, filtered, concentrated, and purified by flash chromatography (1.δ % MeOH in CH2CI2) to give the desired product (45 mg, 64%): MS APCI (+) m/z 458,460 (M+, Br pattern) detected.
Step B: l-[6-(4-Bromo-2-chloro-phenylamino)-7-fliioro-3-methyl-3H-benzoimidazol-5-yl] -2-methoxymethoxy-ethanone lOj
A solution of l-[6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3flr-benzoimidazol-5-yl]-2-methoxymethoxy-ethanol lOi (44 mg, 0.096 mmol) and the Dess-Martin periodinane (49 mg, 0.12 mmol) in CH2CI2 (1.δ mL) is stirred for 1.δ h at rt. The reaction mixture is diluted with ether (3 mL). Saturated aqueous NaHCCh (1 mL) containing sodium thiosulfate pentahydrate (74 mg) is added. The resulting mixture is stirred for 10 min and diluted with EtOAc. The organic layer is washed with saturated aqueous NaHCO3 and brine, dried over MgSO4, filtered, and concentrated in vacuo to give a crude material which is purified by flash chromatography (1.δ% MeOH in CH2C12) to afford the desired product (31 mg, 71%): MS APCI (+) m/z 456, 458 (M+, Br pattern) detected.
Step C: l-[6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazol-5-ylJ-2-hydroxy-ethanone l0g
A mixture of l-[6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3iif-benzoimidazol-5-yl]-2-methoxymethoxy-ethanone lOj (15 mg, 0.033 mmol), 10% aqueous HC1 (0.3 mL), methanol (0.01 mL), and water (0.05 mL) is stirred for 3 days at rt. The reaction mixture is neutralized with saturated aqueous NaHCO3, and diluted with EtOAc. The organic layer is washed with brine, dried over MgSO4, filtered, concentrated in vacuo, and purified by flash chromatography (1.δ% MeOH in CH2CI2) to afford the desired prouduct (7.3 mg, 54%): MS APCI (+) m/z 412, 414 (M+, Br pattern) detected; 1H NMR (400 MHz, acetone-d6) 8 8.64 (s, 1H), 8.34 (s, 1H), 8.16 (s, lH), 7.58 (d, lH), 7.31 (dd, 1H), 6.59 (dd, 1H), 4.94 (s, 2H), 4.06 (s, 3H); 19F NMR (376 MHz, acetone-d6) -132.45 (s, IF).
Example 43
(Formula removed)

l-[6-(4-Bronto-2-chloro-phenylamino)-7-fluoro-3H-benzoimidazol-5-yl]-2-hydroxy-
ethanone (10k)
Step A: l-[6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3H-benzoimidazol-5-yl]-2-methoxymethoxy-ethanol 101
6-(4-Bromo-2-chloro-phenylarnino)-7-fluoro-3H-benzoimidazole-5-carbaldehyde l0f is treated with tributyl-methoxymethoxymethyl-stannane according to the procedure
described in Example 42, Step A to yield compound 101. MS APCI (+) m/z 444, 446 (M+, Br pattern) detected.
Step B: l-[6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3H-benzoimidazol-5-yl]-2-methoxymethoxy-ethanone 10m
To a solution of oxalyl chloride (0.11 mL, 0.22 mmol) in CH2C12 (1 mL) at -78 °C is added DMSO (0.016 mL, 0.22 mmol). After stirring for 3 min, a solution of l-[6-(4-bromo-2-chloro-phenylanmio)-7-fluoro-3fl-benzoimidazol-5-yl]-2-methoxymethoxy-ethanol 101 (25 mg, 0.056 mmol) in methylene chloride (ImL) is added. The resulting solution is stirred for 30 min at -78 °C. TEA (0.1 mL, 0.71 mmol) is added. The reaction mixture is slowly warmed to room temperature, stirred for δ min at room temperature, and diluted with water and CH2CI2. The organic layer is separated, dried over MgSCu, filtered, and concentrated to give the crude product which is directly used without further purification.
Step C: l-[6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3H-benzoimidazol-5-yl]-2-hydroxy-ethanone 10k
l-[6-(4-Bromo-2-chloro-phenylanimo)-7-fluoro-3iy-benzoirnidazol-5-yl]-2-methoxymethoxy-ethanone 10m is deprotected according to the procedure described in Example 42, Step C to yield compound 10k. MS APCI (+) m/z 398, 400 (M+, Br pattern) detected; ]H NMR (400 MHz, CD3OD) 8 8.38 (s, 1H), 8.04 (s, 1H), 7.52 (d, 1H), 7.22 (dd, 1H), 6.53 (dd, 1H), 4.90 (m, 2H); 19F NMR (376 MHz, CD3OD) -133.96 (s, IF).
Example 44

(Formula removed)

l-[6-(4-Bromo-2-chloro-phenylainino)-7-fluoro-3H-benzoimidazol-5-yl]-2-ethoxy-
ethanone (lOn)
Step A: l-[6-(4-Bromo-2-chloro-phenylarnino)-7-fluoro-3H-benzoimidcaol-5-yl]-2-
ethoxy-ethanol lOo
«
To a solution of Uthiomethyl ethyl ether in THF (6 mL) (prepared from 4,4'-di-tert-butylbiphenyl (585 mg, 2.20 mmol), Li (18 mg, 2.59 mmol), and EtOCH2Cl (0.20 mL, 2.05 mmol) by the procedure reported in Tetrahedron 1996, 52, 1643) is added a solution of 6-(4-bromo-2-chloro-phenylammo)-7-fluoro-3^-beiizoimidazole-5-carbaldehyde l0f (29 mg, 0.080 mmol) in THF (1 mL) at -78 °C. The resulting solution is stirred for 1 h and then quenched with saturated aqueous NH4CI at -78 °C, warmed to room temperature, and extracted with EtOAc. The organic layer is washed with brine, dried over MgSCu, filtered, concentrated in vacuo, and purified by flash chromatography (100% CH2C12 to 3% to δ% MeOH in CH2C12) to give the desired product (15 mg, 44%): MS APCI (+) mJz 428,430 (M+, Br pattern) detected.
Step B: 1 -[6-(4-Bromo-2~chloro-phenylamino)-7-fluoro-3H-benzoimidazol-5-yl]-2-ethoxy-ethanone lOn
The title compound is prepared from l-[6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3H-benzoimidazol-5-yl]-2-ethoxy-ethanol l0o according to the procedure described in Example 42, Step B except that the reaction mixture is not treated with saturated aqueous NaHCO3 containing sodium thiosulfate pentahydrate. MS APCI (+)
mlz 426, 428 (M+, Br pattern) detected; 1H NMR (400 MHz, CD3OD) δ 8.36 (s, 1H), 8.04 (s, 1H), 7.51 (d, 1H), 7.21 (dd, 1H), 6.51 (dd, 1H), 4.76 (s, 2H), 3.57 (q, 2H), 1.19 (t, 3H); 19F NMR (376 MHz, CD3OD) -133.96 (s).
Example 45
(Formula removed)

l-[6-(4-Bromo-2-chloro-phenylamino)-7-fluoro~3H-benzoimidazol-5-yl]-2-methoxy-
ethanone (l0p) l-[6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3H-benzoimidazol-5-yl]-2-
methoxy-ethanone 10p is prepared from 6-(4-bromo-2-chloro-phenylarnino)-7-fluoro-3H-
benzoimidazole-5-carbaldehyde l0f and lithiomethyl methyl ether by the procedures
described in Example 44. MS APCI (+) m/z 412, 414 (M+, Br pattern) detected.
Example 46
(Formula removed)

2-Benzyloxy-l-[6-(4-bromo-2-chloro~phenylamino)-7-fluoro-3H-benzoimidazol-5-yl]-
ethanone (10p)
Step A: 2-Benzyloxy-l-[6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3H-benzoimidazol-δ-yl]-ethanol l0r
To a solution of benzyloxymethyllithium in THF (2 mL, prepared from n-Bu3SnCH2OBn (505 mg, 1.23 mmol) and n-BuLi (0.49 mL, 1.22 mmol, 2.δ M solution in hexane) by the procedure reported in J. Am. Chem. Soc. 1978, 100, 1481) is added a solution of 6-(4-bromo-2-chloro-phenylarruno)-7-fluoro-3H-benzoimidazole-5-carbaldehyde l0f (51 mg, 0.14 mmol) in THF (3 mL) at -78 °C. The resulting solution is stirred for 1 h at -78 °C. The reaction is quenched with saturated aqueous NH4CI, and extracted with EtOAc. The organic layer is dried over MgSO4, filtered, concentrated in vacuo, and purified by flash chromatography (100% CH2C12 to 3% MeOH in CH2C12) to afford the desired product (46 mg, 68%): MS APCI (+) m/z 490, 492 (M+, Br pattern) detected.
Step B: 2-Benzyloxy-l-[6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3H-benzoimidt3Zol-δ-ylJ-ethanone lOq
The title compound is prepared from 2-benzyloxy-l-[6-(4-bromo-2-chloro-phenylanimo)-7-fluoro-3i?-benzoimidazol-5-yl]-ethanol lOr by the procedure described in Example 42, Step B except that the reaction mixture is not treated with saturated aqueous NaHCO3 containing sodium thiosulfate pentahydrate: MS APCI (+) m/z 488, 490 (M+, Br pattern) detected; 1H NMR (400 MHz, CD3OD) δ 8.37 (s, 1H), 8.02 (s, 1H), 7.51 (d, 1H), 7.26 (m, 5H), 7.19 (dd, 1H), 6.46 (dd, 1H), 4.77 (s, 2H), 4.58 (s, 2H); 19F NMR (376 MHz, CD3OD) -134.52 (s).
Example 47
(Formula removed)

l-[6-(4-Bromo-2-chloro-phenylaniino)-7-fluoro-3H-benzoimidazol-5-yl]-2-methanesulfonyl-ethanone (10s)
Step A: l-[6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3H-benzoimidazol-5-yl]-2-
methanesulfonyl-ethanol l0t
To a solution of methyl sulfone (65 mg, 0.68 mmol) in THF (1.δ mL) is added a
solution of n-BuLi (0.27 mL, 0.68 mmol, 2.δ M solution in hexane) at -78 °C. After
stirring for δ min, HMPA (0.1 mL) is added. After stirring for additional 10 min, a
solution of 6-(4-bromo-2-chloro-phenylammo)-7-fluoro-3h-benzoimidazole-5-
carbaldehyde l0f (26 mg, 0.069 mmol) in THF (1 mL) is added. The resulting solution is stirred for 1.δ h at -78 °C. The reaction is quenched with saturated aqueous NH4CI, warmed to room temperature, and diluted with EtOAc. The organic layer is washed with water, dried over MgSO4, filtered, concentrated in vacuo, and purified by flash chromatography (3% MeOH in CH2CI2) to give the crude desired product (31 mg, 96%) which is used directly without further purification: MS APCI (+) m/z 462, 464 (M+, Br pattern) detected.
Step B: l-[6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3H-benzoimidazol-5-yl]-2-methanesulfonyl-ethanone 10s
The title compound is prepared from l-[6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3i/-benzoimidazol-5-yl]-2-methanesulfonyl-ethanol l0t by the procedure described in Example 42, Step B except that the reaction mixture is not treated with
saturated aqueous NaHCO3 containing sodium thiosulfate pentahydrate: MS APCI (+) m/z 460, 462 (M+, Br pattern) detected; 1H NMR (400 MHz, acetone-D6) δ 8.44 (s, 1H), 8.33 (s, 1H), 7.59 (s, 1H), 7.32 (d, 1H), 6.68 (dd, 1H), δ.00 (s, 1H), 3.15 (s, 3H); 19F NMR (376 MHz, acetone-4) -132.97 (s).
Example 48
(Formula removed)

l-[6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3H-benz0imidazol-5-yl]-ethane-l,2-
diol(10u)
Step A: l-[6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3H-benzoimidazol-5-yl]-2-
(isopropoxy-dimethyl-silanyl)-ethanol 10v
To a solution of the Grignard reagent prepared from Mg and chloromethyl dimethylisopropoxy silane (Org. Synth. 1992, 69, 96 ) [4.4 mL, 3.26 mmol, 0.74 M solution (based on 90% purity)] in THF, is added a solution of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3/y-benzoiinidazole-5-carbaldehyde l0f (200 mg, 0.54 mmol) in THF (1 mL) at -78 °q. After stirring for 1 h at -78 °C, the reaction is quenched with saturated aqueous NH4CI, and extracted with EtOAc. The organic layer is dried over MgSO4, filtered, concentrated in vacuo to afford the crude desired product which is directly used without further purification.
Step B: l-[6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3H-benzoimidazol-5-yl]-ethane-1,2-diol 10u
To the crude l-[6-(4-bromo-2-Coro-phenylarnmo)-7-fluoro-3H-benzoimidazol-δ-yl]-2-(isopropoxy-dimemyl-silanyl)-ethanol lOv in MeOH-THF (δ mL-δ mL) is added KHCO3 (54 mg, 0.54 mmol), and KF (74 mg, 1.27 mmol), and 30% aqueous H202 (0.20 mL) at rt. After stirring for 3.δ h at room temperature, the reaction mixture is diluted with water, and extracted with EtOAc. The organic layer is dried over MgSO4, filtered, concentrated in vacuo, and purified by flash chromatography (8% to 10 % MeOH in CH2C12) to give the desired product (74 mg, 34%): MS APCI (+) m/z 400, 402 (M+, Br pattern) detected; 1H NMR (400 MHz, CD3OD) 8 8.20 (s, 1H), 7.62 (broad s, 1H), 7.47 (d, 1H), 7.14 (dd, 1H), 6.30 (d, 1H), 4.96 (t, 1H), 3.64 (m, 2H); 19F NMR (376 MHz, CD3OD) -136.87 (s).
Example 49
(Formula removed)

[6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidaziol-5-yl]-
pyridin-2-yl-methanol (lOw)
To a solution of 2-bromopyridine (0.10 mL, 1.04 mmol) in THF (3 mL) at -78 °C
is added n-BuLi (0.39 mL, 0.98 mmol, 2.δ M solution in hexane). After stirring for 10 min at -78 °C, a solution of 6-(4-bromo-2-chloro-phenyIamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carbaldehyde l0h (25 mg, 0.064 mmol) in THF (1 mL) is added. The resulting reaction mixture is stirred for 1.δ h at -78 °C, quenched with saturated aqueous NH4CI, and extracted with EtOAc. The organic layer is dried over MgSO4, filtered, concentrated in vacuo, and purified by flash chromatography (2.δ% MeOH in CH2C12) to
afford the desired product (18 mg, 62%): MS APCI (+) m/z 461, 463 (M+, Br pattern) detected; 1H NMR (400 MHz, CD3OD) 8 8.31 (d, 1H), 8.16 (s, 1H), 7.65 (m, 3H), 7.38 (d, 1H), 7.10 (m, 1H), 7.00 (dd, 1H), 6.11 (dd, 1H), 6.05 (s, 1H), 3.94 (s, 3H); 19F NMR (376 MHz, CD3OD) -135.79 (s).
(Formula removed)

(4-Bromo-2-chloro-phenyl)-(4-fluoro-6-oxazol-5-yl-lH-benzoimidazol-5-yl)-amine
(lOx)
Step A: [6-(4-Bromo-2-chloro-phaiylamino)-7-fluoro-3-(2-methanesulfonyl-ethyl)-3H-
benzoimidazol-5-yl]-methanol Wy
6-(4-Bromo-2-chloro-phenylarmno)-7-fluoro-(2-methanesiilfonyl-ethyl)-3H-benzoimidazole-5-carboxylic acid methyl ester lice (0.300 g, 0.594 mmol) is suspended in a mixture of EtOH (6 ml) and THF (4 ml) under N2. NaBH, (0.112 g, 2.97 mmol) is added. After approximately 4 days stirring, reaction mixture is quenched by the addition of AcOH until the reaction mixture reaches pH 7. The reaction mixture is concentrated to dryness under reduced pressure and the residue partitioned between ethyl acetate and water. The layers are separated and the organic layer is washed with water (3x), brine, and dried (Na2SO4). The organic layer is concentrated under reduced pressure until a white precipitate forms which is collected by filtration to give 0.225 g (79%) clean desired product: LC/MS ESI (+) m/z 478, 476 (M+ Br partem) detected.
Step B: 6-(4-Bromo-2-chloro-pheiiylamino)-7-fluoro-3-(2-methanesulfoJiyl-ethyl)-3H~ benzoimidazole-5-carbaldehyde 10z
[6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-(2-methanesulfonyl-ethyl)-3H-benzoimidazol-5-yl]-methanol lOy (0.050, 0.105 mmol) is dissolved in 1:1 THF:acetone (2 ml) under N2 and MNO2 (0.046 g, 0.524 mmol) is added. The reaction mixture is stirred at room temperature for 16 h, and then at 55 °C for δ h. Additional MNO2 (0.046 g, 0.524 mmol) is added and the reaction mixture stirred at 55 °C for 2 h. The reaction mixture is concentrated to dryness and the residue dissolved in 10:1 methylene chloride:MeOH. The solution is filtered through a silica gel plug eluted with 10:1 methylene chIoride:MeOH. The resulting filtrate is concentrated under reduced pressure to give 41 mg (82%) desired product as a bright yellow solid.
Step C: (4-Bromo-2-chloro-phenyl)-(4-fluoro-6-oxazol-5-yl-lH-benzoimidazol-5-yl)-amine lOx
6-(4-Bromo-2-Chloro-phenylarmino)-7-fluoro-3-(2-methanesulfonyl-ethyl)-3H-benzoimidazole-5-carbaldehyde 10z (0.025 g, 0.053 mmol) is suspended in MeOH (2 ml) and K2CO3 (0.015 g, 0.105 mmol) is added followed by tosylmethyl isocyanide (0.011 g, 0.058 mmol). The reaction mixture is heated to reflux under N2 for 16 h. After cooling, additional tosylmethyl isocyanide (0.011 g, 0.058 mmol) is added and the reaction mixture heated to reflux under N2 for 16 h. The reaction mixture is cooled to room temperature, concentrated under reduced pressure and dissolved in ethyl acetate. The organic solution is washed with water and brine. The combined aqueous washes are extracted with ethyl acetate. The combined organic extracts are dried (Na2SO4) and concentrated under reduced pressure. Purification by flash column chromatography eluted with 20:1 methylene chloride:MeOH gives 4 mg (18%) desired product 10x and 1
mg (4%) (4-bromo-2-chloro-phenyl)-[4-fluoro-l-(2-methanesulfonyl-ethyl)-6-oxazol-5-y1-1H-benzoimidazol-5-yl]-aniine.
(4-Bromo-2-chloro-phenyl)-(4-fluoro-6-oxazol-5-yl-lH-benzoimidazol-5-yl)-amine l0x. LC/MS ESI (+) m/z 409, 407 (M+ Br pattern) detected; 1H NMR (400MHz, MeOH-cL,) 6 8.33 (s, 1H), 8.24 (s, 1H), 7.94 (bs, 1H), 7.51 (d, 1H), 7.33 (s, 1H), 7.07 (dd, lH),6.14(dd,lH).
(4-Bromo-2-chloro-phenyl)-[4-fluoro-1 -(2-methanesulfonyl-ethyl)-6-oxazol-δ -yl-lH-beriZoimidazol-5-yl]-armne. LC/MS ESI (+) m/z 515, 513 (M+ Br pattern) detected; 1H NMR (400MHz, MeOH-d4) § 8.39 (s, 1H), 8.28 (s, 1H), 8.03 (s, 1H), 7.52 (d, 1H), 7.37 (s, 1H), 7.07 (m, 1H), 6.14 (dd, 1H), 3.83 (t, 2H), 2.99 (s, 3H), 1.18 (t, 2H).
Example 51
(Formula removed)

(4-Bromo-2-chloro-phenyl)-[4-fluoro-6-(3HHmidazol-4-yl)-lH-benzoimidazol-5-yl]-
amine (l0aa)
Step A: (4-Bromo-2-chloro-phenyl)-{4-fluoro-l-(2-methanesulfonyl-ethyl)-6-[4-(toluene-
4-sulfonyl)-4,δ-dihydro-oxazol-5-yl]-lH-benzoimidazol-5-yl}-amine 1 Obb
6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-(2-methanesulfonyl-ethyl)-3H-benzoimidazole-5-carbaldehyde lOz (0.050 g, 0.107 mmol) is suspended in EtOH (0.δ ml) under N2 and tosylmethyl isocyanide (0.020 g, 0.105 mmol) is added followed by catalytic NaCN (~1 mg). After 2 h, 2 ml THF is added to assist with solubility. After stirring for 16 h at room temperature, a second equivalent of tosylmethyl isocyanide
(0.020 g, 0.105 mmol) is added. After 8 h, the reaction mixture is concentrated under reduced pressure and used as is in the next reaction: LC/MS ESI (+) nt/z 671,669 (M+ Br pattern) detected.
Step B: (4-Bromo-2-chloro-phenyl)-[4-flnoro-6-(3H-imidazol-4-yl)-lH-bemoimidazol-5-yl]-amine 10aa
(4-Bromo-2-chloro-phenyl)-{4-fluoro-l-(2-methanesulfonyl-ethyl)-6-[4-(toluene-4-sulfonyl)-4,δ-dihydro-oxazol-5-yl]-lH-benzoimidazol-5-yl}-amine lObb (0.072 g, 0.107 mmol) is treated with 2.4 ml of a 2.0 M NH3 in MeOH solution in a sealed pressure tube. The reaction mixture is then heated to 90 °C with stirring for 20 h and furthered stirred at room temperature for 3 days. The reaction mixture is transferred to a round bottom flask and concentrated under reduced pressure. Purification by flash column chromatography, twice, eluted with 10:1 methylene chloride:MeOH, followed by successive trituations with methylene chloride and then diethyl ether gives 3 mg (7%) desired product: LC/MS ESI (+) m/z 408, 406 (M+ Br pattern) detected; 1H NMR (400MHz, MeOH-d4) δ 8.23 (s, 1H), 7.87 (s, 1H), 7.74 (s, 1H), 7.46 (m, 1H), 7.32 (d, 1H), 7.05 (m, 1H), 6.20 (dd, 1H).
Example 52
(Formula removed)
6-(4-Bromo-2-chloro-phenylamino)-7-chloro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-etJwxy)-amide (lOcc)
Step A: 3-Chloro-2,4-difluoro-5-nitro-benzoic acid 2a
3-Chloro-2,4-difluoro-benzoic acid la (3.00 g, 15.6 mmol) is added to a stirred solution of concentrated H2SO4 (16 mL) and fuming nitric acid (0.85 mL, 20.3 mmol). After 3 hours a precipitate forms. The yellow slurry is poured onto ice water (100 mL). The aqueous mixture is extracted with diethyl ether (3x). The organic extracts are dried (Na2SO4) and concentrated under reduced pressure to give 3.50 g (95%) of clean desired product as a pale yellow solid.
Step B: 4-Amino-3-chloro-2-fluoro-5-nitro-benzoic acid 3a
Ammonium hydroxide solution (6.88 g, -30% in water, 58.9 mmol) is added to a solution of 3-chloro-2,4-difluoro-5-nitro-benzoic acid 2a (3.δ g, 14.7 mmol) in water (16 mL) at 0 °C with stirring. Upon completion of the ammonium hydroxide addition the reaction mixture is warmed to room temperature. After δ hours the reaction mixture is cooled to 0 °C and concentrated HC1 is carefully added until the pH of the reaction mixture is near zero. The solid is collected by filtration and washed with water and diethyl ether. The solids are transferred to a round bottom flask as a solution in MeOH and EtOAc and concentrated under reduced pressure to give 2.96 g of a yellow solid. The filtrate is partitioned between diethyl ether and water and the organic layer is washed with brine. The combined organic extracts are dried (Na2SO4) and concentrated under reduced pressure to give 0.65 g of product. Recovered a total of 3.61 g (104%) of pure desired product, that is carried forward without further purification.
Step C: 4-Amino-3-chloro-2-fluoro-5-nitro-benzoic acid methyl ester 4a
To a stirred solution of 4-amino-3-chloro-2-fluoro-5-nitro-benzoic acid 3a (3.61 g, 15.4 mmol) in THF (30 mL) and MeOH (10 mL), TMS diazomethane (9.23 mL, 2.0 M
solution in hexanes, 18.δ mmol) is added. After completion of reaction, the reaction mixture is concentrated via rotary evaporation with acetic acid in the trap. The recovered oily solid is triturated with diethyl ether to provide 1.51 g of a yellow solid. The filtrate is concentrated and triturated with diethyl ether to give an additional 0.69 g of yellow solid. A total of 2.20 g (57%) of pure desired product is recovered.
Step D: 4-Amino-3-chloro-5-nitro-2-phenylamino-benzoic acid methyl ester 5c
4-Amino-3-chloro-2-fluoro-5-riitro-benzoic acid methyl ester 4a (2.20 g, 8.84 mmol) is suspended in MeOH (9.4 mL) and aniline (3.22 mL, 35.4 mmol) is added. The reaction mixture is heated to reflux with stirring under a nitrogen atmosphere. After 19 hours, the reaction is complete. Distilled water (3.22 mL) is added to the reaction mixture and refluxing is continued for one hour. The reaction mixture is cooled to 0 °C in an ice bath for 20 minutes. The reaction mixture is filtered and washed with 3:10 distilled water/MeOH (65 mL total) and then with MeOH. The solid is dissolved with CH2CI2 and concentrated under reduced pressure to give 2.40 g (84%) of pure desired product. MS APCI (-) m/z 320.3 (M-l) detected.
Step E: 4,δ-Diamino-3-chloro-2-phenylamino-bemoic acid methyl ester 6b
4-Amino-3-chloro-5-nitro-2-phenylarnino-benzoic acid methyl ester 5c (0.50 g, 1.55 mmol) is dissolved into 2:1 EtOH/MeOH (15.δ mL). Saturated aqueous NH4CI (15 mL), Zn powder (1.02 g, 15.6 mmol), and THF (10 mL) are added. After stirring for 20 hours, the reaction mixture is diluted with CH2CI2/THF and water. The organic layer is washed with water (3x). The combined organic extracts are dried (Na2SO4) and concentrated under reduced pressure. The solids are triturated with ether to give 0.32 g (70%) clean desired product.
Step F: 7-Chloro-6-phenylamino-3H-benzoimidazole-5-carboxylic acid methyl ester 7c
4,δ-Diamino-3-chloro-2-phenylamino-benzoic acid methyl ester 6b (0.32 g, 1.09 mmol) and formamidine acetate (72 mg, 1.64 mmol) in EtOH (36 mL) are heated, with stirring, to 80 °C. After 44 hours, the reaction mixture is cooled to room temperature and diluted with EtOAc and washed with water (3x), saturated NaHCO3, and brine. The combined organic extracts are dried (Na2SO4) and concentrated under reduced pressure to give 0.33 g (99%) clean desired product as a solid. MS APCI (+) m/z 302.3 (M+l) detected.
Step G: 6-(4-Bromo-phenylamino)-7-chloro-3H-benzoimidazole-5-carboxylic acid methyl ester 8g
7-Chloro-6-phenylamino-3H-benzoimidazole-5-carboxylic acid methyl ester 7c (0.327 g, 1.08 mmol) is dissolved into DMF (16 mL) and NBS (0.193 g, 1.08 mmol) is added. After one hour, the reaction mixture is quenched by the addition of saturated aqueous NaHSO3. The reaction mixture is then partitioned between EtOAc/THF and water. The organic layer is washed with water and brine. The combined organic extracts are dried (Na2SO4) and concentrated under reduced pressure. The recovered solid is triturated with ether to give 0.225 g (54%) pure desired product. MS ESI (+) m/z 382, 384 (M+, Br pattern) detected.
Step H: 6-(4-Bromo-2-chloro-phenylamino)- 7-chloro-3H-benzoimidazole-5-carboxylic acid methyl ester l0dd
6-(4-Bromo-phenylarmno)-7-chloro-3H-benzoimidazole-5-carboxylic acid methyl ester 8g (0.225 g, 0.591 mmol) is dissolved in DMF (2 mL) and NCS (79 mg, 0.591 mmol) is added. After the NCS is in solution concentrated HC1 (0.005 mL, 0.059 mmol) is added. After 2 hours, sodium bicarbonate, water andNaHSO3 are added to the reaction mixture. Solids are filtered and washed with water and ether to give 0.141 g (57%) of clean desired product as a tan solid. MS APCI (-) tn/z 414,416 (M-, Br pattern) detected.
Step I: 6-(4-Bromo-2-chloro-phenylamino)-7-chloro-3-methyl-3H-benzoimidazole-5-carboxylic acid methyl ester Wee
6-(4-Bromo-2-crdorc»-phenylammo)-7-chloro-3H-berizoimidazoIe-5-carboxylic acid methyl ester lOdd (0.141 g, 0.34 mmol), potassium carbonate (0.141 g, 1.02 mmol), and iodomethane (0.063 mL, 1.02 mmol) are dissolved in dimethylformamide (3 mL). After 20 hours, the reaction mixture is diluted with EtOAc and washed with water (3x), potassium carbonate, and brine. The organic layer is dried (Na2SO4) and concentrated to a brown oil. The N3 and Nl alkylated regioisomers are separated by flash chromatography (EtOAc). The recovery of the N3 alkylated regioisomer is 20.4 mg (28%). MS ESI (+) m/z 428,430 (M+, Br pattern) detected.
Step J: 6-(4-Bromo-2-chloro-phenylamino)-7-chloro-3-methyl-3H-benzoimidazole-5-carboxylic acid 10ff
6-(4-Bromo-2-chloro-phenylarmno)-7-chloro-3-memyl-3H-benzoimidazole-5-carboxylic acid methyl ester lOee (21 mg, 0.048 mmol) is dissolved into 2:1 THF/water (1.2 mL) and NaOH (0.190 mL, 1.0 M aqueous solution, 0.190 mmol) is added. After stirring for 4 hours the reaction is diluted with water and acidified to pH 2 by addition of 1.0 M HC1. The mixture is then extracted with 3:1 EtOAc/THF (3x), dried (Na2SO4) and
concentrated to give quantitative yield of desired prodcut as a white solid. MS APCI (+) m/z 414,416 (M+, Br pattern) detected.
Step K: 6-(4-Bromo-2-chloro-phenylamino)-7-chloro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-vinyloxy-ethoxy)-amide lOgg
6-(4-Bromo-2-chloro-phenylammo)-7-chloro-3-methyl-3H-benzoimidazole-5-carboxylic acid l0ff (32 mg, 0.077 mmol), 0-(2-vinyloxy-ethyl)-hydroxylamine (0.010 mL, 0.092 mmol), HOBt (13 mg, 0.093 mmol), triethylamine (0.011 mL, 0.077 mmol), and EDCI (19 mg, 0.10 mmol) are dissolved into dimethylformamide (1.0 mL) and allowed to stir under a nitrogen atmosphere at room temperature for 24 hours. The reaction mixture is diluted with EtOAc, washed with water (3x), 10% potassium carbonate (2x), saturated ammonium chloride, brine, dried (Na2SO4), and concentrated under reduced pressure to give 39 mg of 85% pure material. MS APCI (-) m/z 497, 501 (M-, Br pattern) detected.
Step L: 6-(4-Bromo-2-chloro-phenylamino)-7-chloro-3-meihyl-3H-betizoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide l0cc
Hydrochloric acid (0.78 mL, 1.0 M aqueous solution, 0.78 mmol) is added to a
suspension of 6-(4-bromo-2-chloro-phenylamino)-7-chloro-3-methyl-3H-
benzoimidazole-5-carboxylic acid lOgg (2-vinyloxy-ethoxy)-amide (39 mg, 0.078 mmol) in MeOH (1 mL). After one hour, the reaction mixture is neutralized to pH 7 and concentrated under reduced pressure. The solids are dissolved in EtOAc, washed with brine, dried (Na2SO4), and concentrated under reduced pressure. Flash chromatography (20:1 CH2Cl2/MeOH) provides 9 mg (23%) of pure product: MS APCI (+) m/z 473, 475
(M+, Br pattern) detected; lH NMR (400 MHz, CDC13) 8 8.30 (s, 1H), 8.08 (s, 1H), 7.57 (d, 1H), 7.15 (dd, 1H), 6.21 (d, 1H), 3.97 (s, 3H) 3.86 (m, 2H), 3.57 (m, 2H).
Example 53
(Formula removed)

6-(4-Bromo-2-chloro-phenylamino)-3H-benzoimidazole-5-carboxylicacid(2-hydroxy-
ethoxy)-amide (lOhh)
The above compound is prepared in an analogous fashion to Example 52 except that Step I is eliininated. MS APCI (-) m/z 457, 461 (M-, Br pattern) detected; lH NMR (400 MHz, CD3OD) δ 8.40 (s, 1H), 7.85 (s, 1H), 7.50 (d, 1H), 7.14 (dd, 1H), 6.21 (d, 1H), 3.84 (m, 2H), 3.61 (m, 2H).
Example 54
(Formula removed)

6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-2-methyl-3H-benzoimidazole-5-carboxylic
acid (2-hydroxy-ethoxy)-amide (10ii)
Step A: 4,δ-Diamino-3-fluoro-2-phenylamino-benzoic acid methyl ester 6c
4-Aniino-3-fluoro-5-nitro-2-phenylamino-benzoic acid methyl ester 26a (11.44 g, 37.48 mmol) is suspended in ethanol (400 mL) and ammonium formate (11.80 g, 187.0
mmol) and 20 % Pd(OH)2/C (10.00 g, 18.79 mmol) are added. The reaction mixture is stirred at 95 °C under N2 for 30 minutes. The reaction mixture is cooled to room temperature and then filtered through celite, rinsing with ethanol. The filtrate is concentrated under reduced pressure to give 9.63g (93 %) of the pure desired product as a purple/red solid. MS ESI (+) m/z 276 (M+l) detected.
Step B: 7-Fluoro-2-methyl-6-phenylamino-3H-benzoimidazole-5-carboxylic acid methyl ester 31a
4,δ-Diammo-3-fluoro-2-phenylarnino-benzoic acid methyl ester 6c (0.20 g, 0.73 mmol) is suspended in ethanol (3 mL) and δ M aqueous HC1 (1 mL, δ.00 mmol) is added. The reaction mixture is brought to reflux under N2 and then 2,4-pentanedione (0.150 mL, 1.45 mmol) is added. The reaction mixture is stirred at reflux for 60 minutes. The reaction mixture is cooled to room temperature and treated with saturated aqueous NaHCO3 until the pH of the reaction mixture is pH 7 and is then concentrated under reduced pressure to dryness. The residue is diluted with ethyl acetate and water, poured into a separatory funnel and the layers separated. The ethyl acetate layer is washed with brine, dried (Na2SO4) and concentrated under reduced pressure. The red solid residue is triturated with diethyl ether to yield a light brown solid and a red filtrate. The solid is collected and washed with diethyl ether to yield 0.20 g (91 %) of the pure desired product as a light brown solid. MS ESI (+) m/z 300 (M+l) detected.
Step C: 6-(4-Bromo-2-chloro-phenylamino)- 7-fluoro-2-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide 10U
7-Fluoro-2-memyl-6-phenylamino-3H-benzoimidazole-5-carboxyUc acid methyl ester 31a is converted by the bromination, chlorination, hydrolysis, coupling, and
hydrolysis procedures already described to yield the pure desired product as an off-white solid. MS ESI (+) m/z 457,459 (M+, Br pattern) detected; lH NMR (400 MHz, CD3OD) δ 7.58 (s, 1H), 7.49 (d, 1H), 7.18 (dd, 1H), 6.41 (m, 1H), 3.91 (t, 2H), 3.65 (t, 2H), 2.61 (s, 3H); 19F NMR (376 MHz, CD3OD) -135.84 (s).
Example 55
(Formula removed)

6-(4-Cyano-2-methyl-phenylcunino)-7-fluoro-3H-benzoimidazole-5-carboxylicacid
cyc10propylmethyoxy-amide (llyy)
Step A: 7-Fluoro-6-(4-iodo-2-methyl-phenylamino)-lH-benzoimidazole-5-carboxylic acid methyl ester J Off
7-Fluoro-6-o-tolylamino-liy-benzoimidazole-5-carboxyUc acid methyl ester 7a (1.47 g, 4.92 mmol) is suspended in 1:1 THF:MeOH mixture (44 ml) and cooled to -78 °C under a nitrogen atmosphere. A solution of NIS (1.66 g, 7.39 mmol) in THF (2 ml) is added followed by a MeOH (2 ml) solution of TsOH-H20 (1.87 g, 9.84 mmol). After 30 minutes, the reaction mixture is warmed to 0 °C and 1 ml methylene chloride is added. The reaction is slowly allowed to warm to room temperature with stirring over 16 hours. The reaction mixture is quenched by the addition of 10% Na2S2O4 solution. The reaction mixture is then diluted with water and ethyl acetate and the layers separated. The aqueous layer is extracted with ethyl acetate. The combined organic extracts are dried (Na2SO4) and concentrated under reduced pressure. The recovered solid is triturated with
MeOH to give 1.45 g (69%) pure desired product: MS ESI (+) m/z 426 (M+l) detected; MS ESI (-) m/z 424 (M-l) detected.
Step B: 7-Fluoro-6-(4-iodo-2-methyl-phenylamino)-(2-trimethylsilanyl-ethoxymethyl)-benzoimidazole-5-carboxylic acid methyl ester lOkk
7-Fluoro-6-(44odo-2-memyl-phenylarmno)-lH-benzoimidazole-5-carboxyUc acid methyl ester l0jj (0.200 g, 0.470 mmol) is suspended in DMF (2 ml) under N2 and cooled to 0 °C in an ice-water bath. NaH (60% dispersion in oil, 0.018 g, 0.470 mmol) is added. After, 10 min, the reaction mixture is warmed to room temperature and stirred for 30 min. After cooling to 0 °C, SEMC1 (0.087 ml, 0.494 mmol) is added and the reaction is allowed to warm to room temperature with stirring overnight. The reaction mixture is quenched by the addition of water and brine. The reaction mixture is extracted with ethyl acetate. The combined organic extracts are washed with water and brine, and dried (MgSO4) and concentrated under reduced pressure. Purification by flash column chromatography eluted with 1:1 hexanes:ethyl acetate gives 0.182 g (70%) of desired product as a 1:1 mixture of Nl and N3 isomers as a white foam.
Step C: 6-(4-Cyano-2-methyl-phenylamino)- 7-fluoro-(2-trimethylsilanyl-ethoxymethyl)-benzoimidazole-5-carboxylic acid methyl ester 1011
To a stirred solution of a 1:1 mixture of N1:N3 isomers of 7-fluoro-6-(4-iodo-2-methyl-phenylammo)-(2-trimemylsilanyl-ethoxymemyl)-benzoimidazole-5-carboxylic acid methyl ester lOjj (0.060 g, 0.108 mmol) in 1 ml DMF at room temperature under N2 is added dppf (2 mg, 0.004 mmol) followed by Pd2dba3 (2 mg, 0.002 mmol) and Zn(CN)2 (8 mg, 0.065 mmol) (Tetrahedron Lett. 1999, 40, 8193-8195). The reaction mixture is heated to 120 °C for 45 min. The reaction mixture is cooled to room temperature and
quenched by the addition of δ ml of a 4:1:δ mixture of sat NH4Cl:xonc NKUOH:water. The aqueous layer is extracted with ethyl acetate. The combined organic extracts are washed with water (3x), brine, and dried (MgSO4) and concentrated under reduced pressure. Purification by flash column chromatography eluted with 1:1 hexanes:ethyl acetate gives 38 mg (77%) of desired product as a 1:1 mixture of Nl and N3 isomers: APCI MS (+) m/z 455 (M+l) detected.
Step D: 6~(4-Cyano-2-methyl-phenylamino)-7-fluoro-(2-trimethylsilanyl-ethoxymethyl)-benzoimidazole-5-carboxylic acid 10mm
A 1:1 mixture of N1:N3 isomers of 6-(4-cyano-2-memyl-phenylamino)-7-fl.uoro-(2-1ximemylsilanyl-ethoxvmemyl)-benzoimidazole-5-carboxylic acid methyl ester 1011 (31 mg, 0.068 mmol) is hydrolyzed with aqueous sodium hydroxide as described previously to give 26 mg (87%) of desired product.
Step E: 6-(4-Cyano-2-inethyl-phenylamino)-7-fluoro-(2-trimethylsilanyl-ethoxymethyl)-benzoimidazole-5-carboxylic acid cyc10propylmethyoxy-amide llzz
A 1:1 mixture of N1:N3 isomers of 6-(4-cyano-2-methyl-phenylamino)-7-fluoro-(2-trmietiiylsilanyl-emoxymethyl)-benzoimidazole-5-carboxylic acid 10mm (26 mg, 0.059 mmol) is coupled with EDCI and cyc10propyl methyl hydroxylamine hydrochloride as described previously to give 28 mg (93%) of desired product: APCI MS (+) m/z 510 (M+l) detected.
Step F: 6-(4-Cyano-2-methyl-phenylamina)-7-fluoro-3H-benzoimidazole-5-carboxylic acid cyc10propylmethyoxy-amide llyy
To a slurry of a 1:1 mixture of N1:N3 isomers 6-(4-cyano-2-methyl-phenylammo)-7-fluoro-(2-trmemylsilanyl-emoxyme
acid cyc10propylmethyoxy-amide llzz (28 mg, 0.055 mmol) in 0.δ ml EtOH is added 0.δ ml 10% HC1. The reaction mixture is heated to 50 °C with stirring overnight (Whitten et al, JOC 1986, 51,1891-1894). An additional 0.δ ml 10% HC1 is added and the reaction mixture stirred at 70 °C overnight. The reaction mixture is cooled to room temperature and neutralized to pH ~8 with 1.δ ml IN NaOH. The reaction mixture is extracted with ethyl acetate, dried (MgSO/t) and concentrated under reduced pressure to give 14 mg (60%) of 90% pure product as a mixture of rotatomers: MS APCI (+) m/z 380 (M+l) detected; MS APCI (-) m/z 378 (M-l) detected; lB NMR (400MHz, MeOH-d4) 8 8.41 (bs, 1H), 7.75 (m, 1H), 7.50 (s, 1H), 7.38 (d, 1H), 6.51 (m, 1H), 3.72 (d, 0.δ H), 3.65 (d, 1.δ H), 2.41 (s, 3H), 0.98 (1H, m), 0.58 (d, 1.δ H), 0.40 (d, 0.δ H), 0.25 (d, 1.δ H), 0.19 (d, 0.δ H).
(Formula removed)

6-(4-Ethynyl-2-methyl-phenylamino)-7-fluoro-3H-benzoimidazole-5-carboxylicacid
cyc10propylmethoxy-amide 11aaa
Step A. 7-Fluoro-6-(2-methyl-4-trimethybilanylethynyl-phenylamino)-3H-
benzoimidazole-5-carboxylic acid cyc10propylmethoxy-amide llbbb
7-Fluoro-6-(4-iodo-2-memyl-phenylamino)-3H-benzoimidazole-5-carboxylic acid cyc10propylmethoxy-amide llccc (0.025 g, 0.052 mmol) is dissolved in 1:1 acetonitrile/triethylamine (0.50 mL). Ethynyl-trirnethylsilane (0.013 mL, 0.092 mmol),
Pd(PPh3)2Cl2 (0.004 g, 0.006 mmol), and Cul (0.002 g, 0.011 mmol) are added consecutively and the reaction mixture is stirred at 60 °C for 1 hour under N2. The reaction mixture is cooled to room temperature and concentrated under reduced pressure. The residue is purified by FCC (eluting with 20:1 methylene chloride:methanol) to yield 0.020 g (87%) of the desired product.
Step B: 6-(4-Ethynyl-2-methyl-phenylamino)-7~fluoro-3H-benzoimidazole-5-carboxylic acid cyc10propyhnethoxy-amide llaaa
7-Fluoro-6-(2-memyM-trimethylsilanylethynyl-phenylamino)-3H-benzoimidazole-5-carboxylic acid cyc10propylmethoxy-atnide llbbb (0.020 g, 0.044 mmol) is dissolved in tetrahydrofuran (0.50 mL) and the reaction solution is cooled to 0 °C. TBAF (50 uL, 0.050 mmol, 1 M solution in tetrahydrofuran) is added. The reaction mixture is warmed to room temperature and additional TBAF (25 uL, 0.025 mmol, 1 M solution in tetrahydrofuran) is added. The reaction mixture is stirred at 50 °C for 2 hours under N2. The reaction mixture is cooled to room temperature, a few drops of H2O are added and then it is concentrated under reduced pressure. The residue is purified by FCC (eluting with 20:1 methylene chIoride:methanol) to yield 0.011 g (65%) of the pure desired product. MS APCI (-) m/z 377 (M-l) detected; 1H NMR (400 MHz, CDCI3) δ 10.56 (broad s, 1H), 8.12 (s, 1H), 7.99 (s, 1H), 7.28 (s, 1H), 7.11 (d, 1H), 6.42 (broad, 1H), 3.70 (br s, 2H), 2.96 (d, 1H), 2.37 (s, 3H), 0.85 (m, 1H), 0.50 (m, 2H), 0.22 (m, 2H).
The invention and the manner and process of making and using it, are now described in such full, clear, concise and exact terms as to enable any person skilled in the art to which it pertains, to make and use the same. It is to be understood that the
foregoing describes preferred embodiments of the present invention and that modifications may be made therein without departing from the spirit or scope of the present invention as set forth in the claims. To particularly point out and distinctly claim the subject matter regarded as invention, the following claims conclude this specification.










We claim:
1. N3-benzimidazole derivatives of the formula
(Formula Removed)
and pharmaceutically accepted salts and solvates thereof, wherein:
R1, R2, and R9 are independently selected from hydrogen, halogen, cyano, nitro, trifluoromethyl,
difluoromethoxy, trifluoromethoxy, azido, -OR3, -C(O)R3, -C(O)OR3, NR4C(O)OR6, -
OC(O)R3, -NR4SO2R6, -SO2NR3R4, -NR4C(O)R3, -C(O)NR3R4, -NR5C(O)NR3R4, -
NR5C(NCN)NR3R4, -NR3R4, or
C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, -S(O)j(C1-C6 alkyl), -S(O)J(CR4R5)m-aryl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, -O(CR4R5)m-aryl, -NR4(CR4R5)m-aryl, -O(CR4R5)m-heteroaryl, -NR4(CR4R5)m-heteroaryl, -O(CR4R5)m-heterocyclyl or -NR4(CR4R5)m-heterocyclyl, where each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl portion is optionally substituted with one to five groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR4SO2R6, -SO2NR3R4, -C(O)R3, -C(O)OR3, -OC(O)R3, -NR4C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -OR3, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; R3 is selected from hydrogen, trifluoromethyl, or
C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, where each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl portion is optionally substituted with one to five groups independently selected from oxo,
halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NRSO2R'', -SO2NRR", -C(O)R, -C(O)OR', -OC(O)R, -NRC(O)OR'", -NRC(O)R", -C(O)NR'R", -SR"", -S(O)R"", -SO2R, -NRR' , -NRC(O)NR"R', -NRC(NCN)NR'R', -OR, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R', R" and R'" independently are selected from hydrogen, lower alkyl, lower alkenyl, aryl and arylalkyl;
R"" is selected from lower alkyl, lower alkenyl, aryl and arylalkyl;
Any two of R', R", R"' or R"" can be taken together with the atom to which they are attached to form a 4 to 10 membered heteroaryl or heterocyclic ring, each of which is optionally substituted with one to three groups independently selected from halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; or
R3 and R4 can be taken together with the atom to which they are attached to form a 4 to 10 membered heteroaryl or heterocyclic ring, each of which is optionally substituted with one to three groups independently selected from halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR SO2R"", -SO2NRR", -C(O)R, -C(O)OR, -OC(O)R, -NRC(O)OR"", -NR'C(O)R", -C(O)NR'R", -SO2R"", -NRR", -NR'C(O)NR"R", -NRC(NCN)NR"R", -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; or
R4 and R5 independently represent hydrogen or C1-C6 alkyl, or
R4 and R5 can be taken together with the atom to which they are attached to form a 4 to 10 membered carbocyclic, heteroaryl or heterocyclic ring, each of which is optionally substituted with one to three groups independently selected from halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR SO2R , -SO2NR R , -C(O)R', -C(O)OR, -OC(O)R', -NRC(O)OR "', -NRC(O)R', -C(O)NRR", -SO2R ', -NRR , -NRC(O)NR'R' , -NR'C(NCN)NR"R"', -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R6 is selected from trifluoromethyl, or
C1-C10 alkyl, C3-C10 cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, where each alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl
portion is optionally substituted with one to five groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NRSO2R ', -SO2NRR", -C(O)R, -C(O)OR', -OC(O)R, -NR'C(O)OR"", -NR'C(O)R", -C(O)NR'R', -SO2R", -NRR, -NRC(O)NR"R", -NRC(NCN)NR"R", -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; R7 is selected from
C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, where each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl portion is optionally substituted with one to five groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifiuoromethoxy, azido, -NR4SO2R6, -SO2NR3R4, -C(O)R3, -C(O)OR3, -OC(O)R3, -NR4C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -SO2R6, -NR3R4, -NR5C(O)NR3R4, NR5C(NCN)NR3R4, -OR3, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; A is selected from OR3 or NR4OR3;
R8 is selected from hydrogen, -SCF3, -C1, -Br, -F, cyano, nitro, trifluoromethyl, difluoromethoxy,
trifiuoromethoxy, azido, -OR3, -C(O)R3, -C(O)OR3, -NR4C(O)OR6, -OC(O)R3, -
NR4SO2R6, -SO2NR3R4, -NR4C(O)R3, -C(O)NR3R4, -NR5C(O)NR3R4, -NR3R4, or
C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, -
S(O)j(C1-C6 alkyl), -S(O)j(CR4R5)m-aryl, aryl, arylalkyl, heteroaryl,
heteroarylalkyl, heterocyclyl, heterocyclylalkyl, -O(CR4R5)m-aryl, -NR4(CR4R5)m-
aryl, -O(CR4R5)m-heteroaryl, -NR4(CR4R5)m-heteroaryl, -O(CR4R5)m-heterocyclyl
or -NR4(CR4R5)m-heterocyclyl, where each alkyl, alkenyl, alkynyl, cycloalkyl,
aryl, heteroaryl and heterocyclyl portion is optionally substituted with one to five
groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl,
difluoromethoxy, trifiuoromethoxy, azido, -NR4SO2R6, -SO2NR3R4, -C(O)R3, -
C(O)OR3, -OC(O)R3, -NR4C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -NR3R4,
-NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -OR3, aryl, heteroaryl, arylalkyl,
heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
m is 0, 1, 2, 3, 4 or 5; and j is 1 or 2.
2. N3-benzimidazole derivatives as claimed in claim 1 which is
(Formula Removed)
3. N3-benzimidazole derivatives as claimed in claim 2 wherein
R7 is C1-C10 alkyl, C3-C7 cycloalkyl, C3-C7 cycloalkylalkyl, C3-C7 heterocycloalkyl or C3-C7 heterocycloalkylalkyl, each of which can be optionally substituted with 1 - 3 groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR4SO2R6, -SO2NR3R4, -C(O)R3, -C(O)0R3, -OC(O)R3, -SO2R6, -NR4C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -OR3, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R9 is hydrogen or halogen;
R1 is lower alkyl or halogen; and
R8 is -OCF3, F, C1 or Br.
4. N3-benzimidazole derivatives as claimed in claim 3 wherein R9 is fluoro.
5. N3-benzimidazole derivatives as claimed in claim 4 wherein R1 is methyl or chloro.
6. N3-benzimidazole derivatives as claimed in claim 5 wherein R8 is chloro or bromo.
7. N3-benzimidazole derivatives as claimed in claim 3 wherein A is NR4OR3.
8. N3-benzimidazole derivatives as claimed in claim 2 wherein:
R7 is C1-C10 alkyl, C3-C7 cycloalkyl, or C3-C7 cycloalkylalkyl, each of which can be optionally substituted with 1 - 3 groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR4SO2R6, -SO2NR3R4, -C(O)R3, -C(O)OR3, -OC(O)R3, -SO2R6, -NR4C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -OR3, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R1 is lower alkyl or halogen;
R8 is -OCF3, C1 or Br; and
R9 is fluoro or chloro.
9. N3-benzimidazole derivatives as claimed in claim 8, wherein A is NR4OR3 and
R4 is H.
10. N3-benzimidazole derivatives as claimed in claim 2, selected from:
6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-
carboxylic acid (2-hydroxy-ethoxy)-amide and pharmaceutically acceptable salts thereof.
11. An N3-benzimidazole derivative as claimed in claim 2, selected from:
6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-
carboxylic acid (2,3-dihydroxy-propoxy)-amide and pharmaceutically acceptable salts thereof.
12. An N3-benzimidazole derivative as claimed in claim 2, selected from:
6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-(tetrahydro-pyran-2-ylmethyl)-3H-
benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and pharmaceutically acceptable salts thereof.
13. An N3-benzimidazole derivative as claimed in claim 2, selected from:
6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-
carboxylic acid (2-hydroxy-1,1-dimethyl-ethoxy)-amide and pharmaceutically acceptable salts thereof.
14. An N3-benzimidazole derivative as claimed in claim 2, selected from:
6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-(tetrahydro-furan-2-ylmethyl)-3H-
benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and pharmaceutically acceptable salts thereof.
15. An N3-benzimidazole derivative as claimed in claim 2, selected from:
6-(4-Bromo-2-fluoro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-
carboxylic acid (2-hydroxy-ethoxy)-amide and pharmaceutically acceptable salts thereof.
16. An N3-benzimidazole derivative as claimed in claim 2, selected from:
6-(2,4-Dichloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-
carboxylic acid (2-hydroxy-ethoxy)-amide and pharmaceutically acceptable salts thereof.
17. A benzoimidazole compound selected from:
(Formula Removed)
and pharmaceutically acceptable salts thereof.
18. A benzoimidazole compound selected from:
(Formula Removed)
and pharmaceutically acceptable salts thereof.
19. A benzoimidazole compound selected from
(Formula Removed)
and pharmaceutically acceptable salts thereof
20. A benzoimidazole compound of the formula
(Formula Removed)
and pharmaceutically accepted salts and solvates thereof, wherein:
" is an optional bond, provided that one and only one nitrogen of the ring is double-bonded;
R1, R2, R9 and R10 are independently selected from hydrogen, halogen, cyano, nitro,
trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -OR , -C(O)R , -C(O)OR ,
NR4C(O)OR6, -OC(O)R3, -NR4SO2R6, -SO2NR3R4, -NR4C(O)R3, -C(O)NR3R4,
-NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -NR3R4, or
C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, -S(O)j(C1-C6 alkyl), -S(O)j(CR4R5)m-aryl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, -O(CR4R5)m-aryl, -NR4(CR4R5)m-aryl, -O(CR4R5)m-heteroaryl, -NR4(CR4R5)m-heteroaryl, -O(CR4R5)m-heterocyclyl or -NR4(CR4R5)m-heterocyclyl, where each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl portion is optionally substituted with one to five groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR4SO2R6, -SO2NR3R4, -C(O)R3, -C(O)OR3, -OC(O)R3, -NR4C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -NR3R4,
-NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -OR3, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; R3 is selected from hydrogen, trifluoromethyl, and
C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, where each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl portion is optionally substituted with one to five groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NRSO2R", -SO2NRR", -C(O)R, -C(O)OR, -OC(O)R, -NRC(O)OR ', -NR'C(O)R", -C(O)NRR", -SR', -S(O)R"", -SO2R"', -NRR", -NRC(O)NR"R ', -NRC(NCN)NR'R ', -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; R', R" and R'" independently are selected from hydrogen, lower alkyl, lower alkenyl, aryl and
arylalkyl; R"" is selected from lower alkyl, lower alkenyl, aryl and arylalkyl; or
Any two of R', R", R'" or R"" can be taken together with the atom to which they are attached to form a 4 to 10 membered heteroaryl or heterocyclic ring, each of which is optionally substituted with one to three groups independently selected from halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; or R3 and R4 can be taken together with the atom to which they are attached to form a 4 to 10 membered heteroaryl or heterocyclic ring, each of which is optionally substituted with one to three groups independently selected from halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR SO2R"", -SO2NRR , -C(O)R, -C(O)OR', -OC(O)R', -NR'C(O)OR"", -NRC(O)R", -C(O)NRR", -SO2R"", -NR'R' , -NRC(O)NR"R"', -NRC(NCN)NR R"', -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; or R4 and R5 independently represent hydrogen or C1-C6 alkyl, or
R4 and R5 together with the atom to which they are attached form a 4 to 10 membered carbocyclic, heteroaryl or heterocyclic ring, each of which is optionally substituted with one to three groups independently selected from halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR SO2R"", -SO2NR R' , -C(O)R'' C(O)OR, -OC(O)R', -NR'C(O)OR'', -NR'C(O)R', -C(O)NR'R", -SO2R'', -NR'R' ,
-NRC(O)NR"R ', -NRC(NCN)NR'R ', -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; R6 is selected from trifluoromethyl, and
C1-C10 alkyl, C3-C10 cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, where each alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl portion is optionally substituted with one to five groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NRSO2R'', -SO2NR'R", -C(O)R, -C(O)OR, -OC(O)R', -NRC(O)OR', -NRC(O)R, -C(O)NR'R", -SO2R'', -NRR', -NR C(O)NR"R', -NRC(NCN)NR"R"', -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; R7 is hydrogen; and
C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, where each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl portion is optionally substituted with one to five groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR4SO2R6, -SO2NR3R4, -C(O)R3, -C(O)OR3, -OC(O)R3, -NR4C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -SO2R6, -NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -OR3, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; W is heteroaryl, which is optionally substituted with 1-5 groups independently selected from -NR3R4, -OR3, -R2, and
C1-C10 alkyl, C2-C10 alkenyl, and C2-C10 alkynyl, each of which is optionally
substituted with 1 or 2 groups independently selected from - NR3R4 and -
OR3;
R is selected from hydrogen, -SCF3, -C1, -Br, -F, cyano, nitro, trifluoromethyl, difluoromethoxy,
trifluoromethoxy, azido, -OR3, -C(O)R3, -C(O)OR3, -NR4C(O)OR6, -OC(O)R3, -
NR4SO2R6, -SO2NR3R4, -NR4C(O)R3, -C(O)NR3R4, -NR5C(O)NR3R4, -NR3R4, or
C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, -
S(O)j(C1-C6 alkyl), -S(O)j(CR4R5)m-aryl, aryl, arylalkyl, heteroaryl,
heteroarylalkyl, heterocyclyl, heterocyclylalkyl, -O(CR4R5)m-aryl, -NR4(CR4R5)m-

aryl, -O(CR4R5)m-heteroaryl, -NR4(CR4R5)m-heteroaryl, -O(CR4R5)m-heterocyclyl or -NR4(CR4R5)m-heterocyclyl, where each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl portion is optionally substituted with one to five groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR4SO2R6, -SO2NR3R4, -C(O)R3, -C(O)OR3, -OC(O)R3, -NR4C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -OR3, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; m is 0, 1, 2, 3, 4 or 5; and j is 1 or 2.
21. A benzoimidazole compound as claimed in claim 20 wherein:
R8 is -OCF3, -Br or -C1;
R2 is hydrogen; R1 is lower alkyl or halogen; R9 is hydrogen or halogen; and R10 is hydrogen.
22. A benzoimidazole compound of the formula
(Formula Removed)
and pharmaceutically accepted salts and solvates thereof, wherein:
is an optional bond, provided that one and only one nitrogen of the ring is double-bonded;
R1, R9and R10 are independently selected from hydrogen, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -OR3, -C(O)R3, -C(O)OR3, NR4C(O)OR6, -OC(O)R3, -NR4SO2R6, -SO2NR3R4, -NR4C(O)R3, -C(O)NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -NR3R4, or
C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, -S(O)j(C1-C6 alkyl), -S(O),(CR4R5)m-aryl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, -O(CR4R5)m-aryl, -NR4(CR4R5)m-aryl, -O(CR4R5)m-heteroaryl, -NR4(CR4R5)m-heteroaryl, -O(CR4R5)m-heterocyclyl or -NR4(CR4R5)m-heterocyclyl, where each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl portion is optionally substituted with one to five groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR4SO2R6, -SO2NR3R4, -C(O)R3, -C(O)OR3, -OC(O)R3, -NR4C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -OR3, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; R3 is selected from hydrogen, trifluoromethyl, or
C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, where each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl portion is optionally substituted with one to five groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido,
-NR'SO2R"'", -SO2NR'R", -C(O)R, -C(O)OR, -OC(O)R, -NR'C(O)OR"", -NR'C(O)R", -C(O)NR'R", -SR', -S(O)R"", -SO2R"', -NR'R",
-NR'C(O)NR"R", -NRC(NCN)NR"R", -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R', R" and R'" independently are selected from hydrogen, lower alkyl, lower alkenyl, aryl and arylalkyl;
R"" is selected from lower alkyl, lower alkenyl, aryl and arylalkyl;
Any two of R', R", R'" or R"" can be taken together with the atom to which they are attached to form a 4 to 10 membered heteroaryl or heterocyclic ring, each of which is optionally substituted with one to three groups independently selected from halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R3 and R4 can be taken together with the atom to which they are attached to form a 4 to 10 membered heteroaryl and heterocyclic ring, each of which is optionally substituted with one to three groups independently selected from halogen, cyano, nitro, trifluoromethyl,
difluoromethoxy, trifluoromethoxy, azido, -NRSO2R"", -SO2NRR.", -C(O)R', -C(O)OR', -OC(O)R, -NRC(O)OR"", -NRC(O)R', -C(O)NRR", -SO2R ', -NR'R", -NRC(O)NR"R"', -NR'C(NCN)NR'R ', -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; R4 and R5 independently represent hydrogen or C1-C6 alkyl, or
R4 and R5 together with the atom to which they are attached form a 4 to 10 membered carbocyclic, heteroaryl or heterocyclic ring, each of which is optionally substituted with one to three groups independently selected from halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NRSO2R"", -SO2NRR", -C(O)R, -C(O)OR', -OC(O)R, -NRC(O)OR"', -NRC(O)R", -C(O)NRR , -SO2R"', -NRR", -NRC(O)NR"R "', -NRC(NCN)NR'R', -OR, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; R6 is selected from trifluoromethyl, or
C1-C10 alkyl, C3-C10 cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, where each alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl portion is optionally substituted with one to five groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR'SO2R', -SO2NRR", -C(O)R, -C(O)OR', -OC(O)R', -NRC(O)OR"", -NRC(O)R", -C(O)NRR, -SO2R"", -NR'R', -NRC(O)NR"R", -NRC(NCN)NR"R'", -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; R7 is hydrogen; and
C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, where each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl portion is optionally substituted with one to five groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR4SO2R6, -SO2NR3R4, -C(O)R3, -C(O)OR3, -OC(O)R3, -NR4C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -SO2R6, -NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -OR3, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
W is heteroaryl, which is optionally substituted with 1-5 groups independently selected from -NR3R4, -OR3, -R2, or
C1-C10 alkyl, C2-C10 alkenyl, and C2-C10 alkynyl, each of which is optionally substituted with 1 or 2 groups independently selected from - NR3R4 and -OR3;
R8 is selected from hydrogen, -SCF3, -C1, -Br, -F, cyano, nitro, trifluoromethyl, difluoromethoxy,
trifluoromethoxy, azido, -OR3, -C(O)R3, -C(O)OR3, -NR4C(O)OR6, -OC(O)R3, -
NR4SO2R6, -SO2NR3R4, -NR4C(O)R3, -C(O)NR3R4, -NR5C(O)NR3R4, -NR3R4, or
C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, -
S(O)j(C1-C6 alkyl), -S(O)j(CR4R5)m-aryl, aryl, arylalkyl, heteroaryl,
heteroarylalkyl, heterocyclyl, heterocyclylalkyl, -O(CR4R5)m-aryl, -NR4(CR4R5)m-
aryl, -O(CR4R5)m-heteroaryl, -NR4(CR4R5)m-heteroaryl, -O(CR4R5)m-heterocyclyl
or -NR4(CR4R5)m-heterocyclyl, where each alkyl, alkenyl, alkynyl, cycloalkyl,
aryl, heteroaryl and heterocyclyl portion is optionally substituted with one to five
groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl,
difluoromethoxy, trifluoromethoxy, azido, -NR4SO2R6, -SO2NR3R4, -C(O)R3, -
C(O)OR3, -OC(O)R3, -NR4C(O)0R6, -NR4C(O)R3, -C(O)NR3R4, -NR3R4,
-NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -OR3, aryl, heteroaryl, arylalkyl,
heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
m is 0, 1, 2, 3, 4 or 5; and j is 1 or 2.
23. A benzoimidazole compound as claimed in claim 22 wherein:
R8 is -OCF3, -Br or -C1;
R1 is lower alkyl or halogen; R9 is hydrogen or halogen; and R10 is hydrogen.
24. A benzoimidazole compound as claimed in claim 20, selected from:
[6-(5-Amino-[1,3,4]oxadiazol-2-yl)-4-fluoro-lH-benzoimidazol-5-yl]-(4-bromo-2-
methyl-phenyl)-amine;
[6-(5-Amino-[l,3,4]oxadiazol-2-yl)-4-fluoro-lH-benzoimidazol-5-yl]-(4-chloro-2-methyl-phenyl)-amine;
[6-(5 -Amino- [ 1,3,4]oxadiazol-2-y l)-4-fluoro-1 H-benzoimidazol-5-yl] -(4-bromo-2-chloro-phenyl)-amine;
5-[6-(4-Chloro-2-methyl-phenylamino)-7-fluoro-3H-benzoimidazol-5-yl]-[l,3,4]oxadiazol-2-ol;
(4-Chloro-2-methyl-phenyl)-(4-fluoro-6-[l,3,4]oxadiazol-2-yl-lH-benzoimidazol-5-yl)-amine;
5-[6-(4-Chloro-2-methyl-phenylamino)-7-fluoro-3H-benzoimidazol-5-yl]-[1,3,4]oxadiazole-2-thiol;
(4-Bromo-2-chloro-phenyl)-(4-fluoro-6-oxazol-5-yl-lH-benzoimidazol-5-yl)-amine;
(4-Bromo-2-chloro-phenyl)-[4-fluoro-6-(3H-imidazol-4-yl)-lH-benzoimidazol-5-yl]-amine;
and pharmaceutically acceptable salts thereof.
25. A benzoimidazole compound of the formula
(Formula Removed)
and pharmaceutically accepted salts and solvates thereof, wherein:
is an optional bond, provided that one and only one nitrogen of the ring is double-bonded; R1,R9 and R10 are independently selected from hydrogen, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -OR3, -C(O)R3, -C(O)OR3, NR4C(O)OR6, -OC(O)R3, -NR4SO2R6, -SO2NR3R4, -NR4C(O)R3, -C(O)NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -NR3R4, or
C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, -S(O)j(C1-C6 alkyl), -S(O)j(CR4R5)m-aryl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, -O(CR4R5)m-aryl, -NR4(CR4R5)m-

aryl, -O(CR4R5)m-heteroaryl, -NR4(CR4R5)m-heteroaryl, -O(CR4R5)m-heterocyclyl or -NR4(CR4R5)m-heterocyclyl, where each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl portion is optionally substituted with one to five groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR4SO2R6, -SO2NR3R4, -C(O)R3, -C(O)OR3, -OC(O)R3, -NR4C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -OR3, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; R3 is selected from hydrogen, trifluoromethyl, or
C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, where each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl portion is optionally substituted with one to five groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NRSO2R'"", -SO2NRR", -C(O)R, -C(O)OR, -OC(O)R, -NR'C(O)OR"", -NR'C(O)R", -C(O)NRR", -SR', -S(O)R"", -SO2R", -NRR", -NRC(O)NR"R ', -NRC(NCN)NR"R", -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; R', R" and R'" independently are selected from hydrogen, lower alkyl, lower alkenyl, aryl and
arylalkyl; R"" is selected from lower alkyl, lower alkenyl, aryl and arylalkyl;
Any two of R', R", R"' or R"" can be taken together with the atom to which they are attached to form a 4 to 10 membered heteroaryl or heterocyclic ring, each of which is optionally substituted with one to three groups independently selected from halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; R3 and R4 can be taken together with the atom to which they are attached to form a 4 to 10 membered heteroaryl and heterocyclic ring, each of which is optionally substituted with one to three groups independently selected from halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NRSO2R '", -SO2NR'R", -C(O)R', -C(O)OR, -OC(O)R, -NRC(O)OR"", -NR'C(O)R", -C(O)NRR", -SO2R"", -NRR",
-NRC(O)NR'R ', -NRC(NCN)NR "R ', -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R4 and R5 independently represent hydrogen or C1-C6 alkyl, or
R4 and R5 together with the atom to which they are attached form a 4 to 10 membered carbocyclic, heteroaryl or heterocyclic ring, each of which is optionally substituted with one to three groups independently selected from halogen, cyano, nitro, trifluoromethyl, difiuoromethoxy, trifluoromethoxy, azido, -NRSO2R "", -SO2NR'R", -C(O)R', -
C(O)OR, -OC(O)R', -NR'C(O)OR ', -NR'C(O)R", -C(O)NR'R", -SO2R"', -NR'R",
-NRC(O)NR'R "', -NR'C(NCN)NR"R'", -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; R6 is selected from trifluoromethyl, or
C1-C10 alkyl, C3-C10 cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, where each alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl portion is optionally substituted with one to five groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difiuoromethoxy, trifluoromethoxy, azido, -NRSO2R" , -SO2NRR", -C(O)R, -C(O)0R, -OC(O)R, -NR'C(O)OR"', -NRC(O)R", -C(O)NR'R", -SO2R"", -NRR, -NR C(O)NR'R ', -NR'C(NCN)NR'R ', -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; R7 is hydrogen; and
C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, where each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl portion is optionally substituted with one to five groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difiuoromethoxy, trifluoromethoxy, azido, -NR4SO2R6, -SO2NR3R4, -C(O)R3, -C(O)0R3, -OC(O)R3, -NR4C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -SO2R6, -NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -OR3, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
W is C(O)(C1-C10 alkyl) which is optionally substituted with 1-5 groups independently selected from
-NR3R4, -OR3, -R2, and
C1-C10 alkyl, C2-C10 alkenyl, and C2-C10 alkynyl, each of which is optionally substituted with 1 or 2 groups independently selected from - NR3R4 and -OR3; R2 is selected from hydrogen, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -OR3, -C(O)R3, -C(O)OR3, NR4C(O)OR6, -OC(O)R3, -NR4SO2R6, -SO2NR3R4, -NR4C(O)R3, -C(O)NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -NR3R4, or
C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, -S(O)j(C1-C6 alkyl), -S(O)j(CR4R5)m-aryl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, -O(CR4R5)m-aryl, -NR4(CR4R5)m-aryl, -O(CR4R5)m-heteroaryl, NR4(CR4R5)m-heteroaryl, -O(CR4R5)m-heterocyclyl or -NR4(CR4R5)m-heterocyclyl, where each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl portion is optionally substituted with one to five groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR4SO2R6, -SO2NR3R4, -C(O)R3, -C(O)OR3, -OC(O)R3, -NR4C(O)0R6, -NR4C(O)R3, -C(O)NR3R4, -NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -OR3, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
R8 is selected from hydrogen, -SCF3, -C1, -Br, -F, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -OR3, -C(O)R3, -C(O)OR3, -NR4C(O)OR6, -OC(O)R3, -NR4SO2R6, -SO2NR3R4, -NR4C(O)R3, -C(O)NR3R4, -NR5C(O)NR3R4, -NR3R4, or C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, -S(O)j(C1-C6 alkyl), -S(O)j(CR4R5)m-aryl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, -O(CR4R5)m-aryl, -NR4(CR4R5)m-aryl, -O(CR4R5)m-heteroaryl, -NR4(CR4R5)m-heteroaryl, -O(CR4R5)m-heterocyclyl or -NR4(CR4R5)m-heterocyclyl, where each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl portion is optionally substituted with one to five groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR4SO2R6, -SO2NR3R4, -C(O)R3, -C(O)OR3, -OC(O)R3, -NR4C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -OR3, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; m is 0, 1, 2, 3, 4 or 5; and j is 1 or 2.
26. A benzimidazole compound according to claim 25, selected from:
l-[6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazol-5-
yl]-2-hydroxy-ethanone;
l-[6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3H-benzoimidazol-5-yl]-2-hydroxy-ethanone;
l-[6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3H-benzoimidazol-5-yl]-2-ethoxy-ethanone;
l-[6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3H-benzoimidazol-5-yl]-2-methoxy-ethanone;
2-Benzyloxy-l-[6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3H-benzoimidazol-5-yl]-ethanone;
l-[6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3H-benzoimidazol-5-yl]-2-methanesulfonyl-ethanone;
l-[6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3H-benzoimidazol-5-yl]-ethane-1,2-diol;
[6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazol-5-yl]-pyridin-2-yl-methanol;
and pharmaceutically acceptable salts thereof.
27. A benzoimidazole compound of the formula
(Formula Removed)
and pharmaceutically accepted salts and solvates thereof, wherein:
is an optional bond, provided that one and only one nitrogen of the ring is double-bonded; R1 is lower alkyl or halogen;
R9 and R10 are independently selected from hydrogen, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -OR3, -C(O)R3, -C(O)OR3, NR4C(O)OR6, -OC(O)R3, -NR4SO2R6, -SO2NR3R4, -NR4C(O)R3, -C(O)NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -NR3R4, or
C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, -S(O)j(C1-C6 alkyl), -S(O)j(CR4R5)m-aryl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, -O(CR4R5)m-aryl, -NR4(CR4R5)m-aryl, -O(CR4R5)m-heteroaryl, -NR4(CR4R5)m-heteroaryl, -O(CR4R5)m-heterocyclyl or -NR4(CR4R5)m-heterocyclyl, where each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl portion is optionally substituted with one to five groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR4SO2R6, -SO2NR3R4, -C(O)R3, -C(O)OR3, -OC(O)R3, -NR4C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -OR3, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; R3 is selected from hydrogen, trifluoromethyl, and
C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, where each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl portion is optionally substituted with one to five groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NRSO2R , -SO2NRR", -C(O)R', -C(O)OR, -OC(O)R, -NR'C(O)0R"", -NR'C(O)R", -C(O)NRR", -SR', -S(O)R"", -SO2R"", -NRR , -NRC(O)NR"R", -NRC(NCN)NR"R", -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; R', R" and R'" independently are selected from hydrogen, lower alkyl, lower alkenyl, aryl and
arylalkyl; R"" is selected from lower alkyl, lower alkenyl, aryl and arylalkyl; or
Any two of R', R", R'" or R"" can be taken together with the atom to which they are attached to form a 4 to 10 membered heteroaryl or heterocyclic ring, each of which is optionally substituted with one to three groups independently selected from halogen, cyano, nitro,

trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; or R3 and R4 can be taken together with the atom to which they are attached to form a 4 to 10 membered heteroaryl or heterocyclic ring, each of which is optionally substituted with one to three groups independently selected from halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NRSO2R"", -SO2NRR , -C(O)R, -C(O)OR, -OC(O)R, -NR'C(O)OR"", -NRC(O)R', -C(O)NRR", -SO2R ', -NRR , -NR'C(O)NR'R', -NRC(NCN)NR"R", -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; or R4 and R5 independently represent hydrogen or C1-C6 alkyl, or
R4 and R5 together with the atom to which they are attached form a 4 to 10 membered carbocyclic, heteroaryl or heterocyclic ring, each of which is optionally substituted with one to three groups independently selected from halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR SO2R , -SO2NR'R", -C(O)R"", -C(O)OR, -OC(O)R, -NRC(O)OR'", -NRC(O)R", -C(O)NRR", -SO2R"', -NRR", -NR'C(O)NR'R '", -NR'C(NCN)NR'R '", -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; R6 is selected from trifluoromethyl, and
C1-C10 alkyl, C3-C10 cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, where each alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl portion is optionally substituted with one to five groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NRSO2R"", -SO2NRR", -C(O)R', -C(O)0R', -OC(O)R', -NR'C(O)0R"", -NRC(O)R", -C(O)NR'R', -SO2R"", -NRR, -NR'C(O)NR'R ', -NRC(NCN)NR"R", -OR', aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; R7 is selected from hydrogen, and
C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, where each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl portion is optionally substituted with one to five groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido,
-NR4SO2R6, -SO2NR3R4, -C(O)R3, -C(O)OR3, -OC(O)R3, -NR4C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -SO2R6, -NR3R4, -NR5C(O)NR3R4,
NR5C(NCN)NR3R4, -OR3, aryl, heteroaryl, arylalkyl, heteroarylalkyl,
heterocyclyl, and heterocyclylalkyl;
W is selected from heteroaryl, heterocyclyl, -C(O)OR3, -C(O)NR3R4, -C(O)NR4OR3, -C(O)(C3-
C10 cycloalkyl), -C(O)(C1-C10 alkyl), -C(O)(aryl), -C(O)(heteroaryl) and
-C(O)(heterocyclyl), each of which is optionally substituted with 1-5 groups
independently selected from
-NR3R4, -OR3, -R2, and
C1-C10 alkyl, C2-C10 alkenyl, and C2-C10 alkynyl, each of which is optionally substituted with 1 or 2 groups independently selected from - NR3R4 and -OR3; R8 is selected from OCF3, Br and C1; m is 0, 1, 2, 3,4 or 5; and j is 1 or 2.
28. A benzoimidazole compound as claimed in claim 27, wherein:
R9 is hydrogen or halogen; and
R1 is hydrogen.
29. A benzoimidazole compound as claimed in claim 27, wherein: W is -C(O)OR3 or -C(O)NR4OR3.

Documents:

3046-delnp-2004-abstract.pdf

3046-delnp-2004-assignment.pdf

3046-DELNP-2004-Claims-(01-06-2011).pdf

3046-DELNP-2004-Claims-(15-03-2011).pdf

3046-delnp-2004-claims.pdf

3046-DELNP-2004-Correspondence Others-(01-06-2011).pdf

3046-DELNP-2004-Correspondence Others-(11-08-2011).pdf

3046-delnp-2004-Correspondence Others-(19-03-2012).pdf

3046-DELNP-2004-Correspondence-Others-(15-03-2011).pdf

3046-DELNP-2004-Correspondence-Others-(16-07-2010).pdf

3046-delnp-2004-correspondence-others.pdf

3046-delnp-2004-description (complete).pdf

3046-delnp-2004-form-1.pdf

3046-DELNP-2004-Form-13-(15-03-2011).pdf

3046-delnp-2004-form-13.pdf

3046-delnp-2004-form-18.pdf

3046-delnp-2004-form-2.pdf

3046-DELNP-2004-Form-3-(15-03-2011).pdf

3046-DELNP-2004-Form-3-(16-07-2010).pdf

3046-delnp-2004-form-3.pdf

3046-delnp-2004-form-5.pdf

3046-DELNP-2004-GPA-(15-03-2011).pdf

3046-DELNP-2004-GPA-(16-07-2010).pdf

3046-delnp-2004-GPA-(19-03-2012).pdf

3046-delnp-2004-gpa.pdf

3046-DELNP-2004-Petition 137-(15-03-2011).pdf

3046-DELNP-2004-Petition 138-(15-03-2011).ti.pdf

abstract.jpg


Patent Number 248684
Indian Patent Application Number 3046/DELNP/2004
PG Journal Number 32/2011
Publication Date 12-Aug-2011
Grant Date 04-Aug-2011
Date of Filing 05-Oct-2004
Name of Patentee ARRAY BIOPHARMA INC
Applicant Address 3200 WALNUT STREET, BOULDER, CO 80301, USA
Inventors:
# Inventor's Name Inventor's Address
1 WALLACE ELI M., P.O. BOX 1727, LYONS, CO 80540 USA
2 LYSSIKATOS JOSEPH P., 1720 ELDORADO CIRCLE, SUPERIOR, CO 80027, USA
3 HURLEY BRIAN T., 3725 BIRCHWOOD DRIVE, #22, BOULDER, CO 80304, USA
4 MARLOW ALLISON L., 286 W.SYCAMORE LANE, LOVISVILLE, CO 80027, USA
PCT International Classification Number A61K 314184
PCT International Application Number PCT/US03/07864
PCT International Filing date 2003-03-13
PCT Conventions:
# PCT Application Number Date of Convention Priority Country
1 60/364,007 2002-03-13 U.S.A.